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Abstract 
Poly(ADP-ribose) polymerase 1 (PARP1) is a DNA-binding enzyme involved in 
DNA repair by the base-excision pathway. The inhibition of PARP1 is being 
investigated as a cancer treatment. Rucaparib (CO338) is a potent PARP 
inhibitor currently in Phase II clinical development. In this thesis 31P in vivo MR 
Spectroscopy (MRS) and Dynamic Contrast Enhanced (DCE) MRI were used to 
study acute effects of rucaparib on energy metabolism and tumour vasculature. 
Ex vivo 1H and 31P-MRS, and in vivo [18F]FLT and [18F]FDG-PET, were used to 
study effects of treatment with rucaparib on tumour metabolism and proliferation.  
A2780 and SW620 tumours implanted in mice were scanned in a horizontal 
Varian 7T MR system. Two i.v. injections of the MRI contrast agent gadoteridol 
were given 90 minutes apart with dynamic phosphorus MRS acquired following 
the injection of rucaparib, temozolomide or both drugs in combination. The 
same tumours were evaluated by [18F]FLT- and [18F]FDG-PET after 5 daily 
treatments with rucaparib, temozolomide or the combination, and the livers of 
PARP1 knock out (KO) and wild type (WT) mice treated in a similar manner 
were analysed by  ex vivo 1H and 31P-MRS.   
Tumour uptake of gadoteridol changed significantly after treatment with 
hydralazine and higher doses of rucaparib in SW620 tumours, and following 
hydralazine and 1mg/Kg of rucaparib in A2780 tumours. 31P-MRS studies 
revealed an increase in the inorganic phosphate (Pi) to β-NTP ratio, consistent 
with impairment of tumour energy metabolism following hydralazine treatment. 
[18F]FLT-PET demonstrated a significant reduction in the SUV values in the 
rucaparib/temozolomide combination group in SW620 tumours, and [18F]FDG-
PET revealed a non-significant reduction in tumour metabolism in A2780 
tumours. 1H ex vivo MRS demonstrated an increase in the liver NAD 
concentrations after treatment with rucaparib, but a decrease following the 
treatment with temozolomide, regardless of the PARP1 status.   
ii 
Together, these pre-clinical imaging studies have shown that MR can be used 
to investigate the acute anti-vascular effects of rucaparib, that [18F]FLT-PET 
predicted subsequent changes in tumour volume following combined rucaparib 
and temozolomide treatment, and that ex vivo 1H-MRS can be used in 
mechanistic studies of PARP inhibition. Both MRI/MRS and PET are potential 
pharmacodynamic and surrogate response imaging biomarkers for PARP 
inhibitors. 
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Chapter 1. Introduction 
 1.1 Cancer 
Hippocrates observed tumour angiogenesis for the first time, using the word 
“cancer” to describe the large blood vessels which supply tumours and which 
have a visual similarity with the claws of a crab (reviewed by Feinberg et al., 
2006). However, there are earlier Egyptian papyrus documents dating from 
1600BC which describe eight breast cancer cases treated by cauterization (in a 
review by Visvader, 2011). In the middle of the nineteenth century, Theodore 
Schwann described the properties of cells from animals and plants (Schwann, 
1847), a description which was used by Rudolph Virchow (1859) to develop the 
concept of cellular pathology (Virchow, 1859), and August Foerster to 
categorize tumours  (Foerster, 1865). Based on Virchow’s work, Foerster 
hypothesised that tumours develop from connective cells and that vascular 
tumours grow from already existing small blood vessels as published by Rather, 
1978, and reviewed by Wright and Poulsom, 2012). In the early years of the 
twentieth century, Boveri proposed for the first time that cancer could be caused 
by chromosomal abnormalities in cells (reviewed by Visvader, 2011).   
 
Tumours are very heterogeneous in several aspects including proliferation rate, 
cellular morphology, number and type of genetic lesions and the way they 
respond to treatment. Each aspect of this heterogeneity is very important in the 
study and comprehension of cancer and in the search for possible treatments 
(reviewed by Visvader, 2011). Despite advances in basic cancer research, adult 
solid tumours are still being treated primarily with non-specific cytotoxic drugs 
and radiation. However, recent studies have identified genetic changes and 
epigenetic alterations that underlie cancer and these insights are leading to the 
development of specific and personalised targeted therapies.  
 
There are two main models for the development of cancer: the clonal genetic 
model of cancer and the epigenetic progenitor model of cancer.  
 
Clonal genetic model 
In the clonal genetic model (Figure 1.1), a single cell (cancer stem cell) 
undergoes several genetic alterations which cause continued clonal selection 
and tumour cell heterogeneity. Cancer cells in individual patients are 
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heterogeneous in their phenotype and cells with the capacity to propagate 
and/or sustain the disease represent a subset (reviewed by Greaves, 2010). 
Tumour proliferation, metastatic capacity and resistance to drug treatments are 
some of the consequences of the clonal genetic alterations, and dominantly 
acting oncogenes and silenced tumour suppressor genes give some support to 
the clonal genetic model. Colorectal cancer is an example where a series of 
modifications in oncogenes and tumour-suppressor genes allow evolution from 
small benign masses (adenomas) to advanced stage tumours with metastatic 
capability (reviewed by Feinberg et al., 2006). Gatekeeper genes with a role in 
promoting apoptosis in ageing cells to avoid oncogenesis are often mutated in 
cancer, and mutations in such genes are incorporated into the clonal genetic 
model.  
 
Figure 1.1: Depiction of the clonal genetic model of cancer. A single cell suffers mutations resulting in 
dominantly acting oncogenes (ONC) paired with inactivated tumour suppressors (TSG). Each mutation 
causes selective overgrowth of a monoclonal tumour cell population. The mutation accounts for tumour 
properties like drug resistance and/or metastasis while epigenetic changes are regarded as surrogate 
alterations for mutations. Copied from Feinberg et al. (2006).  
Different oncogenes and different sets of mutations can cause normal stem or 
progenitor cell changes resulting in long term self-renewing capacity. Intra-
clonal genetic diversity is also a fundamental element of cancer and leads to the 
Darwinian selection of sub-clones through major bottlenecks and progressive 
evolution of the disease (Figure 1.2, reviewed by Greaves, 2010). 
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Figure 1.2: Depiction of the clonal evolution of cancer. N stands for normal cells, where A and B are 
intracellular and intercellular/microenvironmental constraints and C decimation by therapy. This last event 
is equivalent to a catastrophic environmental change in speciation. t is time and the different colours in the 
cells represent distinctive mutant genotypes. Copied from Greaves (2010), which in turn was adapted from 
Nowell (1976).  
 
Notwithstanding its strengths, the clonal model has limitations. In colorectal 
cancer, for example, specific stages of tumour progression can be reached 
without known mutations. Furthermore, gene expression alterations can be 
related to properties without underlying gene mutations. Tumour kinetics are 
also hard to correlate with multiple clonally-selected mutations (reviewed by 
Feinberg et al., 2006). 
 
Epigenetic progenitor model 
Pathological epigenetic changes are non-sequence based alterations inherited 
through cell division. These changes represent an alternative to mutations and 
chromosomal alterations for disrupting gene function, and can lead to abnormal 
activation of growth promoting genes and silencing of tumour suppressor genes. 
Examples of pathological epigenetic changes are altered DNA methylation 
(hypo- and hyper-methylation) and/or changes in chromatin structure (reviewed 
by Feinberg et al., 2006). These changes have also been reviewed by Thomas 
Lindhal (1993) and Shikhar Sharma et al. (2010). Although clonal genetic 
changes are common in tumours, epigenetic alterations are present too and 
represent an alternative to genetic changes.  In the early stages of tumour 
genesis, epigenetic changes are present and they are also important in normal 
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tissue. Furthermore epigenetic changes may explain heterogeneity in tumour 
cell growth, invasion, metastasis and resistance to therapy. 
 
Figure 1.3: Depiction of the epigenetic progenitor model.  In a first step, stem/progenitor cells suffer 
epigenetic alterations mediated by abnormal regulation of tumour progenitor genes (TPG). These 
alterations can be caused by internal events in the stem cells or by externally inflicted damage. Secondly, 
tumour suppressor genes (TSG) in solid tumours or oncogenes (ONC) in leukaemia and lymphoma, cause 
mutation of the gatekeeper (GKM). Finally the tumour evolves due to genetic and epigenetic instability. 
Copied from Feinberg et al. (2006).  
 
In the epigenetic progenitor model (Figure 1.3) progenitor cells in a given organ 
or system originate from a polyclonal precursor population of “neoplasia ready” 
cells when they are disrupted by epigenetic changes. In the earliest stages of 
the process mutations are initiated and are specific to the tumour type. These 
mutations can be substituted for by epigenetic changes resulting in oncogene 
activation or tumour suppressor gene silencing. Cancer develops in a manner 
that enhances the ability of tumour cells to evolve and this evolution in 
promoted by epigenetic and genetic plasticity. As opposed to genetic changes 
arising from mutations and chromosomal rearrangements, epigenetics changes 
can be reversed. However, in the process of reversing the epigenetic changes, 
other irreversible genetic changes can be initiated (reviewed by Feinberg et al., 
2006).   
 
Cellular hierarchy within tissues is an important step in identifying cells of origin 
in cancer. In normal tissues stem cells evolve to progenitor cells and then to 
differentiated cells which constitute tissues or organs. Stem cells are candidates 
to become cancer precursors due to their self-renewal and longevity, which 
encases the possibility of sequential accumulation of genetic or epigenetic 
alterations. Nonetheless, any cell with proliferative capacity can originate cancer. 
If the proliferative cell acquires mutations which provide it with an indefinite self-
renewal capacity and avoids cell differentiation, cancer may arise (reviewed by 
Visvader, 2011).  
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A valuable tool in research into cellular cancer origins are genetically 
engineered mouse models. Transgenic or conditionally targeted gene 
technologies are used to study the effect of oncogenes and tumour suppressors 
genes in a whole animal context. This is achieved by the use of cell specific 
engineered expression of oncogenes and/or deletion of tumour suppressor 
genes in vivo. A second approach involves the use of cell sub-populations 
genetically manipulated ex vivo and their subsequent orthotopic transplantation 
into mice to study tumour induction. One example of the development of 
transgenic mice is provided by Josiane Ménissier-de Murcia et al. (1997), where 
the PARP1 gene exon 1 was disrupted generating PARP1-/- (PARP1 deficient) 
mice (de Murcia et al., 1997). Piskunova et al. have studied the effects of the 
PARP1-/- status in aging and carcinogenesis in mice and have shown that 
PARP1-/- mice have a mean life span 13.3% lower than PARP1+/+ mice 
indicating an ageing effect due to the PARP1 deletion. Although the both 
PARP1-/- and PARP1+/+ had a similar incidence of spontaneous carcinogenesis 
(72% approximately), the PARP1-/- had a 20.5% higher incidence of malignant 
tumours as well as an earlier tumour development when compared to PARP1+/+ 
mice (Piskunova et al., 2008). 
 
Cancer hallmarks 
As reviewed by Hanahan and Weinberg (2011) cancer possesses distinctive 
and complementary capabilities which underly tumour growth and metastatic 
dissemination. While normal tissue cells control the production and release of 
growth promoting signals through the cell cycle, cancer cells proliferate 
chronically. The proliferation signalling can be sustained by the production of 
growth factors by the cancer cells or by mutations in signal transduction 
pathways thereby promoting self-proliferation.  
 
Cancer cells also need to evade growth suppressors. Many of these 
suppressors are the products of tumour suppressor genes that downregulate 
cell proliferation. Contact inhibition is a property of normal tissues where cell 
contact with each other leads to the release of growth inhibition factors which 
cause delay or stop cell growth.  
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Failure to engage cell death pathways is also an important hallmark of cancer 
and apoptosis is the name given to the process of programmed cell death. 
Normal cells possess mechanisms to identify the number of divisions they can 
go through and at the end of the lifetime, or if an accumulation of genetic errors 
reaches high levels, the apoptotic machinery is activated to promote cell death. 
In cancer cells, apoptotic machinery is restricted or circumvented by the 
deactivation of apoptosis promoter genes, for example TP53. 
 
Cancer cells, unlike normal cells, have unlimited replicative capability, also 
known as replicative immortality. As mentioned above, normal cells have a pre-
determined number division cycles at the end of which they enter a senescent 
state (nonproliferative but viable) or undergo crisis ending in cell death. 
Telomeres protect the end of chromosomes and, as normal cells divide, 
protection is lost when the telomere becomes eroded to a critical length, at 
which point cells enter into crisis. Telomerase is the enzyme that adds telomere 
repeat segments to the ends of telomeric DNA, and in normal cells telomerase 
is absent. However, telomerase spontaneously immortalizes cells when it is re-
expressed at functionally significant levels, and telomerase activation in 
conjunction with oncogene activation and tumour suppressor gene loss, has 
been shown to be required for full cellular transformation.  
 
During embryogenesis the development of the vascular system relies on the 
growth of new endothelial cells and their assembly into tubes (Hanahan and 
Weinberg, 2011). As summarized by Hanahan and Coussens (2012) adult 
tissues possess quiescent blood vessels and angiogenesis (growth of new 
blood vessels from pre-existing ones) is a transient process which occurs in 
pathophysiological conditions, namely tissue remodelling or during the female 
reproductive cycle (Hanahan and Coussens, 2012). Tumour cells, like normal 
cells, require a supply network to obtain nutrients and oxygen, and to remove 
metabolic waste and carbon dioxide. To acquire the supply network, tumour 
cells release vascular endothelial growth factors (VEGF) which promotes 
angiogenesis and hence tumour growth.  
 
Cancer cells not only invade their surrounding space due to their sustained 
replication, but they also invade nearby blood and lymphatic vessels allowing 
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tumour cells to travel long distances and form small nodules of cancer cells in a 
new location in the body, a process called metastasis. This process is 
potentiated in carcinomas arising from epithelial tissues (Hanahan and 
Weinberg, 2011). 
 
It is not only genetic instability that is responsible for tumour genesis. Cells from 
the immune system can be found in neoplastic lesions to different extents, and 
it was thought that this is a response of the immune system to the arising 
tumour. However, in the early stages of neoplastic progression, inflammation 
can foster the development of neoplasia through the release of cytokines and 
signalling molecules which can accelerate malignancy. This process may 
explain in part how the immune system allows tumours cells to grow and 
develop into tumour masses (review by Hanahan and Weinberg, 2011).  
 
Another distinguishing property of tumours is that tumour cells can reprogram 
their energy metabolism to meet the energy requirements of tumour cells at a 
time when tumour angiogenesis does not provide a reliable vascular system. In 
the early twentieth century Otto Warburg et al. (1927) made the first 
measurements of glucose and lactic acid in tumours. They were able to 
determine that 66% of the glucose used by tumour was used in fermentation 
(anaerobic respiration) while the remaining 34% were used in (aerobic) 
respiration (Warburg et al., 1927). Andrei Drabovich et al. (2012) developed a 
targeted proteomic assay for the accurate quantification of protein expression in 
glycolysis/gluconeogenesis, TCA cycle and pentose phosphate pathways. This 
assay was performed on human MCF-7 breast cancer cells which had been 
grown in conditions designed to mimic the exposure of cells in cancer tissue to 
intermittent hypoxia, glucose deprivation and hormonal stimulation. They were 
able to identify in MCF-7 cell lysate 4074 proteins annotated to 216 distinct 
pathways using the KEGG pathway database, with a total of 2738 proteins 
identified with at least 2 peptides allowing the measurement of protein 
expression in multiple metabolic pathways and monitor differences in protein 
expression between healthy and cancer cells (Drabovich et al., 2012). 
 
Advances in the discovery and understanding of cancer hallmarks have made 
possible the development of targeted therapies which are more effective against 
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specific tumours types. Figure 1.4 is a representation of the cancer hallmarks 
and how they are increasingly being targeted by a new generation of therapies 
(review by Hanahan and Weinberg, 2011).  
 
Figure 1.4: Representation of the acquired capabilities necessary for tumour growth and progression 
(inner circle) with the correspondent drugs being studied to counteract those capabilities. Some of the 
drugs are already in clinical trials. The number of potential drugs is very high, with different molecular 
targets and different modes of action. Copied from Hanahan and Weinberg (2011).  
 
Genomic instability 
An increased susceptibility to alterations in the genome during the life cycle of 
cells is referred to as genomic instability. During cell division genomic instability 
is associated with the failure of parental cells to duplicate the genome in an 
accurate manner and precisely distribute the genomic material between the 
progeny cells. Epigenetic alterations such as abnormal DNA methylation 
including that of tumour suppressor genes and/or chromatin modification are 
also important factors in genomic instability.  There are four major processes in 
the cell division cycle that minimise genomic instability: high fidelity DNA 
replication in S-phase of the cell cycle, precise chromosome segregation in 
mitosis, and coordinated error free cell cycle and sporadic DNA damage repair. 
With genetic instability, the impact of DNA repair can be diverse. Repair can 
either remove the damage and cause alteration in the DNA sequence and/or 
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rearrangement of genome segments during the repair process, in what is known 
as “error prone” repair, or remove the damage and preserve the original DNA 
structure in an “error free” repair process (Shen, 2011). The search for factors 
which cause genomic instability is ongoing, and reducing genomic instability by 
the inhibition of “error-prone” pathways provides another approach to tumour 
treatment (for example Rooney et al., 2003, and Yoon et al., 2011).  In relation 
to PARP, Valérie Schreiber et al.  established a stable HeLa cell line that 
endogenously produced the 46kDa DNA binding domain of human poly(ADP-
ribose) polymerase (PARP-DBD) which resulted in trans-dominant inhibition of 
PARP activity. When treated with N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), 
the PARP-DBD expressing cells exhibited chromosomal instability 
demonstrated by higher frequencies of both spontaneous and MNNG-induced 
sister chromatid exchanges and characteristic nucleosomal DNA ladder 
formation (a hallmark of cell death by apoptosis).  These results suggest a close 
connection between genomic stability and PARP function (Schreiber et al., 1995, 
and reviewed by Kirkland, 2010). 
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1.2 Poly (ADP-ribose) polymerase (PARP) inhibitors 
Poly (ADP-ribose) polymerases (PARPs) are elements of vital importance in the 
DNA base excision repair pathway that are activated by single DNA strand 
breaks, one of a number of DNA repair pathways. 
 
DNA Repair pathways 
In a review by Orlando et al. (2012), DNA repair was defined by the type and 
extent of the damage inflicted in the DNA chain. Damage that results in double 
strand breaks initiates one of two main repair pathways: homologous 
recombination (HR) and nonhomologous end-joining (NHEJ) recombination. 
The damage can be inflicted by endogenous or exogenous damaging factors 
such as metabolic, chemical or radiation injury (Orlando et al., 2012). In NHEJ 
Ku proteins recognise double strand breaks, bind to them and activate DNA-
dependent protein kinase (DNA-PK), which in turn leads to the recruitment and 
activation of end-processing enzymes, polymerases and DNA ligase IV. In 
NHEJ there is an alternative pathway independent of Ku proteins called 
microhomology mediated end joining (MMEJ), or alternative end-joining, which 
also results in sequence deletions.  
 
Homologous recombination (HR) is initiated by DNA single strand generation 
and promoted by several proteins including the MRE11-RAD50-NBS1 complex. 
RAD51, BRCA1 or BRCA2 that subsequently catalyse the repair pathway, in 
which the single stranded DNA invades the complementary undamaged 
template and DNA ligation and substrate resolution is facilitated by the action of 
polymerases, nucleases, helicases and other components. The HR repair 
pathway is also used to restart stalled replication forks and to repair interstrand 
DNA crosslinks (as reviewed by Jackson and Bartek, 2009). However, the HR 
pathway is entirely dependent upon access to the complimentary undamaged 
sister chromatid and hence can only operate when a 4N DNA complement is 
present in the cell during late S, G2 and early M phases. In contrast, NHEJ can 
operate throughout the cell cycle.  
 
Ionizing radiation or alkylating agents cause single strand breaks into DNA. 
These single strand breaks can be repaired by three main repair pathways: 
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nucleotide excision repair (NER), base excision repair (BER) and mismatch 
repair (MMR) (reviewed by Orlando et al., 2012).  
 
As reviewed by Jackson and Bartek (2009), helix distorting base lesions are 
recognized by the nucleotide excision repair system which can follow one of two 
pathways: transcription coupled NER, which targets lesions that block 
transcription, or global genome NER. The damage is excised in the form of a 
22-30base oligonucleotide (resulting in single strand DNA). In MMR a single 
strand incision is triggered by the detection of mismatches or insertion/deletion 
loops. Nuclease, polymerase and ligase enzymes act upon the incision in order 
to repair the damage. Finally, base excision repair involves the recognition of a 
damaged base by a DNA glycosylase enzyme, which mediates the base 
removal prior to completion of repair performed by nuclease, polymerase and 
ligase proteins (Jackson and Bartek, 2009).  
 
PARP1 is a key component of DNA single strand break repair by the base 
excision repair pathway (review by Orlando et al., 2012). Poly(ADP-ribose) 
polymerase-1 (PARP1) is a 116kDa nuclear enzyme present in eukaryotes and 
the first of a superfamily of 18 proteins. As depicted in Figure 1.5, PARP1 is 
composed of three main domains: an N-terminal DNA-binding domain which 
contains two zinc fingers, an automodification domain and a C-terminal catalytic 
domain.    
 
 
Figure 1.5: Representation of the structure of poly(ADP-ribose) polymerase-1 (PARP1) with its three 
domains. Copied from Leung et al. (2011). 
 
 
In 1963, Pierre Chambon et al. reported several characteristics of what was 
then a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. 
Following the addition of nicotinamide mononucleotide to hen liver cell nuclei 
effects on the new RNA-polymerase enzyme were studied. The new enzyme 
was shown to be activated by nicotinamide mononucleotide, DNA-dependent, 
not stimulated by polyA (i.e. was not an RNA binding protein) and not inhibited 
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by nucleoside triphosphates or various ribonucleases (published by Chambon 
et al., 1963, and reviewed by Kummar et al., 2012). In 1976, Payne and Bal 
used autoradiography to assess the in vitro incorporation of [3H]NAD into onion 
embryo and merismatic tissue, and were able to show a high level of cytological 
incorporation into merismatic nuclei. At least 30% of the cells showed “heavy” 
labelling similar to that produced by in vitro DNA polymerase activity (Payne 
and Bal, 1976).  Caplan et al. (1979) subsequently purified poly (ADP-ribose) 
polymerase from calf thymus and demonstrated ADP-ribose transfer from NAD 
as well as kinetic and acceptor characteristics (published by Caplan et al., 1979, 
and reviewed by Hottiger, 2011). 
 
PARP Functions 
Poly(ADP-ribose) polymerases have complex biological roles with numerous 
functions. PARP1 has an important role in DNA repair and genome integrity 
maintenance as discussed in the previous section. Delayed DNA base excision 
repair pathway and high frequency of sister chromatid exchange in PARP1 
deficient cells exposed to ionizing radiation or treated with alkylating agents 
suggest a role for PARP1 function under these conditions. Furthermore, 
genetically modified mice which do not express PARP1 show increased 
mortality when exposed to high levels of ionizing radiation or treatment with 
alkylating agents, when compared to PARP1 wild type mice (de Murcia et al., 
1997).  
 
In a review by Virág and Szabó (2002), the role of PARP1 in regulating the 
function of several transcription factors was discussed with special emphasis on 
inflammatory mediators such as inducible nitric-oxide synthase, intercellular 
adhesion molecule 1 and the major histocompatibility complex class II. PARP1 
also coactivates NF-kB which is a key transcription factor in the regulation of 
inflammatory mediators, and PARP1 is also involved in DNA replication and 
differentiation. In the nuclei of proliferating cells poly(ADP-ribose) undergoes an 
accelerated metabolism. Additionally, a number of replication factors and 
centromere proteins have been shown to be substrates for PARP.  
    
The overexpression of tankyrase-1 (PARP5a) induces gradual and progressive 
elongation of telomeres in telomerase positive human cells, and PARP1 has 
also been implicated in the maintenance of telomere length. PARP1 activation 
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is thought to mediate cell death in the form of necrosis; whereas mild 
genotoxicity activates PARP facilitating DNA repair and cell survival, severe 
DNA damage causes PARP overactivation which translates into NAD+ and ATP 
depletion and, therefore, necrosis.  It has also been shown that the base 
excision machinery can use poly(ADP-ribose) polymer as an emergency source 
of energy for the synthesis of ATP (Virág and Szabó, 2002). 
  
Besides PARP-catalysed covalent poly(ADP-ribosylation), poly(ADP-ribose) 
polymers are able to bind non-covalently to specifc (ADP-ribose)n binding motifs 
in proteins, modifying their function, and a final function of poly(ADP-
ribosylation) may be the regulation of the cytoskeletal organization (Virág and 
Szabó, 2002). 
 
Although PARP1 is a molecular sensor for DNA single strand breaks and has a 
key role in the repair of these lesions, PARP2 is also activated by DNA strand 
breaks and genetic instability has been shown to increase in PARP2-deficient 
mice. PARP1 and PARP2 display partially redundant functions (reviewed by 
Schreiber et al., 2006). This redundancy has been demonstrated by the 
generation of PARP1 and PARP2 knockout mice. PARP1 mice are viable and 
fertile indicating that PARP1 activity is not required in the absence of genotoxic 
stress. However, these mice and cells derived from them are hypersensitive to 
ionizing radiation and alkylating agents. In response to DNA damage PARP1 
deficient cells still generate poly(ADP-ribose) suggesting the presence of a 
second PARP enzyme (PARP2). PARP2 knockout mice were developed, and 
again showed viability and fertility but once more delayed DNA repair after 
exposure to alkylating agents (reviewd by Curtin, 2005). Double null PARP1 
and PARP2 knockout mice lack viability dying early in development at the 
beginning of gastrulation (de Murcia et al., 2003). 
 
PARP3 is thought to have a role in double strand break DNA repair, and studies 
have shown that PARP3 is recruited to laser-induced DNA damage sites. In 
human cells depleted of PARP3 delayed double strand break repair is found 
together with reduced survival in response to irradiation and after PARP1 
inhibition. Mouse models with PARP1 and PARP3 disruption reveal increased 
radiosensitivity suggesting a conjoint role in double strand break repair. 
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Although the exact molecular mechanism involved remains uncharacterized, it 
has been hypothesised that PARP3 promotes an alternative non-homologous 
end joint repair pathway (De Vos et al., 2012). 
 
PARP1 in DNA damage repair 
As illustrated in Figure 1.6, when a DNA strand suffers a break, PARP1 and 
PARP2 use their DNA binding domain to connect to the break. Once attached, 
hydrolysis of NAD+ with consequent release of nicotinamide and one proton 
(H+) starts the catalytic domain transfer of the ADP-ribose moiety to nuclear 
protein acceptors. The formation of an ester bond between the amino acid 
acceptor and the first ADP-ribose initiates the reaction. The formation of a 2’-1’’ 
glycosidic bond is involved in the polymer elongation, and the polymer branches 
after on average twenty ADP-ribose units with branching points every forty to 
fifty ribose units. Branching reactions share the chemistry with the elongation 
reaction due to the equivalent orientation of the 2’ OH of the ribose groups 
relative to the adenine in the elongation mode or to the nicotinamide in the 
branching mode of NAD+. To degrade poly(ADP-ribose) glycosidic bonds 
between ADP-ribose units are cleaved by endo- and exo-glycolytic activities of 
the nuclear enzyme poly(ADP-ribose) glycohydrolase (PARG). In heavily 
damaged cells NAD+ is extensively consumed by the activity of PARP, and 
regenerated by PARG and NAD+ recycling enzymes (Schreiber et al., 2006). 
 Figure 1.6: Representation of DNA damage and repair and the role of PARP. Copied from Schreiber et al. 
(2006).  
 
PARP is thought to be rapidly activated under several pathophysiological 
conditions with activation due to the action of DNA damaging anticancer drugs, 
the most relevant to the studies described in this thesis. Acute and chronic 
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inflammatory disorders are also important pathologies where PARP is involved 
at different levels by functioning as a co-activator of the NF-kB and AP-1 
transcription factors. When activated, these transcription factors trigger the 
synthesis of inflammatory mediators such as nitric oxide, and subsequently 
peroxinitrites and highly reactive hydroxyl radicals. All these toxic species can 
cause extensive DNA damage which in turn activates the DNA repair function of 
PARP. Acute neuronal and myocardial cell death following ischaemia 
reperfusion injury also induces PARP overactivation in association with the 
flavoprotein apoptosis inducing factor (AIF) release. Activation and consequent 
toxic effects are decreased in PARP1 or PARP2 knockout mice or by PARP 
inhibitors. These observations indicate a potential benefit of therapeutically 
targeting PARP1 and PARP2 in order to treat inflammatory, neurological or 
cardiac disorders, and several drugs are being studied, some of which have 
reached human clinical trials (Schreiber et al., 2006).  In 2012 Leonardo 
Cavone and Albano Chiarugi reported preliminary studies of PARP inhibition in 
mice for multiple sclerosis treatment (reviewed by Cavone and Chiarugi, 2012).  
 
Lastly, poly(ADP-ribose) metabolism is perturbed in tumour cells. PARP1 gene 
expression is upregulated although there is no increase in mRNA levels. For 
example, in low-grade malignant non-Hodgkin’s lymphoma cells have a high 
cellular PARP content when compared with normal lymphocytes. PARP activity 
has also been found to be upregulated in hepatocellular carcinomas when 
compared with normal liver tissue (reviewed by Virág and Szabó, 2002).   
 
Synthetic Lethality 
The development of PARP inhibitors has allowed the concept of synthetic 
lethality to be studied in patients for the first time. Normal cells possess 
redundant and interconnecting pathways to prevent lethality caused by single 
mutations. Tumour cells, as a result of the loss of genetic material can rely for 
their growth and viability on non-redundant pathways. When that is the case, 
disruption of the remaining active pathway will eventually cause therapeutic 
effects. Synthetic lethality is therefore defined as the absence of lethality by the 
disruption of one normal pathway in normal cells but the presence of lethality in 
tumour cells lacking redundant pathways following inhibition of the remaining 
pathway. In accordance with this hypothesis, candidate genes or proteins can 
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be screened for and identified as targets by the use of gene knockout cell lines 
or by siRNA in conjunction with small molecule chemicals or drugs (reviewed by 
Leung et al., 2011).  
In particular, synthetic lethality underlies the anti-proliferative activity of PARP 
inhibitors in DNA repair-defective tumour cells. Hence the formation of   single 
strand breaks in homologous recombination (HR) DNA repair pathway deficient 
cells induces hypersensitivity to PARP inhibition. The single strand breaks can 
be the result of endogenous DNA damage or external damaging agents such as 
ionizing radiation and alkylating agents, and homologous recombination defects 
derive mainly from BRCA1 or BRCA2 gene mutations. In tumours which meet 
both requirements, single strand breaks induced by, for example, alkylating 
agents, if not repaired by PARP activity, become double strand breaks and, due 
to the homologous recombination deficiency, the tumour cells accumulate 
damage and cannot survive. PARP inhibition in HR-defective cell is an excellent 
example of synthetic lethality (published by Bryant et al., 2005, and Farmer et 
al., 2005, and reviewed by Orlando et al., 2012).  
 
PARP inhibitors 
In the early 1980s, 3-substituted benzamides (simple analogues of 
nicotinamide) were shown to increase alkylating agent cytotoxicity (Durkacz et 
al., 1980). These first generation PARP inhibitors represent early examples of 
the development of drugs to enhance antitumour activity in chemo- and 
radiotherapy. A second generation of PARP inhibitors with increased potency 
and specificity was developed in the 1990s, Banasik et al. (1992) reporting a 
screening study of 170 compounds and reviewed by Curtin (2005). Third 
generation PARP inhibitors were shown to possess increased potency and 
improved pharmacokinetic properties which allowed pre-clinical studies to 
assess potential efficacy in cancer treatment. Examples of this effort were 
published by Calabrese (2003) and Thomas (2007), resulting in the 
identification of the first PARP inhibitor for clinical trials (Calabrese et al., 2003; 
Thomas et al., 2007). PARP inhibitors exhibit enhanced anti-proliferative activity 
when used in combination with DNA single strand break-inducing treatments 
such as the alkylating agent temozolomide, ionizing radiation or topoisomerase-
I inhibitors, (for example, Calabrese et al., 2003; Daniel et al., 2009; Spagnolo 
et al., 2012)  
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Similarities between the sensitization effect caused by the absence of PARP1 in 
PARP1-/- cells and PARP1 inhibition in PARP1+/+ cells on the cytotoxic effects of 
anticancer drugs indicates that lack of PARP1 activity is the underlying cause in 
both cases. Contributions to chemosensitization due to inhibition of other 
members of the PARP family are not known due to the lack of isoform specific 
inhibitor (Wahlberg et al., 2012). It is important to note that PARP inhibition is 
not only toxic to BRCA1 or BRCA2 deficient tumour cells, but that inhibition is 
also toxic to normal cells with BRCA2 deficiency, suggesting that PARP 
inhibitors may have a role in the prophylactic treatment of women that are 
heterozygous for the BRCA2 gene (reviewed by Schreiber et al., 2006). Hay et 
al. reported that PARP inhibition in mouse small intestine BRCA2 deficient cells 
increases apoptosis to high levels 6 hours after treatment with evidence of 
tissue repopulation 12 hours after treatment. Also, the repopulation rate was 
higher in the treated mice when compared against the non-treated ones (Hay et 
al., 2005). In a review by De Soto and Deng (2006) state that BRCA-/- pre-
cancerous cells have higher sensitivity to PARP inhibition when compared to 
wild type cells whilst cancer cells respond differently to PARP inhibition 
depending on the conditions. They propose that in early stages of 
tumourgenesis BRCA1 and BRCA2 mutant cells are sensitive to PARP 
inhibition, however, in later stages of BRCA deficient tumour cells might 
become insensitive to PARP inhibition due to further mutations which can lead 
to cancer development (De Soto and Deng, 2006). However, a prolonged PARP 
inhibition may leave DNA mutations unrepaired which can lead to malignancy 
similar to a BRCA carrier. Studies over a long period of time are required to find 
the effects of a long treatment with PARP inhibitors (Weil and Chen, 2011).  
 
PARP inhibitors which are now in clinical trials include ABT888, AZD2281, INO-
1001, BSI-201 and CO338 (rucaparib). These and other PARP inhibitors and 
their clinical status are summarized in Table 1.1. These agents have different 
pharmacokinetic and clinical properties, for example, CO338 (rucaparib) is 
already in Phase II clinical trials where it has been given over 5 days combined 
with temozolomide by intravenous infusion. Pharmacodynamic measurements 
of PARP activity in peripheral blood lymphocytes revealed 74-97% PARP 
inhibition following the administration of 200mg/m2 of temozolomide combined 
with 12 mg/m2 of CO338 (rucaparib) (reviewed by Rodon et al., 2009).  
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Agent Company Route Clinical status 
CO338/rucaparib Clovis i.v. (oral) Phase I/II combination 
AZD2281/olaparib AstraZeneca/Kudos oral Phase II/III combination 
ABT888/veliparib Abbott oral Phase I/II combination 
BSI-201 iniparib BiPar/Sanofi-Aventis i.v. Phase II/III combination 
INO-1001 Inotek i.v. Phase Ib complete 
GPI21016 MGI Pharma/Eisai oral Phase I 
CEP-9722 Cephalon oral Phase I 
MK4827 Merck & Co. oral Phase I 
BMN-673 Biomarin/Lead Pharmaceuticals  Pre-clinical 
 
Table 1.1: PARP inhibitors in clinical development. Adapted from Calvert and Azzarati (2011). 
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1.3 Biomarkers 
A biomarker has been defined by Newton et al. (2011) as “an objectively 
measurable substance that may be used as an indicator of a biological or a 
pathological state. When applied to a disease process, a biomarker can be 
used to detect disease, predict prognosis or predict response to a 
pharmacological agent. A biomarker must facilitate an improvement in life 
expectancy or quality of life in order to be of use in clinical practice.” (Newton et 
al., 2011).  
 
Possibly the first description of a cancer biomarker was offered by Henry Jones 
in 1848 when he described peculiar reactions (precipitation temperature 
dependent) in urine samples from cancer patients by boiling with strong nitric 
acid (Jones, 1848). In the 1960’s the prostate specific antigen (PSA) was 
described as a screening biomarker for prostate cancer and it is still being used 
today (reviewed by Mishra and Verma, 2010).  
 
Several disciplines and technologies have been applied to the study of cancer 
biomarkers. In the presence of a tumour, traditional techniques such as biopsy 
or more invasive surgical procedures can be carried out. However, in the 
absence of tumour or to avoid an invasive procedure, alternative techniques are 
available. These techniques include analysis of circulating tumour cells 
(published by Cristofanilli et al., 2004, reviewed by Tanaka et al., 2012), 
mutation specific PCR on circulating tumour DNA (published by Anker et al., 
1997, and reviewed by Aung et al., 2010), and proteomic approaches to study 
serum or plasma (published by Li et al., 2002, and reviewed by Mani et al., 
2011). Measuring autoantibodies specific for tumour cells is a further non-
invasive technique (Harlow et al., 1981; Petras et al., 1998; Neumann et al., 
2011). Imaging tumours in situ at the molecular level is also possible (Jeswani 
and Padhani, 2005). The diagram in Figure 1.7 depicts biomarkers grouped by 
different criteria. These definitions are not rigid and a consensus around cancer 
biomarker terminology has yet to be reached (Sawyers, 2008). 
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Figure 1.7: Organizational diagram for different cancer biomarkers. On the right are the main criteria by 
which the biomarkers on the left are organized. Adapted from Mishra and Verma (2010).  
 
Prognostic biomarkers measure features that differentiate between benign and 
malignant tumours. These biomarkers are also important in staging the tumour 
and help clinicians to decide what the appropriate treatment is. Predictive 
biomarkers are used by clinicians to select the most appropriate treatment and 
response biomarkers assess the effect of a specific treatment on the tumour. 
Different patients will respond differently to treatments so biomarkers are very 
important. Even once a treatment is selected, it is necessary to decide the 
appropriate dose and schedule at which point pharmacokinetic and 
pharmacodynamic biomarkers are important.  
 
Regarding samples for invasive biomarker studies, DNA, RNA, protein and 
carbohydrates can be used. DNA can be collected from tissue, saliva, 
cerebrospinal fluid, bone marrow or tumour cells circulating in the blood. At a 
molecular level, DNA markers include single nucleotide polymorphisms, loss of 
heterozygosity, variation in the copy number of genes, chromosomal 
translocations/fusions, micro-satellite instability, and gene mutations. Also 
epigenetic modification of nucleic acids and associated proteins (histones and 
non-histones) can also act as biomarkers. Quantitative Reverse Transcription 
Polymerase Chain Reaction (RT-qPCR) and Serial Analysis of Gene 
Expression (SAGE) are examples of methods used in the search for biomarkers 
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at the level of RNA expression, and micro RNAs (miRNA) are also potential 
biomarkers.  
 
Proteins have also been widely used to generate biomarker data and methods 
to study proteins in cancer include two-dimensional fluorescence difference gel 
electrophoresis (DIGE) (Alban et al., 2003), and mass spectrometry (MS) 
(Semmes et al., 2005), with studies extending to quantitative proteomics (Chen 
et al., 2007). Mass spectrometry has also been used in the detection of disease 
associated carbohydrate biomarkers such as N-linked and O-linked glycans (An 
et al., 2006; Alley et al., 2010), and glycobiomarkers may be more stable than 
RNA or proteins so they are suitable for epidemiological studies.  
 
Less invasive biomarker technologies, namely imaging techniques, include X-
ray, computed tomography (CT), magnetic resonance imaging (MRI), 
radionuclide techniques (PET and SPECT) or ultrasound. These techniques can 
be used to screen, diagnose or stage tumours, and to determine the response 
to treatment as reviewed by Mishra and Verma (2010). 
 
As shown in Figure 1.8, the development of a biomarker follows a long path 
before it is available for general use. 
 
Figure 1.8: Diagram of the development of cancer biomarkers in the USA. After identification, the 
biomarker needs to be evaluated for a particular clinical application and analytically and clinically validated 
prior to US Food and Drug Administration (FDA) approval and before the Center for Medicaid and 
Medicare Services (CMS) determine the “reasonable and necessary” improvement in patient care. 
Adapted from Ludwig and Weinstein (2005).  
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There are five conceptual phases in the development of the biomarker: a pre-
clinical discovery phase, clinical assay development and validation, 
retrospective longitudinal studies, prospective evaluation and use in routine 
cancer management. Although biomarkers should be validated in prospective 
and well controlled clinical trials, in reality clinical studies are usually 
retrospective, often generating inconsistent results and involving few patients. In 
an attempt to speed up the process and lower the costs, multi-institutional 
teamwork can facilitate analytical and clinical validation (reviewed by Ludwig 
and Weinstein, 2005, and Sawyers, 2008).  
 
Magnetic Resonance Imaging (MRI) can provide not only anatomical 
information but also physiological information making it valuable for detecting 
the size, location and extent of tumour lesions as well as their response to 
treatment. The principles of MRI will be explained in subsection 1.4.1 with more 
detail in the case of Dynamic Contrast Enhanced (DCE) MRI, which can provide 
important information regarding a range of tumour properties. The use of 
contrast agent allows the measurement of differences in the uptake of the agent 
in the tumour before and after the treatment, as well as other parameters such 
as tumour perfusion, permeability and tumour vascular function (Castellani et al., 
2009). DCE-MRI is of vital importance in the non-invasive evaluation of new 
antiangiogenic and antivascular drugs, and the assessment of the delivery of 
therapeutic agents to the cancer cells, as reviewed by O’Connor et al. (2007). A 
different approach being developed is the attachment of functional contrast 
agents to specific ligands or targeting moieties enabling them to be substrate 
specific to cellular processes.  
 
Diffusion-weighted (DW) MRI is used to measure parameters associated with 
the rate and distance of water molecule diffusion, and does not require the 
injection of contrast agents. DW-MRI can be useful to assess the likely access 
of a drug to cells in the tumour (Haider et al., 2007).    
 
An alternative technique in MR which can be used to provide biomarker data is 
Magnetic Resonance Spectroscopy (MRS). The principles underlying MRS are 
explained in subsection 1.4.2 in more detail. Through a voxel located in the 
tumour it is possible by MRS to measure concentrations of biochemicals or 
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drugs and their metabolites in cells. This information can be used in 
pharmacokinetic and pharmacodynamic studies. Using proton (1H) MRS 
concentrations of lactate, choline derivatives, inositides, creatine compounds 
and glutamine/glutamate, for example, can be measured (Ackerstaff et al., 
2001; Benveniste et al., 2012). Using phosphorus (31P) MRS adenosine 
triphosphate (ATP), phosphomonoesters like phosphocholine, and inorganic 
phosphate, for example, can be measured(Yan et al., 2011). Intracellular pH 
can also be measured with 31P-MRS (Nath et al., 2012), and changes in the 
metabolites present in cells can be used as pharmacodynamics and response 
markers following treatment. In pharmacokinetic studies, MRS can also provide 
direct measurements of drug concentrations not only in tumours but also other 
organs throughout the body (liver, kidneys, brain, for example). Drugs which 
contain fluorine have relatively high magnetic resonance sensitivity, and 
background fluorine signals in living tissue are not usually detected (McIntyre et 
al., 2011). On a direct comparison, 31P-MRS is less sensitive than 1H-MRS 
(usually described as 6.63% sensitivity of 1H-MRS) and so it needs much larger 
volume elements to achieve good signal-to-noise (SNR) ratios for the 
metabolites of interest. However, it covers a wider chemical shift range (around 
30ppm for biological phosphates) and does not face the same solvent 
suppression challenges as 1H-MRS (Gadian, 1995).   
 
The principles underlying Positron Emission Tomography (PET) will be 
explained in more detail in section 1.5. As an imaging technique based on the 
injection and detection of radioactive agents in the patient, PET can provide 
distribution/uptake information for the labelled agent in the tumour and/or across 
the body of the patient. [18F]-Fluoro-2-deoxy-2-D-glucose (FDG) is the gold 
standard PET tracer and its uptake is widely used as a metabolism biomarker in 
tumours. However, [18F]FDG lacks specificity as other metabolically hyperactive 
tissues or sites of inflammation can have an increased uptake of glucose 
(Rebollo Aguirre et al., 2009).  
 
[18F]-3'-Deoxy-3'-fluorothymidine (FLT) is used in PET as a marker of DNA 
synthesis and cell proliferation. FLT-PET can provide information about cellular 
proliferation within a tumour without relying in volume changes (Grierson et al., 
2004). Other labelled compounds that have been used as PET tracers include 
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[11C]-thymidine, which also marks cellular proliferation (Ullrich et al., 2008), 
[15O]-H2O used as a marker of tissue perfusion (Shi et al., 2010), and [15O]-CO 
which is a marker of blood volume as published by Kurdziel et al. (2003) and 
reviewed by Kluetz et al. (2010). Amino acid metabolism can also be studied 
through PET by the use of, for example, [11C]-methionine (published by 
Bergström et al., 1983, and reviewed by Langen et al., 2008), and tricarboxylic 
acid cycle activity can be studied with [11C]-acetate (Ho et al., 2003). Labelled 
antibodies and peptides are also in development to study receptors on tumour 
cell membranes. With the current development of gene therapies, PET methods 
are also being developed to monitor in vivo gene expression, and 2’-fluoro-
2’deoxy-1β-D-arabinofuranosyl-5-[124I]iodouracil ([124I]-FIAU) is an example of a 
gene marker (Carlin et al., 2009). There is also an increasing interest in imaging 
drug resistance pathways, and [11C]-daunorubicin and [11C]-verapamil have 
been used to monitor P-glycoprotein-mediated multidrug resistance in rodent 
tumour models (Wanek et al., 2012).  
 
PET can also be used to study pharmacokinetics of drugs. To do so, drugs of 
interest need to be radiolabelled with positron emitting isotopes such as 11C, 13N, 
18F or 124I, and examples of drugs labelled for PET imaging include [18F]-5FU 
(Zissen et al., 2011), [11C]-temozolomide (Saleem et al., 2003), [13N]-cisplatin 
(Ginos et al., 1987), and [18F]-tamoxifen (Inoue et al., 2009).  
 
Although it has many advantages, PET also has its limitations. Not all drugs can 
be labelled. The parent drug needs to contain, for example, a fluorine atom to 
be labelled with [18F]; however, even then, it might not be possible to achieve 
radiolabelling. If the radiolabelling requires protracted chemical and purification 
steps it may not be feasible due to the short half-life of many PET isotopes, and 
the precursors necessary for radiolabelling may also not be available or the 
position of the label may not metabolically stable. PET images or physical 
resolution can be quite poor and there is also a lack of chemical resolution, i.e. 
PET images do not directly distinguish between the parent radiotracer and its 
metabolites. Lastly, the costs of the equipment and the radiochemistry 
necessary might also be a limitating factor as reviewed by Workman et al. 
(2006).  
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In Table 1.2 are indicated the positron-emitting nuclides of common usage in 
PET with their individual half-life in minutes.  
 
Nuclide Half-life (min) 
11C 20.4 
13N 9.96 
15O 2.03 
18F 109.8 
68Ga 68.3 
82Rb 1.25 
99mTc 52 
124I 6 x 103 
 
Table 1.2: Positron-emitting nuclides of interest in PET.  Adapted from Bailey and Towsend (2005). 
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1.4 Magnetic Resonance Imaging 
Purcell, Torrey and Pound, independently with Bloch, Hansen and Packard, 
formed the two physics groups which in 1946 began the nuclear magnetic 
resonance field.  Purcell and Bloch demonstrated empirically the nuclear 
magnetic resonance phenomenon by proving that, when placed in a magnetic 
field, some nuclei (including hydrogen) would rotate with a frequency 
proportional to the field strength due to their intrinsic magnetic moment (Buxton, 
2002). From 1946 until the 1970s the main use for Magnetic Resonance (MR) 
was in physics and chemistry, with the use of Magnetic Resonance Imaging 
(MRI) expanding from the 1970s onwards (Reiser et al., 2008). 
  
It was Bloch who first hypothesized that charged particles, when spinning, 
create a magnetic field and act like a bar magnet (Hashemi et al., 2003). Nuclei 
have a ground state of non-zero angular momentum or angular spin, I, when 
they possess an odd number of protons and/or neutrons. This property is a 
result of the intrinsic angular moments and the orbital angular momentums of 
the protons and neutrons which constitute the nuclei. The angular momentum of 
an atomic nucleus is proportional to the magnetic moment, µ, and the 
proportionality factor is the gyromagnetic ratio, γ, which is a characteristic of 
each nuclide. The hydrogen atom is widely used in MR studies due to 3 
characteristics: it has a spin quantum number (s) of ½, it is the most abundant 
nucleus in biological systems and it has the largest gyromagnetic ratio of all 
stable nuclei (Reiser et al., 2008).  
 
The angular spin of atomic nuclei is the result of the summation of the spins of 
all the individual components of the nucleus, i.e. protons and neutrons. In the 
example of the hydrogen atom, the nuclear spin is caused by the spin of a 
single proton. From quantum theory, each atomic nucleus has specific energy 
levels and, in the case of hydrogen example, the proton has two energy states 
which can be + 𝟏
𝟐
 or - 𝟏
𝟐
, the different energy states depending on the direction 
that each proton is spinning. The proton can either spin about its axis, creating 
a magnetic field, pointing north (“parallel”), or south (“anti-parallel”), depending 
on the direction of spin. The protons in different energy levels can pair in order 
to cancel out each other’s magnetic field and create a total nuclear magnetic 
field which is null. In nuclei with an odd number of protons there will be one 
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unpaired proton in one of the energy states which will create a nuclear net 
magnetic field or magnetic dipole moment that is non-zero (Hashemi et al., 
2003). When subject to a magnetic field, the proton suffers a torque by its net 
magnetic field which will make the dipole align with the external magnetic field 
(excluding any other effects). However, due to the angular spin of the proton, it 
does not align instantly with the magnetic field but rather precesses around it 
(Buxton, 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Depiction of the precession phenomenon of a magnetic dipole. B0 stands for the external 
magnetic field which exerts a torque in the magnetic dipole that due to its spin will precess at an angle with 
the gravitational field rather than aligning with the external magnetic field. ω0 is the precession frequency 
and is proportional to the magnetic field. Adapted from Buxton (2002).  
As illustrated in Figure 1.9 the frequency of precession of the proton in the 
magnetic field, ω0, is the frequency of nuclear magnetic resonance, also named 
the Larmor frequency, and it is directly proportional to the strength of the 
external magnetic field. The equation describing the Larmor frequency (ω0) is: 
𝜔0 = 𝛾𝐵0 
where B0 stands for the external magnetic field and γ is the previously defined 
gyromagnetic ratio, unique for each nucleus. The units for ω0 are MHz/T and 
the Larmor equation is the fundamental equation in magnetic resonance 
imaging (Buxton, 2002). As stated previously, all the protons in the nuclei have 
their own magnetic dipole moment which in the absence of a magnetic field 
allows them to spin around their own axis in random directions, cancelling each 
other. When placed in a magnetic field, the protons will align with the external 
magnetic field. Although approximately half will be parallel and the other 
antiparallel, and hence cancel each other, more will align with the direction of 
the magnetic field, B0, creating a net magnetization, M0, which is in the same 
direction as B0 (Hashemi et al., 2003). As indicated above, once the proton is 
magnetic dipole 
spin 
axis 
ω0 
B0 
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placed in a magnetic field, it precesses around the magnetic field axis. The first 
few rotations only approximate towards the magnetic field axis, but after several 
rotations the proton will be aligned with the magnetic field as the alignment is 
the lowest energy state for the system. If the proton is aligned in a direction 
opposite to the magnetic field it is in the highest energy state and will have to 
return to the lowest state, precessing towards alignment and releasing the 
remaining energy as, for example, random thermal motions of molecules. The 
time a proton takes to undergo this relaxation process is called T1 or the spin 
lattice relaxation time. 
 
The net magnetization of a sample, M0, has the same direction as the external 
magnetic field, B0, and so cannot be measured. However, if M0 changes 
direction and diverts from B0 it will subsequently relax and precess towards the 
lower energy state. To obtain directional deviation the net magnetization vector 
is altered with a radio frequency (RF) pulse, which is an electromagnetic wave 
and, hence, an oscillating magnetic field (albeit several orders weaker than B0). 
If the RF pulse has a frequency that matches the precession frequency, ω0, a 
resonance phenomenon will take place and M0 will precess in a spiral moving 
away from the B0 axis as long as the RF pulse is on. The angle formed by the 
tipped M0 and B0 is called the flip angle, θ (Figure 1.10).  
 
Figure 1.10: Representation of the interaction of a RF pulse and the net magnetization, M0, of a sample 
and how that causes M0 to precess away from the axis of the external magnetic field, B0. The angle 
between M0 and B0 at the moment the RF pulse is turned off, is represented by the flip angle, θ. Adapted 
from Hashemi et al. (2003).  
Tipping of nuclei, a proton in the case of hydrogen, can only occur if the RF 
pulse and its magnetic field, B1, oscillate at the precessional frequency of the 
nuclei. Under such conditions the RF pulse adds energy to the protons in a 
process called resonance. When the RF pulse is turned off the net 
magnetization precesses back to alignment with B0, which translates into a 
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moving magnetic field that in the presence of a coil will induce a current in it. 
This current is measurable and proportional to the precessing magnetization 
and is called the free induction decay (FID), free because as soon as the RF 
pulse is off the nuclei can precess freely, decay because the signal is transient 
and induction because it induces a current in the coil (Buxton, 2002).  
  
All magnetic resonance imaging requires a magnet to provide the external 
magnetic field, B0, and there are three main types of magnets: permanent 
magnets, resistive magnets and superconducting magnets. The first are 
permanently on and have low costs and maintenance. The resistive magnets 
use the electromagnetic principle by which an electric current running through a 
magnet generates a magnetic field, and these magnets can be turned on and 
off. Finally the superconducting magnets are a special version of resistive 
magnets with the difference that they operate near absolute zero temperatures 
so the resistance to electrical current is negligible. In superconducting magnets 
very strong electric currents generate high strength magnetic fields without 
generating too much energy. To achieve and maintain the low temperatures 
cryogens have to be used, namely liquid nitrogen and/or liquid helium, making 
these magnets very expensive to run. Nevertheless superconducting magnets 
are the most common magnets available in the market.  
 
Another essential component in NMR is the coil. A coil is composed of several 
loops of wire which can either generate a magnetic gradient (gradient coil) or an 
oscillating magnetic field (RF coil). RF coils can provide the transmission and/or 
reception of RF pulses.  Gradient coils can cause variations in the magnetic 
field which can be used for spatial location or to create a more homogeneous 
magnetic field, B0 (shim coils). The transmitter/receiver coils have different 
configurations, from surface to volume coils, and are optimized for different 
imaging requirements, for example, the time of acquisition, spatial resolution, 
and signal to noise ratio (SNR). 
 
The flip angle caused by an RF pulse can be controlled by the strength of the 
pulse (B1) and its duration, τ. The flip angles are commonly 90° or 180°, but 
partial flips where the angle is less than 90° can be used depending on the 
study. The relaxation time, T1, defined above, refers to the longitudinal 
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relaxation time that the spins take to realign with the magnetic field, B0, axis. It 
is also the time the spins take to dissipate the energy accumulated during the 
RF pulse to the surrounding lattice, thus T1 is also known as the spin-lattice 
relaxation time.   
 
Using a xyz axis, net magnetization, M0 can be described as the sum of the 
vectors Mz where the z axis has the same direction as B0, and Mxy where xy is 
the perpendicular plane to B0. In the resting state, Mz is equivalent to M0 as the 
vector does not possess a component in the xy axis. If a 90° pulse is used to tip 
M0, Mz will become null and the Mxy will become equal to M0. As soon as the RF 
pulse is off, Mz starts to increase as Mxy starts to decrease as a result of the 
precessing of M0 towards alignment with B0. At the same moment, all the spins 
are in phase (lined up in the same direction and spinning at the same 
frequency). However, due to interactions with other spins (each proton has its 
own spin and creates its own small magnetic field as a moving particle) and/or 
due to the inhomogeneities of B0, the spins start to spin out of phase. If T1 is the 
relaxation time that represents the time Mz takes to increase from 0 to M0, T2 
represents the time Mxy takes to go from M0 to zero. This is called the 
transverse relaxation time or spin-spin relaxation time and, in the case of 1H 
spins within water molecules in vivo, is five to ten times shorter than T1. T2 
depends mainly on the tissues in the sample, and so cannot be controlled. T2* 
is equally affected by the spin to spin interaction as well as by the external 
magnetic field inhomogeneities, making it shorter than T2. Both T1 and T2 are 
inherent properties of the sample tissue and so not directly controllable (i.e. only 
by means of contrast agent injection).  
 
Only one signal, from one FID, is not enough to acquire any spatial information 
from the sample, as it represents signals from all the protons of the sample with 
no spatial discrimination. One solution is the use of gradient coils to spatially 
encode the signal. This translates into several RF pulses emitted while the 
gradient across the sample varies, returning multiple FIDs which will allow the 
reconstruction into an image. (Hashemi et al., 2003) The series of RF pulses 
have to have an interval between them to allow the spin to recover before it is 
tipped again. This interval period is called the Repetition Time (TR). After a net 
magnetization M0 is tipped by an RF pulse into the xy plane (Mxy) it will start to 
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precess back to alignment with the z axis with a time constant T1. After a period 
of time (TR) another RF pulse is applied to the sample tipping Mz back to the xy 
plane. If TR is very long (>5xT1), the spin will have recovered and Mz will be 
equal to M0 before the second RF pulse. In most cases TR is smaller (<5xT1) so 
that at the moment the spin is tipped again, M2 is smaller than M0. The result in 
terms of signal for this chain of RF pulses will be a series of exponential curves 
that do not reach full magnetization.  
 
The interval between the turning off of the RF pulse and the acquisition of the 
FID is controllable and is the echo delay time (TE). Due to this time delay in the 
acquisition time, the FID is only a fraction of the maximum signal intensity. 
However, the FID can be corrected by knowledge of the T1 and T2 curves. As 
discussed above, T1 is specific for each tissue/material and different tissues can 
be imaged in the same scan. If TR is too short, the differences between tissues 
will be impossible to determine as the signal acquired will be too weak. If on the 
other hand TR is too long, the differences in T1 will not allow differentiation of 
the tissues. Ideally, TR should be chosen according to the T1 of the tissue being 
studied. Another approach to enhancing tissue contrast is to vary the TE. Due 
to the different compositions of different tissues, T2 and T2* are different, and TE 
can be varied to exploit the differences. If TE is too short, although the signal 
strength will be high, there will be little difference between tissues. If on the 
other hand TE is long, the differences in T2/T2* in different tissues will 
accentuate the tissue contrast but with a low SNR. For example, water, due to 
its sparse molecular structure, has a long T2 and also a long T1; solids, in 
contrast to water, have a compact structure which translates into a short T2 and 
an intermediate T1. Fat has natural motional frequencies identical to the Larmor 
frequencies where energy transfer to and from the lattice is very efficient when 
T1 is very short T2 intermediate (Hashemi et al., 2003).  
 
MRI is a technique which allows anatomical imaging, very often in three 
dimensions. Therefore, the localization of a signal acquired from a patient is 
essential. The knowledge that the resonant frequency generated by an atom is 
directly proportional to the strength of the magnetic field at the nucleus location 
is used in the creation of magnetic field gradients in the magnet. Three gradient 
coils are part of the MRI scanner and each generates linear variation in the 
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magnetic field along each axis. However, there are alternative means of 
providing localization in MRI, and slice selection, frequency encoding and phase 
encoding are three ways of allowing localization in three spatial directions. In 
slice selection, the RF pulse used is constricted to a narrow range of 
frequencies centred on the intended frequency ν0. Due to the gradient field, only 
a narrow spatial band in the body will resonate according to the band of 
frequencies in the RF pulse. The location of the slice changes when the central 
frequency ν0 changes and/or with variation in the gradient, and the slice 
thickness is dependent on the bandwidth of the RF pulse. If the slice selection is 
able to narrow the location of a signal to a spatial band, the location in the plane 
perpendicular to the magnetic field B0 direction is still missing, and hence 
frequency and phase encoding are used. Considering the direction of B0 as 
being the z axis, after an excitation RF pulse a negative field gradient pulse is 
turned on along the x axis. This negative x-axis pulse is followed by another 
one, this time a positive x-gradient, causing a gradient echo to occur halfway 
through the second gradient pulse. The gradient echo can be defined as a 
gradient which causes dephasing spin vectors to change their precession 
direction by 180°, forcing them to refocus and phase once more. The frequency 
encoding process results in a sum of signals over a range of frequencies along 
the same direction. Each frequency corresponds to a different signal and signal 
amplitude which, by means of a Fourier Transform, is converted into a spatial 
location along the x axis. However, the signal is still a line over the y axis. To 
overcome this issue, a phase encoding technique is used. Similar to the 
frequency encoding technique, phase encoding applies a gradient along the y 
axis which makes the transverse magnetization precess at different rates along 
the axis while the gradient is on. When the gradient is turned off the spins 
precess at the same rate but at a different phase, depending on their position in 
the y axis, allowing a precise location of the FID signal (Buxton, 2002).  
 
As discussed above, MRI scans are performed with the use of not one single 
RF pulse but several RF pulses over a period of time. The RF pulses are 
optimized (frequency, TR, TE) for each study and are used several times in a 
sequence. There are three “classical” pulse sequences: saturation recovery 
sequence, inversion recovery sequence and spin-echo sequence. A system is 
said to be saturated when the longitudinal magnetization has just been flipped 
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into the xy plane (perpendicular to B0 direction) by a 90° pulse. Therefore, a 
saturation recovery sequence is formed by a series of 90° pulses emitted with a 
certain time interval between them (TR) (Figure 1.11). 
 
Figure 1.11: Pulse scheme for the saturation recovery sequence. Adapted from Reiser et al. (2008).   
As shown in Figure 1.12, the inversion recovery method differs from the 
saturation recovery technique by using a 180° pulse (an inversion pulse which 
inverts by 180° relative to the longitudinal magnetization) before the emission of 
a 90° RF pulse (readout pulse). There is a time interval between the 180° and 
90° pulse which is called the inversion time Ti. At t=Ti there is a partially relaxed 
net magnetization along the z axis which the 90° pulse will rotate into the xy 
plane. As soon as the 90° pulse is off the FID signal is acquired. 
 
Figure 1.12: Pulse scheme of the inversion recovery sequence. Adapted from Reiser et al. (2008).  
As described above, T2 and T2* are dependent on fluctuating local magnetic 
fields and inhomogeneities of B0. While the effect of fluctuating local magnetic 
fields cannot be reversed, spatial inhomogeneities in the magnetic field B0 can 
be compensated for by the use of a spin-echo sequence.   
 
 
 
Figure 1.13: Pulse scheme of the spin-echo sequence. Adapted from Reiser et al. (2008).  
In a spin-echo sequence a first 90° RF pulse is used to tip the magnetization to 
the xy plane. Once the RF pulse is off, the precession rate towards B0 is 
different across the components of the magnetization ending the initial phase 
coherence. After a brief time interval, τ, a 180° pulse is emitted along the x axis 
180° 90° 
τ 
acquisition 
t τ 
TE 
180° 90° 
Ti 
acquisition 
t 
90° 90° 90° 
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t 
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causing the magnetization components to be mirrored in that axis. This pulse 
inverts the distribution of the components causing the faster precessing 
components to follow the slower ones, at which point all the components phase 
at a time which is the double of τ, maximizing the signal and generating a spin-
echo. The FID signal acquisition then starts at t = TE = 2τ (Figure 1.13). The 
180° pulse makes the spin-echo signal independent of the inhomogeneities of 
the magnetic field B0 but still dependant on the local fluctuating magnetic fields 
(Reiser et al., 2008).  
 
An MR image can be described as a picture of different precessing 
magnetizations at a finite time point. At that moment the magnetization will have 
a transverse magnetization value and a local phase angle. Different spins will 
have different magnetization values and different phase angles, depending on 
their precession rate, so the MRI image is a distribution of signal intensities in a 
xy axis. The imaging process involves measurement of a data matrix in which 
the signal induced by one phase encoding step constitutes a line in the matrix. 
The repetition of phase encoding steps allows the construction of a data matrix, 
named k-space, in which axes are referred to as spatial frequencies (Buxton, 
2002). The image can then be reconstructed by means of a two dimensional 
Fourier method. The slice selection is made by an RF pulse, as previously 
explained, and the spatial encoding of the spin in the slice is achieved by a 
combination of frequency and phase encoding by means of two orthogonal 
gradient fields. The repetition of this process N times with the MR signal being 
measured M times will create a matrix of NxM data points. The Fourier 
transformation of this k-space matrix returns an MR image of the selected slice 
with a resolution of NxM pixels. This method can be extended to a three 
dimensional method by replacing the slice selection gradient by a second phase 
encoding gradient. The RF pulse will excite all the spins inside the volume of 
the RF coil and the spatial information is then encoded by two phase encoding 
gradients and one frequency encoding gradient. The third element in the k-
space matrix is the number of phase encoding steps, K. In this case, the image 
sequence needs to be repeated NxK times and the Fourier transform of the k-
space matrix will return an image with NxMxK pixels (Reiser et al., 2008). 
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1.4.1 Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-
MRI)  
The development of MRI has benefited the diagnosis, grading and classification 
of tumours, to such an extent that it is now used for planning of therapy 
approaches in many tumour types. MRI can provide not only clear anatomical 
information on structures, but also helps to identify pathological changes in 
structures. Tumour and tissue morphology can be imaged in several planes or 
even in three dimensions. With the introduction of contrast agents MRI acquired 
more tools for diagnostic or staging information, and gadolinium-based contrast 
agents usually have low molecular weights and are paramagnetic (substances 
with unpaired orbital electrons which cause an increase in the local magnetic 
moment) (Jackson et al., 2005).  
 
Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) is a 
technique where several images are acquired before, during and after the 
administration of a contrast agent. The result of this procedure is influenced by 
several properties of the tumour, namely tumour perfusion, vessel permeability 
and extravascular/extracellular space. DCE-MRI is currently used in cancer 
detection, diagnosis, staging and treatment response assessment.  DCE-MRI 
provides measurements of permeability and its aberration, and tumour 
microvascular measurements using DCE-MRI are indicators of tumour grade, 
microvessel density, vascular endothelial growth factor (VEGF) function and 
recurrence and/or survival outcomes. These properties allow DCE-MRI to be 
used as both a pharmacodynamic and surrogate response biomarker. DCE-MRI 
can assess the uptake and clearance of contrast agents in tumour tissue 
providing information about tumour tissue properties at a microvascular level. 
Microvascular properties can be altered by treatment with anti-vascular drugs, 
making DCE-MRI a valuable non-invasive imaging biomarker. In the imaging of 
brain lesions DCE-MRI provides insight into the extent of the lesion, its 
microcirculatory properties, angiogenic profile and heterogeneity. Lastly, by 
characterizing changes in tumours prior to volume changes, DCE-MRI can be 
used to predict the outcome of a specific treatment (Reiser et al., 2008).  
 
During the initial phase of growth, cancer can develop without vasculature by 
obtaining nutrients and expelling waste materials through simple diffusion. 
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However, this limits the size the tumour can achieve and consequently tumours 
start to develop vasculature through angiogenesis. Tumours are formed by 
metabolically active cells with a high demand for oxygen and nutrients, and 
hence new vasculature does not develop with a normal tissue morphology. The 
vasculature in tumours can be very heterogeneous with distorted and coarse 
capillaries, and the vessels are often fragile and insufficiently differentiated. 
Gaps or holes are frequently observed in the capillaries, with enlarged inter-
endothelial junctions and an incomplete or non-existent basement membrane.  
All these defects make the transcapillary permeability very high, in some cases 
high enough to allow the leakage of red blood cells. 
 
Figure 1.14: a) An avascular tumour releases VEGFs promoting angiogenesis of blood vessels to supply 
the tumour with nutrients and oxygen. The new blood capillary can be formed from existing small vessels. 
The capillary develops until it reaches another vessel to allow blood circulation. b) Voxel of a tumour 
vessel which might be used in the imaging by MRI. Usually, high resolution MRI is required to distinguish 
the smaller capillaries. c) zoomed region of a tumour vessel. The different numbered lines represent time 
intervals which correlate with the graph in the lower left. On the right the injection of contrast agent at t=2 is 
followed by the diffusion of the contrast agent through the gaps in the capillary to the extravascular space. 
That translates with a peak of contrast agent (and MR signal) at t=3 which precedes an clearance of the 
contrast agent. Copied from Jackson et al. (2005). 
As it can be seen in Figure 1.14, straight after the injection of contrast agent 
given intravenously to a subject it will distribute throughout the vascular system. 
Healthy tissue is provided with a consistent vascular network, and hence the 
contrast agent travels through with minimal leakage, causing a momentary 
increase in the MR signal. However, when it reaches a tumour, due to the leaky 
nature of the vasculature, the contrast agent extravasates into the extravascular 
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space by simple diffusion. This extravasation causes a substantial increment in 
the MR signal from the tumour which persists over time when compared with 
normal tissues. After a period of time, the contrast agent returns to the vessel 
and is cleared from the blood system through the kidneys and excreted. 
Variations in regional blood flow or haematocrit, which can be proportional to 
blood vessel density and the vascularization of the tumours, or variations in the 
surface area permeability of the endothelial membranes, are mechanisms which 
underlie the signal enhancement patterns visible in DCE-MRI. More aggressive 
tumours can induce faster angiogenesis which can accentuate abnormalities in 
the new capillaries, and this feature can result in DCE-MRI being a marker of 
angiogenic activity.  
 
DCE-MRI data can be acquired by two methodologies: relaxivity-based 
methods and susceptibility-based methods. Relaxivity-based methods use T1 
weighted acquisitions. Susceptibility-based methods use T2 or T2* sequences to 
acquire the data. Both methods have advantages and disadvantages, and are 
used for different applications. In the studies described in this thesis only 
relaxivity-based DCE-MRI has been used in which T1 weighted images assess 
relaxivity effects while dynamic data are being acquired. Relaxivity contrast 
mechanisms rely strongly on the contrast agent and so effects can only be 
visualized in the immediate region surrounding the contrast agent location 
(Jackson et al., 2005). That is due to the fact that for imaging at fields of 0.1T or 
higher, the relaxivity of bound water (1/T1m) is given by the equation: 1
𝑇1𝑚
= 𝐶
𝑟𝐺𝑑𝐻
6 �
3𝜏𝑐1 + 𝜔𝐻2𝜏𝑐2� 
where C represents several physical constants, rGdH is the Gd-water distance, τc 
is a correlation time for magnetic fluctuation and ωH is the Larmor frequency 
(Dumas et al., 2010).  
  
The pulse sequences used to acquire T1 weighted DCE-MRI commonly employ 
gradient echo-based sequences such as GRASS, FISP or FFE. 
  
In DCE-MRI, the essential element is the contrast agent. There are several 
different contrast agents available for MRI studies and many more being 
developed. Paramagnetic gadolinium chelates are the most commonly used 
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contrast agents (Jackson et al., 2005), the gadolinium ion interacting with 
nearby hydrogen nuclei. This interaction results in a shortening of the T1 lattice 
relaxation time in local tissue water, which increases the signal intensity in T1 
weighted images. The enhancement of the signal depends on physiological and 
physical factors, such as tissue perfusion, arterial input function, volume of the 
extracellular extravascular leakage space, capillary permeability and capillary 
surface area (O’Connor et al., 2007). Table 1.3 lists some available gadolinium-
based contrast agents.  
 
Generic name Product/Trade Name 
Gadopentetate dimeglumine Magnevist 
Gadoterate meglumine Dotarem 
Gadodiamide Omniscan 
Gadoteridol ProHance 
Gadobutrol Gadovist 
Gadoversetamide Optimark 
Gadobenate disodium MultiHance 
Gadoxetate disodium Primovist/Eovist 
Gadofosveset trisodium Vasovist/Ablavar 
  
Table 1.3: Gadolinium-based contrast agents. Copied from Singer (2010).   
 
Contrast agents are predominantly excreted by the kidneys and share similar 
pharmacokinetics, the only exception being gadobenate disodium (MultiHance) 
which has weak protein binding properties and can be excreted through the liver. 
Gadomer-17 or albumin-GdDTPA are examples of macromolecular agents with 
molecular weights (35 and 65 kDa, respectively) which allows them to remain in 
the intravascular space for several hours. Nevertheless, these complexes still 
leak out of very permeable capillaries so can be used as a measurement of 
endothelial permeability (Jackson et al., 2005).  
 
A DCE-MRI study starts with the injection of a contrast agent into the subject. 
The MRI images are acquired from a single slice or a group of slices covering 
the tissue of interest. Morphological and/or functional parameters can be 
extracted from the MRI image, such as fractional plasma volume and 
transendothelial permeability, which can be used to model the tissue 
vascularization. A Region Of Interest (ROI) can be then drawn to define the 
highly vascularized tumour area (Castellani et al., 2009). 
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From the simple signal intensity vs time curve a description of the contrast 
agent distribution can be inferred. However, for a more robust analysis of 
contrast agent kinetics, the signal intensity must be converted to contrast agent 
concentration although the relationship is not linear.  Calculation of the initial 
area under the contrast agent concentration vs time curve (IAUC) provides a 
model-free and reasonably reproducible biomarker for use in clinical trials.  
However, there are still uncertainties in the relationship between the IAUC and 
the underlying tumour physiology. Simple pharmacokinetic models, describing 
the volume transfer coefficient for the contrast agent between the blood plasma 
and the extracellular/extravascular leakage space (EES) (Ktrans) and the size of 
the EES (νe), complement IAUC in the analysis of the effect of antiangiogenic 
and vascular disrupting agents in clinical trials (O’Connor et al., 2007). The use 
of these measurements to assess antiangiogenic and antivascular therapeutics 
response has been recommended by Leach et al. (2003).Lancaster et al. (2005) 
and Walker-Samuel (2006) have demonstrated that IAUC correlates very 
strongly with Ktrans and νe being a quantitative parameter obtained without 
mathematical modelling. In Table 1.4 is shown a comparison between 
parameters measured by DCE-MRI based on a paper published by Cheng 
(2009). 
 
“Quantitative” parameters: Ktrans, νe   “Semi-quantitative” parameter: IAUC 
• Model-based; 
• Pharmacokinetic parameters 
measuring blood flow and/or 
endothelial permeability; 
• Hard to measure due to parameters 
coupling, arterial input function (AIF) 
measurement, water exchange and 
model fit instability. 
• Non-model-based; 
• Does not require AIF measurement; 
• Is not affected by noisy data; 
• Lack of clear biological association. 
 
 
Table 1.4: Comparisons between parameters measured by DCE-MRI. Adapted from Cheng (2009).  
 
There are several models that have been applied to clinical trial data to 
calculate Ktrans and νe. The exact meaning of Ktrans depends on the kinetic model 
used for the analysis of the DCE-MRI data, and within the same patient cohort 
changes in Ktrans may reflect different physiological processes in different 
individuals such as reduced blood flow, reduced permeability or a combination 
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of both. The analysis techniques chosen have to accommodate a compromise 
between relatively simple but unspecific or unstable models and physiologically 
congruency. Although DCE-MRI is more complex than simple anatomical 
imaging, T1 weighted DCE-MRI provides very relevant information about tumour 
biology and response to treatment (O’Connor et al., 2007).  
 
 
1.4.2 Spectroscopy – 1H/ 31P 
The frequency of nuclear spins is not only determined by the gyromagnetic ratio, 
and if this was the only differentiating factor nuclei of the same element or 
isotope would resonate at the same frequency in a homogeneous magnetic field, 
regardless of the molecule they were in. However, the resonance frequency of a 
nucleus is also influenced by the chemical environment surrounding it. The 
spinning nuclei are shielded by the electrons which surround them, and in an 
external magnetic field (B0) the electrons rotate around B0 in an opposite sense 
to the precession of the proton spin. Electrons are negatively charged particles, 
and hence their movement will create a magnetic field, μe, which opposes B0. 
Consequently, the nucleus will sense a reduced external magnetic field and, 
therefore, have a different resonance frequency.  This property is termed the 
chemical shift. The effective magnetic field, B, that the nucleus is exposed to 
can be expressed by the following equation: 
𝐵 = 𝐵0(1 − 𝜎) 
 where B is the effective magnetic field to the nucleus, B0 is the external 
magnetic field and σ is the shielding constant. This constant is dimensionless, 
and depends on the chemical environment of the nucleus. The chemical shift is 
also expressed in terms of ppm as the expression in Hertz units would make it 
dependant on the magnetic field strength. Chemical shift, δ, can be 
mathematically defined as: 
𝛿 = 𝜐 − 𝜐𝑟𝑒𝑓
𝜐𝑟𝑒𝑓
× 106 
 where ν is the frequency of the investigated compound and νref is the frequency 
of a reference compound. The ideal reference compound must be chemically 
inert and produce a strong (singlet) resonance signal in a region of the spectra 
away from all the other resonances. For proton (1H) spectroscopy 3-
(trimethylsilyl)propionic-2,2,3,3-d4 acid (TSP) is typically the reference used. In 
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phosphorus (31P) spectroscopy methylenediphosphonic acid (MDP) is one of 
the compounds used as a reference (de Graad, 2007).  
 
Magnetic resonance spectroscopy (MRS) is performed in the same scanner as 
standard magnetic resonance imaging. The technique exploits the absorption of 
electromagnetic radiation from RF pulses and data are presented as plots of 
absorption frequency vs peak intensities. The frequencies absorbed have their 
intensity modulated by the molecular composition of the sample. In theory MRS 
can be performed on any nuclei with an odd number of protons and neutrons, 
as in MRI. However, if the sum of the number of protons and neutrons is not an 
odd number, the SNR will be insufficient to achieve good quality data.  
 
In MR spectra peak intensities correspond to the relative number of chemically 
equivalent protons or other magnetic nuclei. Any resonance frequency is 
represented in ppm. In the case of 1H-MRS, protons in different local chemical 
environments will generate different resonance frequencies, providing 
spectroscopic differentiation of chemical compounds which can be very 
important physiologically.  
 
Spectroscopic data can be acquired by single voxel or multi-voxel techniques 
(Reiser et al., 2008). Three of the more commonly used sequences for single 
voxel spectroscopy are Stimulated Echo Acquisition Mode (STEAM), Point-
Resolved Spectroscopy (PRESS) and Image Selected in vivo Spectroscopy 
(ISIS). PRESS uses three slice selective radiofrequency (RF) pulses. To avoid 
observing signals from spins that experience only one or two of the RF pulses 
this sequence incorporates spoiler gradients. It has a rather large TE. The 
STEAM sequence also has three slice-selective RF pulses  and spoiler 
gradients as PRESS, however, the interval between the second and third 
pulses do not contribute to the effective echo time. Reducing TE results in a 
lower sensitivity when compared with PRESS but the ability to detect 
metabolites with short T2 or complex coupling patterns. The ISIS sequence 
does not use echo formation. In this sequence a 180º slice-selective pulse is 
used to prepare the magnetization prior to the excitation of the entire 
magnetization of the object by a 90º non-selective pulse. Although the data 
acquisition is performed immediately after the 90º pulse allows the detection of 
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signals that decay rapidly, motion during the accumulation of data can result in 
severe localization errors. Also, localized shimming is not possible with ISIS, in 
contrast with PRESS and STEAM. ISIS is commonly used for 31P-MRS 
(Gadian, 1995). Multi-voxel techniques increase the volume that can be imaged, 
and allows a comparison between normal and abnormal tissue concurrently and 
also two and three dimensional chemical shift imaging (CSI). This multi-voxel 
data are acquired at the cost of the acquisition time which increases when 
compared with the single voxel techniques, and can be acquired using either 
PRESS or STEAM sequences (Reiser et al., 2008).  
 
As stated above, MRS can be performed on any nucleus with a magnetic 
moment. In an in vivo MRS experiment, metabolically and pharmacologically 
more relevant nuclei which have a magnetic moment are proton (1H), carbon-13 
(13C), fluorine (19F), sodium (23Na) and phosphorus (31P). Although it is a limited 
number, each of these nuclei can provide extensive information about a large 
number of metabolites or drugs. Glutamate, GABA and aspartate are examples 
of important neurotransmitters that can be detected by 1H-MRS, and lactate is 
an important metabolite. Similarly, the tricarboxylic acid cycle can be studied in 
vivo and non-invasively by 13C-MRS, and intracellular pH, magnesium 
concentrations and energetically important metabolites like ATP can be 
assessed by 31P-MRS.  
 
1H-MRS 
A high gyromagnetic ratio and high natural abundance makes the proton the 
most sensitive nucleus for magnetic resonance imaging, and 1H-MRS can 
identify and quantify numerous biologically relevant compounds including 
cerebral metabolites. However, 1H-MRS faces some limitations, even in the 
brain, where it has been widely used, notably that the water resonance signal is 
several fold larger than that of low concentration metabolites, and other 
extracranial signals can also dominate the smaller metabolite signals and the 
spectral resolution can be diminished by inhomogeneities in the magnetic field. 
The water signal can be suppressed using a 180° saturation pulse focused 
around 4.7ppm which is the resonance frequency for protons in the water 
molecule. Optimizing the spatial localization, better shimming and/or gradient 
pulses can increase the SNR for the relevant spectrum.  
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1H-MRS has a further limitation; the chemical shift range is of 10ppm for non-
exchangeable protons. Several metabolite resonances overlap because of this, 
and hence their separation and quantification becomes very difficult. Therefore 
several spectral editing techniques have been developed to separate 
overlapping resonances. Spectral editing includes techniques to discriminate 
scalar-coupled from uncoupled spins. Techniques used for spectral editing 
include two dimensional NMR, where two different nuclei, i.e. 1H and 31P 
present in the same sample, can be imaged, and the information is coupled to 
establish connections and identify atoms in molecules. 
 
Absolute concentrations can, in principle, be calculated from spectra acquired 
by MRS, and expressed in mmol/L or mmol/g of tissue. Quantification is 
possible because the thermal equilibrium magnetization (M0) is directly 
proportional to the number of spins (n) which is proportional to the molar 
concentration. However, in an NMR scan an induced current proportional to the 
transverse magnetization is measured, rather than the thermal equilibrium 
magnetization. From first principles, the following equation describes the signal 
that a metabolite M induces in a receiver coil after a specific NMR sequence: 
𝑆𝑀 = 𝑁𝑆 × 𝑅𝐺 × 𝜔0 × [𝑀] × 𝑉 × 𝑓𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 × 𝑓𝑐𝑜𝑖𝑙 × 𝑁𝑝 
where NS is the number of scans, RG the receiver gain, ω0 the Larmor 
frequency, [M] the molar concentration, V the volume size, fsequence and fcoil 
functions which describe the signal modulation induced by the NMR pulse 
sequence and the coil, and Np the number of protons of the reference and the 
number of protons of the metabolite being studied. In these last elements, TR, 
TE, T1 and T2 number and type of RF pulses are included in the fsequence factor 
while the geometry and quality of the RF coil are elements of the fcoil factor. 
These last elements and factors are usually unknown making direct quantitation 
of the metabolite impossible. However, the concentration of the metabolite can 
be calculated by using a known concentration of a reference compound [R], and 
hence the concentration of metabolite M can be calculated by the equation: [𝑀] = [𝑅] 𝑆𝑀
𝑆𝑅
𝐶𝑀𝑅 
where SR is the signal collected by the receiver coil from the reference 
compound and CMR is a correction factor which arises from differences in T1 and 
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T2, diffusion, gyromagnetic ratio and several other differences between the 
reference compound and the studied metabolite. An alternative to this absolute 
quantitation is the expression of the metabolite level as a ratio to other 
metabolites. Although faster, metabolite ratios are ambiguous, and more 
generally, quantitation can be performed not only in 1H-MRS but also with the 
other nuclei as long as a suitable reference is provided. 
 
An important feature of 1H-MRS and MRI in general is that numerous 
metabolites can be analysed in a single spectrum. Figure 1.15 shows an 
example of a 1H-MRS spectrum acquired from an in vivo experiment using a rat 
brain in an 11.75T magnet (de Graaf, 2007).  
 
Figure 1.15: 1H-MRS spectrum acquired from an in vivo experiment with a rat brain at 11.75T. Although 
water suppression has not being used, the water peak has been removed from the spectrum, hence the 
gap between 4 and 6ppm. 17 different metabolites can be discerned: NAA (N-acetyl Aspartate), Glu 
(Glutamine), ATP(Adenosine Triphosphate), PCr(Phosphocreatine), Cr(Creatine), Glx(Glutamate+ 
Glutamine), Tau(Taurine), tCho (total Choline), tCr(total Creatine), Asp (Aspartate), Gln (Glutamine), 
Glu(Glutamate), GABA(γ-Aminobutyric Acid), Ala(Alanine), Lac(Lactate). Copied from de Graaf (2007).  
 
31P-MRS 
31P-MRS, similarly to 1H-MRS, has been widely used in pre-clinical and clinical 
research. Phosphorus has lower sensitivity when compared with 1H-MRS and 
has a 100% natural abundance which coupled with relatively large chemical 
shift dispersion under in vivo conditions (~30ppm) allows the acquisition of high 
quality and well resolved spectra in short scan times even at lower (clinical) 
magnetic fields. 31P-MRS can detect and quantify all the key metabolites 
involved in energy metabolism, and can also be used indirectly to measure 
intracellular pH. Due to its lower sensitivity, bigger voxels are required to 
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compensate losses in the SNR and only metabolites in reasonably high 
concentrations are detected. There are only a limited number of resonances in 
in vivo 31P-MRS spectra and their chemical shift is sensitive to intracellular pH 
(and ionic strength, i.e. magnesium which complexes with phosphorus). 
Phosphocreatine (PCr) is by convention used as an internal chemical shift 
reference and assigned a chemical shift of 0.00ppm. ATP has chemical shifts of 
-2.48ppm (γ phosphorus), -7.52 ppm (α phosphorus) and -16.26ppm (β 
phosphorus) while inorganic phosphate has a chemical shift of 5.02ppm at a pH 
of 7.2 and with full magnesium complexation (Figure 1.16) (de Graaf, 2007).  
 
Figure 1.16: 31P-MRS spectra from a in vivo scan of A) rat skeletal muscle, B) brain and C) liver. The 
metabolites identified are: inorganic phosphate (Pi), phosphocreatine (PCr), α,β and γ peaks of adenosine 
triphosphate (ATP), phosphomonoesters (PME), phosphodiesters (PD) and nicotinamide adenine 
dinucleotide (NADH). Copied from de Graaf (2007).  
Figure 1.16 also shows that it is also possible to detect phosphomonoesters 
and diesters (PME and PD). In the liver PCr can be absent; however, its 
presence in some situations indicates that surrounding muscular tissue is 
contaminating to the spectrum.  
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 A detailed study of artifacts encountered in the analysis of phosphorus 
metabolites by in vivo and ex vivo MRS has been published (Howe et al., 1993).  
 
As stated above, the chemical shift of compounds with phosphorus is affected 
by physiological parameters such as intracellular pH and magnesium 
concentration. When a phosphate containing compound complexes with 
magnesium the chemical environment of nearby nuclei is changed and hence 
its chemical shift changes. The pH can be described using a modified 
Henderson-Hasselbach relationship: 
𝑝𝐻 = 𝑝𝐾𝑎 + log �𝛿 − 𝛿ℎ𝑎𝛿𝑎 − 𝛿 � 
where δ refers to observed chemical shift, δa and δha are the chemical shifts of 
unprotonated and protonated forms of compound α and pKa is the logarithm of 
the equilibrium constant for the acid-base equilibrium between ha and a.  
 
Although almost all the resonances in 31P-MRS spectra are pH dependent, the 
most common way to measure the pH is from the distance between inorganic 
phosphate and phosphocreatine. However, this measurement cannot be used 
in all situations. Phosphocreatine is not detectable in liver or kidney or under 
pathological conditions such as tumour ischemia, hypoxia and anoxia. Also, the 
inorganic phosphate might be very low or shadowed by more intense 
resonances (e.g. in the heart). If phosphocreatine and inorganic phosphate are 
detectable in the tissue, pH determination has an accuracy of 0.05 pH units. In 
a similar fashion, ATP chemical shifts provide information regarding the free 
magnesium concentration (de Graaf, 2007). 
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1.5 Positron Emission Tomography   
Positron Emission Tomography (PET) is an imaging technique with an 
increasing role in the diagnosis and staging of malignant disease, and in 
monitoring therapy response.  
 
The development and progress of PET imaging systems was originally limited 
by innate physics. However, the introduction of novel scintillation crystal 
technology and detector electronics combined with the widespread availability 
of fast, efficient and iterative image reconstruction algorithms has resulted in a 
dramatic reduction in clinical imaging times combined with the required 
resolution, sensitivity and signal-to-noise properties (Dresel, 2007). In addition, 
the combination of PET functional imaging with anatomical imaging techniques 
such as Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) 
allows co-registration of anatomical/functional images, removing the need to 
transfer patients between equipment/facilities reducing greatly the time to 
perform multi-modal imaging scans.  
 
Atoms are the central unit of matter. An atom (X) is composed of a nucleus 
encasing protons (Z) and neutrons (N) and orbiting electrons. The sum of 
protons and neutron in a nucleus is the mass number A and a unique 
combination of protons and neutrons in a nucleus form a nuclide which can be 
represented by: 𝑿𝑵𝒁𝑨  . 
 
Radionuclides are unstable atoms due their nucleus being formed by an 
unstable composition of neutrons and protons or excess energy. These 
radionuclides decay into more stable configurations by the emission of radiation 
including α, β- or β+ particles, or by electron capture and isomeric transition.  
 
The unstable radionuclides decay randomly and proportionally to the number of 
radioactive atoms in the sample. Activity is the measure of the rate of decay of 
unstable nuclei in a specific instant and can be translated in the following 
equation:  
𝑨𝒕 = 𝑨𝟎𝒆−𝝀𝒕 
where At is the activity of a nuclide after time t, A0 is the amount of activity 
present initially and λ is the decay constant which is calculated by: 
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𝝀 = 𝐥𝐨𝐠𝒆(𝟐)
𝒕𝟏
𝟐
 
where t1/2 is the half-life for that radionuclide. Half-life is a unique characteristic 
of each radionuclide and is the time required to reduce to one half the initial 
activity. This physical half-life is for the free element and needs to be corrected 
for drug/tracer clearance when the radionuclide is in a pharmaceutical 
compound and has been delivered to a patient. In the setting of clinical imaging, 
the process of elimination of the radiolabelled drug by the body will characterize 
the biological half-life which is the time the biological system takes to eliminate 
half of the administered dose. 
 
The decay process specific to PET is the positron decay whereby a radionuclide 
rich in protons will decays by the emission of a positron (β+) along with a 
neutrino (ν). The positron is a subatomic particle with an equivalent mass to an 
electron but with a positive charge while the neutrino is a particle, produced 
during the β+ and electron capture decay of the radionuclide, with no charge or 
mass but variable energy. In simple terms, the excess proton in the nucleus is 
converted into a neutron plus a positron and a neutrino. This process is 
described by the following equation: 
𝒑+𝟏
𝟏 → 𝒏𝟎
𝟏 + 𝜷+𝟏𝟎 + 𝝊 
where p stands for proton, n for neutron, β+ for positron and ν for neutrino. The 
neutron is one electron mass heavier than a proton and so the right hand side 
of the decay equation has two more electron mass units than the left side. In 
order to conserve the energy in both sides of the equation, the radionuclide 
must have transition energy of at least 1.022 MeV. This value comes from the 
application of Einstein’s Special Theory of Relativity where it is established that 
there is an equivalency relationship between energy and mass. Applying this 
equation to one electron which has a rest mass (m) of 9.11x10-31 kg and the 
speed of light (c) that is 3x108 m/s we obtain: 
𝑬 = 𝒎𝒄𝟐 = 𝟗.𝟏𝟏 × 𝟏𝟎−𝟑𝟏 𝒌𝒈 × (𝟑 × 𝟏𝟎𝟖)𝟐 𝒎. 𝒔−𝟏 = 𝟖.𝟐 × 𝟏𝟎−𝟏𝟒 𝑱 
Using the conversion factor between energy in joules to energy in electron volts 
(eV): 
≡
𝟖.𝟐 × 𝟏𝟎−𝟏𝟒 𝑱
𝟏.𝟔 × 𝟏𝟎−𝟏𝟗 𝑱. 𝒆𝑽−𝟏 = 𝟓𝟏𝟏 𝒌𝒆𝑽 
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Hence the transition energy of a radionuclide in positron decay to be two times 
511 keV. 
 
Positrons are considered light charged particles and so move in a zigzag path, 
and their range is dependent on the density of the matter they pass through. 
The positron loses kinetic energy as it passes through matter by ionisation or by 
radiation after inelastic scattering which contributes to its zigzag path. The path 
length for the positron depends on the initial energy that the positron is emitting 
which is characteristic of the parent radionuclide. 
 
As illustrated in Figure 1.17, once the positron is almost at rest it will interact 
with an electron, resulting in the annihilation of both particles with the emission 
of electromagnetic energy. The electromagnetic energy is released in the form 
of two photons of 511 keV emitted at 180° to each other. This annihilation 
occurs outside the nucleus of the atom and, depending on the parent 
radionuclide, several millimetres away from the emission nucleus, adding 
uncertainty to the localisation of the decaying atom. As an example, the 
maximum range for a positron emitted by an 18F atom is 2.4 mm.  
 
Figure 1.17: From left to right: a proton (P) in an unstable parent nucleus decays to a neutron (N) emitting 
a neutrino (ν) and a positron (e+) which will annihilate with an electron (e-) and emit two 511 keV gamma 
photons (γ). 
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The high energy photons emitted by the annihilation of the positron can interact 
with matter by 3 main mechanisms: photoelectric effect, Compton effect and 
pair production, depending on the energy of the electromagnetic radiation as 
briefly explained bellow. 
 
The photoelectric process happens when γ radiation moving through an 
absorber transfers its entire energy to an electron from an inner shell of the 
atom causing the ejection of an electron. The vacancy in the shell will be filled 
by an electron transiting from an upper shell with the emission of the energy 
difference between both shells in the form of characteristic x-rays or by the 
Auger process. In the Compton scattering process the γ radiation transfers part 
of its energy to an electron in an outer shell of the absorbent atom. Due to its 
position in an outer shell, the binding energy of the electron is small and can be 
considered almost free, and this translates into the ejection of the electron from 
the outer shell while the γ radiation loses some energy and suffers a change in 
its path (scattering). Finally pair production happens when γ-rays with energy 
above 1.022 MeV interact with an absorber atom producing an electron and a 
positron. The combination of the three above mentioned processes creates a 
process of attenuation of the γ radiation. Attenuation can be expressed by a 
mono-exponential function when a well collimated source of photons and 
detector are considered: 
𝐼𝑥 = 𝐼0𝑒−𝜇𝑥 
where Ix refers to the beam intensity measured through a material of thickness x, 
I0 the beam initial intensity and μ the attenuation coefficient of the material. In 
PET as well as in SPECT (Single Photon Emission Computed Tomography) the 
attenuation of the γ radiation is a critical factor to consider and attenuation 
correction is provided in some reconstruction algorithms. 
 
Radiation detection exploits the interaction of ionising radiation with matter by 
detecting the energy lost or deposited by the radiation passing through the 
detector and converted into a measurable electrical signal or charge. Radiation 
detectors can be proportional (gas) chambers, semi-conductors or scintillation 
detectors. Gas chamber and semi-conductor detectors have low detection 
efficiency while scintillation detectors, due to their higher density, provide the 
highest stopping efficiency for 511 keV photons. Four main characteristics are 
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crucial in the selection of the PET detector: stopping power for 511 keV photons, 
scintillation decay time, light output per keV of photon energy and the energy 
resolution of the detector. The stopping power of the detector refers to the mean 
travelling distance of the photons, before they stop after complete energy 
deposition and is dependent on the density of the detector material. Scintillation 
decay time is the time interval between the γ ray interaction with an atom of the 
detector material (exciting it to a higher energy level), and the decay of that 
same atom to a ground state (of lower energy) emitting visible light (scintillation). 
Measured in nanoseconds, the scintillation time of the detector depends on the 
material which constitutes the detector and its efficiency is higher the shorter 
the scintillation decay time is. The energy resolution is improved not only by a 
higher light output but also by higher homogeneity in the crystal structure of the 
detector. Table 1.5 presents examples of crystals used in PET detectors and 
their properties. 
 
Property NaI(Tl) BGO LSO YSO GSO BaF2 
Effective Z 50 74 66 34 59 52 
Density (gm/cm3) 3.7 7.1 7.4 4.5 6.7 4.9 
Scintillation decay time (ns) 230 300 40 70 60 0.6 
Photon yield per keV 38 6 29 46 10 2 
Relative light output 100 15 75 118 25 5 
Linear attenuation coefficient, 
µ (cm-1) 
0.35 0.96 0.87 0.39 0.70 0.44 
Energy resolution (% at 511keV) 6.6 20 10 12.5 8.5 11.4 
 
Table 1.5: Properties of typical PET detector crystals. The crystal material acronyms stand for thallium-
doped sodium iodide NaI(Tl), bismuth germinate (BGO), lutetium oxyorthosilicate (LSO), cerium-doped 
yttrium oxyorthosilicate (YSO), gadolinium oxyorthosilicate (GSO) and barium fluoride (BaF2). Extracted 
from Saha (2005).   
 
The crystals are disposed in a matrix in the detector. The visible light 
(scintillation) produced by the interaction between γ radiation and the detector 
material needs to be transformed into a measurable electrical pulse, and 
transfer is achieved by photomultiplier tubes (PMT) attached to the crystal 
detector matrix. The photomultiplier consists in a vacuum glass tube with a 
photocathode in the entrance window (usually an alloy of cesium and antimony), 
ten dynodes in the middle and an anode in the other end. There is a high 
voltage difference of -1000 volts between the photocathode and the anode split 
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into 100 volt increments between each dynode. A scintillation photon will 
deposit its energy in the photocathode triggering the release of a photo-electron. 
Due to the positive potential between the photocathode and the first dynode the 
photo-electron will accelerate to the first dynode with increased energy. The 
impact of the photo-electron with the first dynode will cause the release of 
multiple secondary electrons which will accelerate towards the second dynode 
due to the positive potential difference, and for each electron, several 
secondary electrons will be released at impact. As shown in Figure 1.18, this 
process is repeated until the last dynode releases a pulse of electrons towards 
the anode which transmits the signal to a preamplifier.  
 
Figure 1.18: Schematic diagram of a photomultiplier tube and a photograph of a hexagonal 6 cm-diameter 
tube (inset). Seven to ten light photons cause the release of approximately one to three electrons 
approximately. Copied from Bailey and Towsend (2005).  
The signal delivered to the preamplifier is then amplified to a detectable pulse, 
which is analysed by a pulse height analyser before reaching the computer. The 
pulse height analyser is responsible for separating the true coincidences (the 
ones which arise from a single positron-electron annihilation) from single events 
(single photons reaching the detector), randoms (two nuclei decay at 
approximately the same time but only two of the four photons reach the 
detectors causing a localisation error), multiple (three or more photons are 
detected in the same time window) and scattered events (due to Compton 
interaction one photon loses energy and changes direction). There are several 
detector conformations for PET scanners but the most usual is a ring of 
detectors which surround the patient bed. 
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 The patient being scanned is injected with a PET tracer which has a positron 
emitting radionuclide incorporated in it. The two 511 keV photons resulting from 
the annihilation of the positron-electron interaction are detected within an 
electronic time window (in the order of 10 nanoseconds) and by a pair of 
opposite detectors (in a ring) when travelling along a straight line between the 
centres of the two detectors (line of response, LOR).  
 
Figure 1.19 (copied from Saha, 2005) depicts the positron-electron annihilation, 
signalled as a *, and how the resulting photon detection generates a record in 
the sinogram.  
 
Figure 1.19: Representation of the detection of a true coincidence and its registration in a sinogram. 
Extracted from Saha (2005). 
The resulting pair of 511 keV photons are emitted along the LOR and detected 
in the pair of opposite detectors within the time window. Because the time 
difference of the photons arrival is not measured, it is not possible to determine 
the exact annihilation point. However, the distance of the LOR from the centre 
of the scan field (r) and the angle between r and the vertical axis of the field (φ) 
are stored in sinograms. The sinogram is a two dimensional histogram of the 
coordinates of the LORs in a specific plane (events in the same LOR will add up 
in the same pixel of the sinogram), and the end of a PET scan acquisition, the 
sinogram is a composite of all the coordinates of all the LORs over the scan 
time.  
The sinogram can be affected by several factors during data acquisition. PET 
scanners have a few thousand detectors coupled to hundreds of PMTs. 
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Normalization of the data allows the correction of variations in the gain of 
different PMTs, sensitivity of a detector pair and physical variation in the 
detector. Due to the fact that the radiation is emitted within a body, attenuation 
may occur. To compensate for that effect attenuation correction based on the 
knowledge of the attenuation coefficient and the thickness of the organ, tissue, 
body, that the radiation has to go through is applied. Random coincidences can 
also be minimized by the use of faster electronics, shorter time windows or a 
combination of standard time windows (which contain true and random events) 
and a delayed time window in the same energy window (which will only have 
the random events and will be subtracted from the acquisition in the standard 
time window). Scatter events are mainly discarded by the pulse height analyser 
due to energy differences in each detector. Another factor to be considered is 
the dead time, the time interval between a 511 keV photon interaction with the 
detector and the recording of a true coincidence event in the computer. At high 
count rates this is a serious problem which can be minimized by the use of 
faster electronic components and shorter scintillation decay time detectors. 
 
Several methods of 2D and 3D data reconstruction are available, from simple or 
filtered backprojection to iterative reconstruction, and the method used will be 
defined by the acquisition method and the results sought. Figure 1.20, copied 
from Bailey and Towsend (2005), depicts a step by step reconstruction of a 2D 
PET image using filtered back projection. 
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Figure 1.20: Representation of a step by step filtered back projection reconstruction, illustrating the 
several corrections applied over the process to obtain the best possible image. Copied from Bailey and 
Towsend (2005).  
In this thesis the method of reconstruction used was 3D-OSEM which is an 
iterative reconstruction method. Iterative methods perform an initial estimate of 
an image and the projections of that estimated image are computed and 
compared with the measured projections in the sinogram. In the case of 
differences between both projections, corrections are made to improve the 
estimated image and further iteration takes place and another comparison is 
performed. This process is repeated until the differences between the estimated 
projections (of the estimated image) are negligible when compared with the 
measured projections (Bailey and Towsend, 2005; Saha, 2005). 
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In the specific case of Ordered Subset Expectation Maximization (OSEM) the 
projection data are grouped in ordered subsets. Each subset is subject to a 
standard Expectation Maximization algorithm using a matrix of weights 
(differences between the estimated image and the observed projections counts) 
which correspond to the ray sums. The resulting reconstruction is used as a 
starting value for the next subset. In the OSEM algorithm one iteration is a 
single pass through all the specified element subsets and each iteration starts 
with the reconstruction obtained in the previous iteration. This algorithm 
provides an accelerated reconstruction when compared with a standard 
Expectation Maximization (published by Hudson and Larkin, 1994, and 
reviewed by Beyer et al., 2011).  
 
1.5.1 PET tracers  
The radioactive tracer principle is attributed to George Charles de Hevesy who 
in 1923 used small non-toxic amounts of 212Pb to study the uptake of solutions 
in bean plants. A year later he performed the first pre-clinical experiment when 
he followed the circulation of antisyphilic drugs labelled with 210Bi injected intra-
muscularly in rabbits (Bailey and Towsend, 2005).  
 
Positron emitter radionuclides which are the basis of PET can be produced in a 
cyclotron. In the cyclotron, charged particles are accelerated in circular paths 
under vacuum by the effect of a strong electromagnetic field. Targets are placed 
at the end of a window through which the accelerated particles will travel. The 
collision of the accelerated particles into the target promotes nuclear reactions 
and the production of the radionuclide. The material in the target and the energy 
of the accelerated particles will determine the radionuclide product.  
 
For PET purposes, the radionuclides produced have to be positron emitting. For 
this project the most important is fluorine 18 (18F). Fluorine 18 has a half-life of 
109.8 minutes and can be produced by the bombardment of an 85 to 99% 
enriched H218O target with 11 to 18 MeV protons. The mixture resulting from the 
target is loaded into a carbonate ion exchange resin column where the parent 
H218O is forced out by neon gas and recovered for reuse. A potassium 
carbonate solution is then used to elute the 18F- ions from the column. This ion 
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can then be used for radiolabelling several tracers or pharmaceutical 
compounds (Saha, 2005).  
 
Several other radionuclides can be produced in a radiochemistry facility and 
used in the labelling of PET tracers or pharmaceutical compounds depending 
on the nature of the study, the physiological process being studied and the 
radionuclide half-life required. Table 1.6 extracted from Aboagye et al. (2001) 
describes some radiotracers used in oncology and the processes they study. 
 
Radiotracer Process studied 
6-[18F]fluorodeoxyglucose Tumour glucose utilization 
2-[11C]thymidine Cell proliferation 
3’-[18F]fluorothymidine Cell proliferation 
[11C]methionine Protein synthesis 
[15O]H2O Tumour blood flow 
[15O]CO Tumour blood volume 
[11C]HCO3 pH (intra and extracellular) 
[18F]fluoromisonidazole Tumour hypoxia 
16α-[18F]fluoro-17β-oestradiol Oestrogen receptor status 
5-[124I]iodo-2’-fluoro-1β-D-arabinofuranosyluracil 
Gene expression (HSV1 tk 
reporter) 
9-(1-[18F]fluoro-3-hydroxy-2-
propoxy)methylguanine 
Gene expression (HSV1 tk 
reporter) 
[11C]daunorubicin Multidrug resistance phenotype 
[124I]Annexin-V Apoptosis 
[124I]VG76e VEGF levels 
 
Table 1.6: Ligands and tracers used in oncology and the corresponding physiological process they are 
designed to study. Extracted from Aboagye et al. (2001).  
 
The method used for the synthesis of some radiotracers labelled with 18F and 
commonly used in PET will be briefly explained. 
 
Fluorine is widely used in the development of radiolabelled pharmaceutical 
compounds due to its electronegativity, the fact that it forms strong bonds with 
carbon atoms in organic chemistry and as 18F is a positron emitter. As 
mentioned before, the half-life of 18F is 109.8 minutes. The incorporation of 
radioactive fluorine into molecules has been subject to extensive study by 
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synthetic chemists, and elemental fluorine is used in electrophilic fluorination 
reactions, and arenes, alkenes and active methylenes can be selectively 
fluorinated by xenon fluorides.  18F-F2, a high polarized element with a partial 
positive charge is commonly used in electrophilic fluorination, in which electron 
rich substrates like alkenes or aromatic compounds act as nucleophiles and 
become fluorinated. One example in oncology is the electrophilic fluorination of 
uracil to generate the antitumour agent 5FU. Using 18F-F2, in the presence of 
acetic anhydride and a trace of acetic acid, 5-18F-FU is synthetized. Nucleophilic 
fluorination occurs when inorganic and other ionic fluorides are used (reviewed 
by Alauddin, 2012).  
 
[18F]Fluoro-2-deoxy-2-D-glucose 
[18F]-Fluoro-2-deoxy-2-D-glucose (2-FDG) is one of the most commonly used 
radiotracers in PET. Its applications include the assessment of glucose 
metabolism in heart, lungs, brain, and in tumours. In the latter, it is used to 
acquire static or, in some research applications, dynamic data sets which 
assess Standardised Uptake Values (SUVs) over the scan time. This 
information is used in diagnosing, staging and monitoring cancer, and its 
treatment and response. [18F]FDG is used is several tumours types, e.g. 
Hodgkin’s disease, non-Hodgkin’s lymphoma, colorectal, breast, skin and lung 
cancer, and has also been approved for use in Alzheimer disease diagnosis as 
reviewed by Alauddin (2012).  
 
[18F]FDG is an analogue of glucose in which an 18F atom replaces the hydroxyl 
group at position 2 as illustrated in Figure 1.21. As summarized in Figure 1.22, 
in cancer cells, metabolism can be upregulated and these cells are glucose avid 
so the [18F]FDG will be taken up by cells through facilitative glucose 
transporters. Once inside the cell [18F]FDG is phosphorylated by hexokinase (in 
cancer cells hexokinase II is predominately expressed) to [18F]FDG-6-
phosphate which is not metabolised and is trapped in the cell. There can be 
dephosphorylation by glucose-6-phosphatase but this enzyme is often under 
expressed in cancer cells. Although widely used, [18F]FDG-PET is not always 
specific for tumours and false positive results can be generated by inflammation 
and active muscles, as reviewed by He and Guo (2008). 
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Figure 1.21: Nucleophilic fluorination in the synthesis of [18F]FDG. Extracted from Alauddin (2012). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.22: Schematic representation of the glucose and [18F]FDG pathways in the cell. K1, K1, K3, K4 are 
rate constants while HK represents hexokinase and Glut stands for facilitative glucose transporters. 
Adapted from He and Guo (2008).  
As shown in Figure 1.21, the reaction used for [18F]FDG synthesis is 
nucleophilic displacement of an acetylated sugar derivative (glucose) by 
reaction with a fluoride ion followed by hydrolysis. The precursor for the 
nucleophilic reaction is a 2’-triflate of mannose acetate radiofluorinated with 
K18F/Kryptofix 2.2.2. and hydrolysed by acid (HCl). The solution goes through a 
series of columns to purify it from free fluoride and other impurities, and a 
0.22μm filter is used for sterilization of the final pure product (reviewed by 
Alauddin, 2012).  
 [18F]FDG synthesis takes about 50 minutes and can achieve a yield of 60% 
(Saha, 2005).  
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[18F]3'-Deoxy-3'-fluorothymidine 
[18F]-3'-Deoxy-3'-fluorothymidine ([18F]FLT) is another PET tracer used for early 
detection and diagnosis of tumours, and treatment response assessment 
following therapy. [18F]FLT is a proliferation marker, and brain tumours, 
malignant lymphomas, lung, colorectal and oesophageal cancer are some of 
the malignancies where [18F]FLT PET has been investigated as reviewed by 
Alauddin (2012).  
   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.23: Schematic representation of the salvage DNA synthesis pathways imaged by [18F]FLT in 
cells. TK1 stands for thymidine kinase-1, dNT deoxynucleotidase, TMPK for thymidylate kinase, NDPK 
nucleotide diphosphate kinase. FLTMP, FLTDP and FLTTP stand for fluorothymidine mono, di and 
triphosphate respectively. Adapted from Grierson et al. (2004).  
 
In order to maintain intracellular nucleotide pools for DNA replication, 
proliferating cells utilize the DNA salvage pathway (Figure 1.23). [18F]FLT entry 
into the pathway is controlled by the cytosolic enzyme thymidine kinase 1 (TK1). 
This enzyme is expressed during the S-phase of the cell cycle. Once inside the 
cytoplasm, [18F]FLT is phosphorylated successively by TK1, thymidylate kinase 
(TMPK) and by nucleotide diphosphate kinase (NDPK) forming mono to 
triphosphates. Although there can be degradation of thymidine triphosphate, 
incorporation into DNA is rapid. In the case of [18F]FLT, due to the fact it does 
not possess a 3’-hydroxyl on the deoxyribose ring, it cannot be incorporated in 
the DNA polymer (Grierson et al., 2004).  
 
[18F]FLT is produced by the nucleophilic reaction of 18F-sodium fluoride with the 
precursor 2,3’-anhydro-5’-0-benzoyl-2’-deoxythymidine (Figure 1.24). The 
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precursor preparation follows a standard organic synthesis and is described in 
Machulla et al.(2000). 18F-Sodium fluoride forms a mixture with Kryptofix 2.2.2 
and potassium carbonate in acetonitrile which is heated at 120°C for 5 minutes, 
followed by the addition of the precursor in dimethyl sulfoxide (DMSO) to the 
dried residue and drying for 10 minutes at 160°C. Sodium hydroxide is used to 
hydrolyse the 5’-0-protecting group, and finally the solution is filtered to isolate 
the [18F]FLT which is further purified by HPLC (Saha, 2005).  
 
 
 
Figure 1.24: Preparation of [18F]FLT. Copied from Bailey and Towsend, 2005.  
 
[18F]FLT is produced with an overall yield of approximately 45% and a 
radiochemical purity above 95% in a 60 minutes process (Saha, 2005). 
However, with [18F]FLT this yield has been achieved only in recent years (Yun 
et al., 2003; Oh et al., 2004), as previously the yield was much lower, about 7% 
(Grierson and Shields, 2000; Machulla et al., 2000). This latter value is a much 
lower yield when compared with [18F]FDG and the complexity and price of the 
precursors make [18F]FLT an expensive and less available tracer. 
 
A number of studies have compared [18F]FDG and [18F]FLT scanning. In 2005 
van Westreenen et al. published a study where [18F]FLT-PET and [18F]FDG-
PET were performed in 10 patients with oesophageal cancer. [18F]FDG-PET 
detected all oesophageal cancers while [18F]FLT-PET failed to detect two. In 
comparison the median Standardized Uptake Value (SUV) for [18F]FDG-PET 
was 6.0 while [18F]FLT median SUV was 3.4 (van Westreenen et al., 2005). In 
2007, Yamamoto et al. published an article were they studied the relationship 
between [18F]FDG and [18F]FLT uptake, and Ki67 immunohistochemistry. This 
study in non-small cell lung cancer also demonstrated a mean [18F]FLT SUV 
significantly lower than the [18F]FDG value (Yamamoto et al., 2007). In 2011 
Mileshkin et al. also studied non-small cell lung cancer patients treated with 
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erlotinib (a tyrosine kinase inhibitor) to assess changes in [18F]FDG and 
[18F]FLT uptake in relation to clinical outcome. In this study patients had 
[18F]FDG and [18F]FLT scans at baseline (prior to treatment), at day 14 and at 
day 56. The median FDG uptake corrected for lean body mass (SUV max) was 
higher (approximately 5.63) than FLT uptake (SUVmax, 2.5) at baseline, and 
both [18F]FDG- and [18F]FLT-PET provided useful early information about 
erlotinib response (Mileshkin et al., 2011).  
  
1.5.2 Labelled Drugs in PET 
PET can be a useful tool in drug development from early drug discovery to 
clinical trials by providing data relating to tumour pathophysiology, target 
selection and validation, lead generation and optimization as well as pre-clinical 
and clinical development. PET has the advantage of very high sensitivity 
coupled with being a non-invasive technology. During the drug development 
process, information regarding drug absorption, distribution, metabolism and 
excretion (i.e. pharmacokinetics) can influence decisions and PET can provide 
data that complement conventional plasma-derived pharmacokinetic results.  
 
PET studies provide data on the kinetics, and distribution of drugs in healthy 
and diseased tissue, and drug clearance. Pharmacokinetic parameters that can 
be quantified by PET include peak radioactivity, time to reach peak radioactivity, 
standardised uptake value (SUV) as well as drug concentrations in tissues 
relative to that in the blood. Uptake and efflux-related kinetic parameters can 
also be inferred from the mathematical modelling of tissue PET data. 
Parameters include selective binding, distribution from plasma to tissue and 
from tissue to plasma, and the tissue volume of distribution (Aboagye et al., 
2001).  
 
As referred to in the section 1.3, certain cancer drugs can be labelled with 
positron emitting isotopes in order to perform PET pharmacokinetic studies. An 
example of a tumour type where drugs have been labelled for PET studies is 
glioma. 
 
Temozolomide is an alkylating agent of [5,1-d]-1,2,3,5-tetrazine series with 
good oral bioavailability and clinical activity in the treatment of malignant 
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melanomas and gliomas.  Temozolomide has a pH dependent activation, i.e. it 
is stable at acid pH but the rate of activation increases rapidly on passing 
through neutral to basic pH. Temozolomide can be labelled with [11C] in two 
sites, at the 4-carbonyl and 3-N-methyl positions of the molecule; the former 
generating [11C]CO2 during activation, and the latter being incorporated into 
DNA. The two [11C]-labelled versions of temozolomide PET studies were used 
to demonstrate both biodistribution and activation (Saleem et al., 2003).  
 
5-Fluorouracil (5-FU) is an antitumour drug from the fluoroprymidine family 
which, following metabolism, inhibits thymidylate synthetase and is incorporated 
into DNA and RNA. Although it was first reported in 1958, 5-FU is still used in 
cancer therapy alone or in combination with other drugs for colorectal, gastric 
and advanced pancreatic cancer. [18F] labelled 5-FU tumour uptake has been 
shown to be a positive predictive biomarker for patient selection, and the drug 
can also be labelled with [11C] (Seki et al., 2007).  
 
As a final example, tamoxifen is an antiestrogen which binds to and primarily 
blocks the function of the estrogen receptor. Tamoxifen inhibits the growth of 
estrogen-dependent breast cancers, and can be labelled with [18F] and used in 
the detection of primary and secondary estrogen receptor positive tumours, and 
in monitoring toxicity as described by Yang et al. (1993) and reviewed by 
Benard and Turcotte (2005).  
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1.6 Aims of the studies performed in this thesis 
The overall aim of the project described in this thesis was to develop and 
optimize pharmacodynamic and surrogate response biomarkers for the PARP 
inhibitor rucaparib in pre-clinical models.  
 
Based on previous experiments (Calabrese et al., 2004; Ali et al., 2009), it was 
hypothesised that the acute vascular effects of rucaparib could be measured by 
DCE-MRI. Experiments were performed in SW620 and A2780 human tumour 
xenograft bearing mice. Hydralazine was chosen as a positive control and 
treatment groups were rucaparib, temozolomide and the combination of 
rucaparib and temozolomide. Anticipating that acute effects on vasculature 
would influence tumour energy metabolism in vivo 31P-MRS experiments were 
also performed and the ratio of the inorganic phosphate (Pi) and βNTP 
concentration was measured in each sample. 
 
To allow comparison with the in vivo MRS data, absolute quantification and 
greater sensitivity and discrimination, ex vivo MRS experiments the A2780 
tumour cell line were performed. Initially a protocol was developed for the 
quantification of relevant metabolites in cells and in tissues using the method of 
addition procedure. Tumour cells were again treated with rucaparib, 
temozolomide or the combination of rucaparib and temozolomide. To further 
validate ex vivo MRS as a biomarker for PARP1 activity and PARP inhibition, ex 
vivo MRS studies were performed on extracts of livers from WT and PARP1 KO 
mice treated with either rucaparib, temozolomide or the combination of 
rucaparib and temozolomide. 
 
Lastly, a second imaging biomarker technique, PET, was evaluated as a 
potential surrogate response biomarker, using 2 tracers: [18F]FDG and [18F]FLT. 
The [18F]FDG-PET studies were performed to determine the impact of 5 days 
treatment with rucaparib, temozolomide or rucaparib in combination with 
temozolomide, on glucose metabolism, and the relationship between tumour 
volume variation and [18F]FDG uptake was evaluated. In similar studies with 
[18F]FLT-PET the relationship between changes in [18F]FLT uptake and the 
outcome of the treatment was evaluated.  
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Together, the studies described in this thesis represent the first comprehensive 
multimodality evaluation of imaging biomarkers for the investigation of PARP 
inhibitors.  
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Chapter 2. Materials and Methods 
2.1 Materials  
RPMI 1640, without L-glutamine, with Phenol Red, Foetal Bovine Serum Gold 
(EU Approved), 175 cm² cell culture flasks with filter caps and surface treated, 
trypsin EDTA (1:250), L-glutamine (200mM), penicillin/streptomycin (100x) and 
C-Chip disposable haemocytometers were purchased from PAA Laboratories 
Ltd., Termare Close, Houndstone Business Park, Yeovil, Somerset, BA22 8YG, 
United Kingdom (UK).   
 
One ml, 5 ml, 10 ml, 25 ml pipettes individually wrapped, NMR tubes (economy 
standard borosilicate glass 0.020 mm concentricity, 0.070 mm camber, 178 mm 
length, 4.97 mm O.D. 4.20 mm I.D. Norell) and 5100 Cryo 1°C freezing 
container (“Mr. Frosty”) were purchased from Fisher Scientific UK Ltd., Bishop 
Meadow Road, Loughborough, LE11 5RG, UK.  
 
Nineteen, 23, 25, and 30 gauge needles, 0.5 ml insulin, 1 ml, and 5 ml syringes, 
industrial methylated spirits (Denatured Alcohol), Decon 90, saline and water for 
injection were purchased from Nu-Care Products Ltd., Unit 21, Broadmead 
Business Park, Broadmead Road, Stewartby, Bedfordshire, MK43 9NX , UK.  
 
3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP), 
methylenediphosphonic acid (MDP), adenosine 5'-triphosphate disodium salt 
hydrate (ATP), adenosine 5'-diphosphate sodium salt, from bacterial source 
(ADP), adenosine 5'-monophosphate sodium salt minimum 99% (AMP), 
adenosine 5'-diphosphoribose sodium salt (ADP ribose), β-nicotinamide 
adenine dinucleotide hydrate from yeast (NAD), dimethyl sulfoxide (DMSO), 
deuterium oxide (D2O, 99.9% isotopic purity), phosphocholine chloride calcium 
salt tetrahydrate (PCh), Chelex® 100 sodium form, 50-100 mesh (dry) were 
purchased from Sigma-Aldrich Company Ltd., The Old Brickyard, New Road, 
Gillingham, Dorset, SP8 4XT, UK. 
 
Eppendorf tubes (1.5 ml), 7 ml bijou containers, 15 ml centrifuge tubes, 20 ml 
universal containers, 50 ml Falcon tubes (skirted and non-skirted) were 
purchased from Scientific Laboratory Supplies Limited, Wilford Industrial Estate, 
Ruddington Lane, Wilford, Nottingham, NG11 7EP, UK. 
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Polyethelyne (PE) tubing for cannulation and contrast agent/radiotracer 
administration (BPTE-T10, 0.11” ID, 0.24” OD, non-sterile; BPTE-T10, 0.23” ID, 
0.38” OD, non-sterile) were purchased from Linton instrumentation UK, Units 1-
2, Forge Business Centre, Upper Rose Lane, IP22 1AP, Palgrave, Diss, Norfolk, 
UK. 
 
Two hundred and 1000 μl pipettes, and 200 and 1000 μl pipettes tips loose 
were purchased from STARLAB (UK), Ltd, Unit 4 Tanners Drive, Blakelands, 
Milton Keynes, MK14 5NA, UK, and 20, 200 and 1000 μl pipettes were 
purchased from Gilson Scientific Ltd, 20 Charles Street, Luton, Bedfordshire 
LU2 0EB, UK. 
 
Introcan Safety® 24G 0.7x19 mm catheter and Hystoacryl® were purchased 
from B. Braun Medical Ltd., Thorncliffe Park, Sheffield, S35 2PW, UK. 
 
The Cryo-Cup Grinder for tissue grinding was purchased from BioSpec 
Products, PO Box 788, Bartlesville, OK 74005, USA.  
 
Heparin sodium, 1000 units/ml for tail vein cannulation was purchased from 
Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, United Kingdom. 
 
The contrast agent used in the DCE-MRI experiments, gadoteridol, under the 
commercial name ProHance was purchased from Bracco International, 
Amsterdam, Netherlands. 
 
The nude CD1 mice used to implant human tumour xenografts were purchased 
from Charles River UK Ltd., Manston Road, Margate, CT9 4LT, United Kingdom.  
 
Temozolomide was a gift from the Cancer Research Campaign, UK and 
rucaparib was a gift from Pfizer UK; however, rucaparib has been licensed to 
Clovis Oncology, 2525, 28th Street, Suite 100, Boulder, CO 80301, United 
States of America (USA). 
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The [18F]fluoro-2-deoxy-2-D-glucose and the 3'-deoxy-3’-[18F]fluorothymidine 
used in the PET studies were purchased from PETNET Solutions, Heathfield 
Way, Nottingham City Hospital, Gate 1, Hucknall Road, Nottingham, NG5 1PB, 
UK. 
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2.2 Cell culture 
Two cell lines were used to perform all the experiments: the colon cancer cell 
line SW620 (American Type Culture Collection, Manassas, VA, USA), and the 
ovarian cancer cell line, A2780 (Health Protection Agency, Porton Down, 
Salisbury, UK). These cell lines were provided in frozen vials stored in the NICR. 
Both cell lines were grown in monolayer culture in complete 1640 RPMI 
supplemented with 10% (v/v) foetal bovine serum (FBS), 2 mM L-glutamine, 
100 units/ml penicillin and 100 µg/ml streptomycin. The cell lines were 
independently authenticated and shown to be mycoplasma free. These cells 
were chosen based in previous studies with PARP inhibitors (Calabrese et al., 
2003, Thomas et al., 2007, and Ali et al., 2009 for the SW620) and preliminary 
studies performed by Lan-zhen Whan (NICR, personal communication) in 
A2780 cells. 
 
For every new culture started, the vial with frozen cells was defrosted in a water 
bath, the contents of the vial poured into a universal with 19 ml of media at 37ºC, 
centrifuged at 1000 rpm for 5 minutes and resuspended in an appropriate 
volume for transfer into a culture flask.   
 
Cells were incubated in a humidified atmosphere of 20% O2, 5% CO2 and 75% 
N2 (v/v/v) at 37ºC and kept in exponential growth phase by passage as soon as 
cultures reached 80-90% confluence. The passage method included a primary 
wash of the cells in 10 ml of PBS followed by the addition of 10 ml of trypsin-
EDTA to harvest the cells, prior to centrifugation for 5 minutes at 1000 g, 
resuspension and dilution in an appropriate volume of fresh media. 
 
Cell cultures were checked on a daily basis and media replaced every 2 days.  
To freeze cells for storage, the contents of the flask were trypsinised, 
centrifuged and resuspended into media with 10% DMSO (v/v) and dispensed 
into several cryovials, frozen in a 5100 Cryo 1°C freezing container ("Mr. 
Frosty", ) in a -80ºC freezer, and transferred to a liquid nitrogen tank.  
 
Cells for implantation into nude CD1 mice were trypsinised, resuspended in 
fresh media at a density of 8-10x106 cells in 50µl.  
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2.3 Cell extract spectroscopy 
Initially, a “methods of addition” approach was used to validate the protocol and 
quantify of the relevant cellular metabolite. Once the protocol was optimized, 
experiments were performed in which cells were treated with the relevant 
compounds and harvested. The cells were extracted using a perchloric acid 
extraction protocol and analysed as described under Nuclear Magnetic 
Resonance Spectroscopy (MRS). 
 
2.3.1 Methods of addition 
Modern chemical instruments, despite their high sensitivity and linearity, have 
output values which are still dependent on the conditions of the measurement 
and the response, R, of the equipment. The concentration of a compound in a 
sample can be estimated by the addition of known standards and the 
endogenous concentration calculated by the extrapolation of the calibration 
curve. In the experiments, known volumes (NVs, where N is running multiple 
integer 0,1,2, etc.) of a standard of known concentration of standard (Cs) were 
added to sample aliquots of known volume, Vx, containing an unknown 
concentration, Cx, of the analyte and diluted to have a constant total volume 
across all the samples (Vt) (Figure 2.1). 
  
 
 
 
 
 
 
 
 
 
Figure 2.1: Calibration curve established from the addition and measurement of standards. Adapted from 
Bader (1980) and Schumann et al. (1992).  
However, the absolute value is still dependent on the response so a suitable 
method of addition will provide a reduced standard error estimation of the 
unknown compound. The response of a linear instrument is directly proportional 
to the concentration of the compound by a constant of proportionality, k. 
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𝑅 = 𝑘 × 𝐶 
In a series of additions R becomes 
𝑅𝑁 = 𝑘 �𝑉𝑥𝐶𝑥𝑉𝑡 + 𝑁𝑉𝑠𝐶𝑠𝑉𝑡 � 
if the volumes are replaced by the volume fractions (quotient between volume of 
compound and total volume) for unknown (fx) and standard (fs) the equation 
becomes: 
𝑅𝑁 = 𝑘(𝑓𝑥𝐶𝑥 + 𝑁𝑓𝑠𝐶𝑠) 
which represents a linear regression depicted by a straight line when plotted 
against N as in Figure 2.1, in which kfsCs is the slope, m, and kfxCx is the 
intercept. Hence the unknown concentration Cx can be calculated from  
𝐶𝑥 = 𝑏𝑉𝑠𝐶𝑠𝑚𝑉𝑥  
(Bader, 1980; Schumann et al., 1992)  
This method has been used in a wide range of techniques namely high-
performance liquid chromatography (HPLC) (Sakkiadi et al., 2007), thin layer 
chromatography (TLC) (Shariatgorji et al., 2009), spectrophotometry (Safavi 
and Tohidi, 2007), and magnetic resonance spectroscopy (MRS) (Talebpour et 
al., 2004).    
 
In the specific case of cell extract spectroscopy (and later in tissue extract 
spectroscopy) used in this thesis, known concentrations of each metabolite 
were added to aliquots of the sample, each being derived from 1.5x108 cells. To 
each aliquot was added a fixed volume of liquid either containing no metabolite 
(0 mM), or with metabolite at one of two different concentrations. All samples 
were then processed in an identical manner (subsection 2.3.3). Signals in the 
NMR spectrum were then quantified and the results plotted against the 
expected concentration of added metabolite. The slope of the fitted straight line 
provided an estimate of the recovery in the extraction procedure, and the 
interception of the fitted line with the x-axis provides the concentration of 
metabolite derived from the original cell sample. Ideally, a good linear fit is 
obtained with recovery of >50%. 
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2.3.2 Cell treatment and harvesting 
The cells were cultured as described previously (section 2.2) and split into 12 
175 cm² cell culture flasks at 5x107 cells per flask for A2780 cells, and 4.5x107 
cells per flask for SW620 cells. The 12 flasks for each cell line were divided into 
4 groups of 3 as each treatment required at least 1.5x108 A2780 cells to start 
the experiment. The interval between the seeding of the cells and the treatment 
was 40 hours (with medium replacement 24 hours after seeding).  
 
There were four treatment groups: 
• Control;  
• 0.1 μM  rucaparib; 
• 180 μM  temozolomide;  
• 0.1 μM rucaparib combined with 180 μM temozolomide.  
 
Concentrations were based upon previous in vitro studies performed by Huw 
Thomas (Thomas et al., 2007) and Lan-zhen Whan (NICR, personal 
communication), and where the GI50 concentration for temozolomide, and a 
rucaparib concentration that results in significant chemosensitization. On the 
day of treatment the media was replaced by 25 ml of fresh media (in the control 
group) or by 25 ml of the media with the appropriate concentrations of drugs 
added (remaining groups). The flasks were returned to the incubator for 6h. 
 
Before the extraction procedure started it was necessary to harvest the cells 
and Figure 2.2 summarizes the harvesting protocol. 
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Figure 2.2: Flow chart summarizing the cell harvesting protocol.  
 
Cells were counted using a disposable C-Chip haemocytometer and the tubes 
were kept in a -80°C freezer until extraction.  
 
 
The medium was poured off and cells were washed with 10 ml of PBS. 
The PBS was discarded and 10 ml of trypsin were added for 5 minutes prior to 
neutralization by the addition of 10 ml of full medium. 
The mixture of cells, trypsin and medium was transferred into a 50 ml Falcon 
tubes which were centrifuged at 1000 g for 5 minutes, the supernatant 
removed. 
Cells were resuspended in 45 ml of ice cold saline (first dilution factor 45) in a 
Falcon tube. 
first dilution factor 45 
0.5 ml of the sample was transferred into a bijou and 4.5 ml of ice cold saline 
added for cell counting. 
second dilution factor 
10 
The content of the bijou was added to the Falcon tube and centrifuged at  
1000 g for 5 minutes. 
Once the cells were centrifuged, the supernatant was removed and the tubes 
dipped into liquid nitrogen to freeze the cells. 
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2.3.3 Extraction Procedure 
This extraction procedure used was adapted from an existing protocol kindly 
supplied by Mrs Loreta Rodrigues from CR UK Cambridge Research Institute 
(Cambridge, UK). 
The protocol is described in Figure 2.3. 
 
 
 
 
Two ml of 6% (v/v) perchloric acid were added to each thawed tube containing 
1.5x108 cells, and mixed thoroughly on a vortez mixer and left on ice for 10 - 
15 minutes. 
Cell debris was removed by centrifugation at 1000 g and 4°C for 15 minutes. 
The supernatant was decanted into new tubes and neutralised with 20% (v/v) 
KOH using one or two drops of universal indicator to determine the pH. To 
facilitate smaller pH correction 5% (v/v) KOH and 2% (v/v) PCA were used. 
Once the pH was corrected to a value between 6.5 and 7.5, Chelex® 100 
beads were added  to the samples at a concentration of 50 mg per ml of 
neutralised supernatant and the pH readjusted. 
Samples were then mixed thourougly on a vortex mixer and left on ice for 
between 15 and 30 minutes following by transfer of the supernatant into 50 ml 
Falcon tubes.  
These tubes were kept in a -20°C freezer or dipped into liquid nitrogen prior to 
immediate transportation (in dry ice) to the School of Chemistry. 
The samples were freeze dryed overnight with pierced parafilmed replacing 
the tubes caps to avoid sample loss while allowing an efficient drying process. 
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Figure 2.3: Flow chart summarizing the cell extraction protocol.  
 
The dipping the tubes in liquid nitrogen mentioned in Figure 2.2 is intended to 
stop metabolism in the sample. To avoid the recovery of enzymatic activity the 
samples are always kept frozen in dry ice or in -80°C freezers. Perchloric acid 
addition to the sample enables metabolic fingerprinting studies by precipitating 
proteins in a solid phase and extracting hydrophilic metabolites in the liquid 
phase (Lin et al., 2007). The Chelex® 100 beads complex with divalent ions in 
the sample which could affect the 31P-MRS signal (Walsh et al., 1991). The 
freeze drying step not only avoids metabolic activity taking place, but also 
enables the replacement of H2O by D2O to avoid contamination of proton MRS 
signal by the protons of the solvent.   
 
2.3.4 Spectroscopy 
All NMR spectroscopy experiments on the cell and tissue extracts were 
performed on an 11.4T Bruker Avance III 500MHz NMR spectrometer located in 
the Northern Institute for Cancer Research Laboratories, School of Chemistry, 
Newcastle University (Bedson Building). The samples were placed in the 
magnet tray and left to acquire proton spectra in daytime hours and the 
phosphorus spectra (with the MDP already added) overnight or during 
weekends. 
  
The following morning the samples were resuspended in 0.5 ml of D2O and 
transfered to 1.5 ml labelled Eppendorf tubes. Residual sediments left after 
the freeze drying and resuspension process were removed by centrifugation 
in an Eppendorf at 8000 g for 5 minutes. 
0.4 ml of the final solution was transferred into a NMR tube tube which 
already contained 10 μl of 41 mM TSP as the internal chemical shift reference 
and quantitation standard in the proton spectroscopy protocol.  
Once the proton spectrum was acquired, 10 μl of 42 mM MDP was added to 
each individual sample to act as an internal reference for the phosphorus 
spectroscopy protocol. 
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The proton acquisition protocol included a standard single 90° pulse-acquire 
experiment with a water pre-saturation pulse at 4.7 ppm, delay time of 5 
seconds, acquisition time of 2.34 seconds and 64 averages (total repetition time, 
TR, of 7.34 seconds) as represented in Figure 2.4. Overall the sequence would 
run for approximately 7 minutes and 45 seconds. In this 1H sequence the TR is 
longer than expected T1 values, giving minimal saturation effects about 95% 
signal recovery. 
 
Figure 2.4: Design of the proton acquisition sequence.  This sequence used a pre-saturation 180° pulse at 
4.7 ppm to totally saturate the water signal, followed by a standard 90°pulse for the protons followed very 
closely by the FID signal acquisition. Figure kindly provided by Carlo Bawn. 
 
For proton spectra acquisition, 1 mM TSP (the final concentration in the NMR 
tube) was used as the reference for quantification. After acquisition terminated, 
10 μl of 42 mM MDP was added to the tube to give a final 1 mM concentration 
in the NMR tube, and allow quantification of the phosphorus spectrum. 
 
The phosphorus spectra were acquired using a standard single 90° pulse- 
acquire experiment using inverse-gated decoupling of 1H nuclei. The sequence 
had a delay time of 2 seconds, an acquisition time of 0.4 seconds and 4000 
averages to improve the signal to noise ratio (SNR) as depicted in Figure 2.5. 
In this 31P sequence the TR being similar to expected T1 values, there will be 
some partial saturation. This is a compromise due to limited SNR and scanning 
time constraints. In this sequence as well as for the 1H spectra acquisition 
sequence, the flip angle used was 90°. 
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Figure 2.5: Design of the phosphorus acquisition sequence.  This sequence used a standard single 90° 
pulse-acquire experiment using inverse-gated decoupling of 1H nuclei. On the bottom half of the sequence, 
there is a 90°pulse for phosphorus followed by FID signal acquisition. At that same moment, as seen in the 
top half, a continuous wave starts which keeps the proton signal decoupled from the phosphorus signal to 
avoid the Nuclear Overhauser Effect (NOE) (Keepers and James, 1984), and make the quantification of 
the phosphorus data more accurate. Figure kindly provided by Carlo Bawn. 
 
Data analysis 
The results of the MRS experiments were analysed using the Bruker software 
package TopSpinTM. Data were loaded into the software which applied a Fourier 
Transform, followed by a phasing step. After the phasing, the references peaks 
(TSP for proton and MDP for phosphorus) were set as zero order phases. The 
other peaks were phased in first and second order phasing steps based on the 
zero order phases of the references. After the phasing process, a baseline 
correction step was performed which was usually automatic but was performed 
manually if required (using a polynomial function correction). Finally, the 
individual peaks were defined manually and integrated for relative quantitation 
(by comparison with the internal reference). 
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2.4 DCE-MRI 
All the in vivo experiments were reviewed and approved by the relevant 
Institutional Animal Welfare Committees and performed accordingly to national 
law under a UK Home Office license. 
 
All the DCE-MRI experiments were performed in a Varian 7T horizontal bore 
preclinical MR system using human tumour xenografts grown in CD1 nude mice 
purchased from Charles Rivers. This specific strain is immunodeficient (a lack 
of thymus prevents the production of T-cells) and hairless (albino background) 
making it very well suited for xenografting and tumour biology research (Rice 
and O’Brien, 1980; Chia et al., 2005).  
 
For implantation, 6-8x106 cells per 50 μl of media were prepared and implanted. 
Each implant was performed under anaesthesia. The animals were returned to 
the animal housing facility and checked daily for tumour growth.  
 
DCE-MRI experiment setup 
When tumours reached an average size of 10x10 mm, mice were anaesthetized 
in a mixture of 2% isoflurane/oxygen (v/v). For DCE-MRI purposes, the tail vein 
was cannulated using a 30G needle attached to a 1 ml syringe containing 20 
units/ml of heparin (100 μl of heparin diluted in 4.9 ml of saline) via a BPTE-T10, 
0.28 mm ID, 0.61 mm OD tubing. Once the tail vein was successfully 
cannulated, the cannula was glued to the tail using Hystoacryl® and when the 
glue was dry the animal was transferred into the 7T scanner. The mouse was 
placed in a prone position and breathing monitored throughout the experiment 
by a breathing pillow placed under the abdomen. The temperature inside the 
magnet was also measured and controlled by a fibre-optic sensor. Both sensors 
were connected to a console which allowed regulation of the dose of 
anaesthetic as well as the temperature of the air propelled by the fan into the 
magnet (PC-sam software, SA Instruments, Inc., 65 Main Street, Stony Brook, 
NY  11790, USA). The cannula tubing was then cut and connected to a BPTE-
T10, 0.58 mm ID, 0.97 mm OD tubing which was attached to a 1 ml syringe by 
a 23G needle which contained 25 mM gadoteridol.  
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A Rapid 1H-31P 12 mm surface coil (RAPID Biomedical GmbH, Technologiepark 
Wuerzburg-Rimpar, Kettelerstrasse 3-11, 97222 Rimpar, Germany) was placed 
over the tumour (i.e. the tumour was inserted into the coil lumen) and once 
secured in place the tray was inserted into the magnet ready for scanning. 
 
DCE-MRI data acquisition protocol 
This first part of the protocol was executed using the proton channel of the 
coil/receiver. Firstly a scout scan with 5 images over three planes was 
performed to confirm good positioning of the coil over the tumour and that the 
tumour was in the centre of the magnet. A proton power calibration was 
performed using a SPULS sequence, i.e. an array of 23 pulse width (pw) 
elements from 30 to 250 μs under a repetition time of 5 seconds and a 
transmitter pulse power (tpwr) of 45 decibels (dB).  The pulse returning the 
biggest peak was used for the proton signal. When pulse width value was 
defined, the repetition time was reduced to 0.5 seconds and a manual global 
shim was performed to improve the magnetic field homogeneity for 1H DCE-
MRI and for 31P-MRS. The shimming parameters were saved to allow them to 
be restored if the system required a reset. Another scout scan was then 
acquired, this time to allow the placement of a voxel over the tumour for 
localized shimming. The voxel size was dependant on the tumour size, and a 
PRESS sequence (represented in Figure 2.6) was used with a repetition time of 
approximately 1030 ms and without water suppression.  
 
Figure 2.6: Design of a PRESS sequence. This sequence based in a double spin echo and allows the 
acquisition of 1D NMR spectra from a delimited area. Copied from Schreiber (2008).  
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This shimming enhancement was based on the global shimming previously 
performed and the shim settings were also saved. Once the shimming process 
was finished, the PRESS protocol was used to acquire a 1H NMR spectrum of 
the tumour localized area and the water peak linewidth was recorded. A third 
scout scan was then performed for the selection of the 10 slices of 2 mm 
thickness (no gap) to be used in a GEMS sequence as depicted in Figure 2.7.  
 
Figure 2.7: Design of a GEMS sequence. This gradient echo 2D multi slice sequence enables the use of 
shorter repetition time (tr) and a reduced flip angle. Copied from Schreiber (2008).  
 
The parameters for the GEMS acquisition sequence included a repetition time 
of 100 ms, 2 averages, a 256x256 matrix, and a FOV of 35x40 mm. The slices 
were placed in order to be across the tumour in an axial direction, the middle 
slice in the centre of the tumour for later single slice acquisitions. For later 
gadolinium concentration calculations, a FSEMS sequence (depicted in Figure 
2.8) was used to acquire T1 estimates. The parameters of this sequence 
included a repetition time of 1200 ms, one averaged, a 256x256 matrix and an 
array of inversion recovery (IR) pulses with 8 TI values starting at 10 ms and 
with a maximum values of 900 ms. This sequence uses sinc 90° excitation 180° 
refocusing pulses. The inversion pulse is adiabatic to try to provide a uniform 
response over the volume of interest, minimising flip angle variations occurring 
with the surface coil, the fact that it also uses sinc pulses makes it less effective 
and diminishes the quality of the T1 information and consequently the 
gadolinium concentration estimations. 
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Figure 2.8: Design of a FSEMS sequence. This fast spin echo multi-slice sequence selects the number of 
echoes in an echo train and at the same time determines which echo will configure the centre of k-space. 
Copied from Schreiber (2008).  
 
The previous GEMS sequence was used to acquire 100 images of the same 
central single slice of the tumour. Using the same 35x40 mm FOV, one 2 mm 
thick slice central in the tumour was selected. The repetition time was reduced 
to 23.44 ms and only one average acquired per image, which translates to a 10 
minute scan time. Once the sequence started, approximately 0.1 mmoles/kg of 
gadoteridol in a volume of 200 μl was injected intravenously after block 6. The 
injection was given manually over the 6 seconds during the current block 
acquisition and constituted the pre-treatment injection of contrast agent for 
comparison with the post-treatment scan.  
 
Thirty minutes after the first injection of gadoteridol, the mouse was treated as 
described below. For both tumour types the treatment groups were:  
• Control (10μl of saline per g of body weight);  
• 5 mg/kg of hydralazine (10 ml/kg of a 0.5 mg/ml solution in saline);  
• 1 mg/kg of rucaparib (10 ml/kg of a 0.1 mg/ml solution in water for 
injection);  
• 5 mg/kg of rucaparib (10 ml/kg of a 0.5 mg/ml solution in water for 
injection);  
• 50 mg/kg of rucaparib (10 ml/kg of a 5 mg/ml solution in water for 
injection);  
• 68 mg/kg of temozolomide (10 ml/kg of a 6.8 mg/ml solution in saline);  
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• 1 mg/kg of rucaparib combined with 68 mg/kg of temozolomide (10 ml/kg 
of a 0.1 mg/ml solution in water for injection with 10 ml/kg of a 6.8 mg/ml 
solution in saline);  
• 5 mg/kg of rucaparib combined with 68 mg/kg of temozolomide (10 ml/kg 
of a 0.5 mg/ml solution in water for injection with 10 ml/kg of a 6.8 mg/ml 
solution in saline).  
All the treatments were given manually by i.p. injection. The drug was in a 1 ml 
syringe connected to an i.p. cannula by an BPTE-T10, 0.58 mm ID, 0.97 mm 
OD tubing and a 23G needle. In the combination groups two i.p. cannulas were 
inserted in the mouse and glued with Hystoacryl® prior to its transfer to the 
magnet.  
 
Approximately 80 minutes after the first contrast agent injection, a fourth scout 
scan was performed to confirm that there was no displacement in the mouse 
position which could affect the results. Another T1 dedicated FSEMS sequence 
was used to acquire T1 estimates of the tumour slice before a second injection 
of contrast agent during another dynamic GEMS sequence. All the parameters 
of the FSEMS (T1) and GEMS (dynamic) sequences were repeated as 
described for the first contrast agent injection. The second injection of contrast 
agent was then given 90 minutes after the first injection of gadoteridol, i.e. 60 
minutes after the drug(s) treatment had been administered, using the same 
dose of approximately 0.1 mmoles/kg  gadoteridol in a volume of 200 μl was 
given i.v.. 
 
DCE-MRI data analysis 
The data were analysed using ImageJ (v1.44) software, a freeware Java-based 
image processing program (Schneider et al., 2012). The 100 images from each 
dynamic acquisition were gathered into one stack with 100 elements. One ROI 
around the tumour was drawn, which was automatically propagated to all the 
elements in the stack as exemplified in Figure 2.9 a). For each image the mean 
pixel intensity was measured inside the ROI, and the same ROI was used in the 
stack corresponding to the second injection of gadoteridol as represented in 
Figure 2.9 b) and c).  
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  a) 
 
 
  b) 
 
 
Figure 2.9:  a) Proton image of an A2780 tumour with the ROI used in the DCE-MRI analysis drawn in it; 
b) Montage of 1 in every 10 of the 100 slices used in the dynamic DCE-MRI acquisition, pre (top) and post 
(bottom) the injection of hydralazine in the same tumour-bearing mouse.  
 
This analysis provided a curve in a graph where time versus mean pixel 
intensity was plotted. The Area Under the Curve (AUC) for 120 seconds after 
the injection of the contrast agent of each curve was then calculated. This 
calculation was performed using Prism 5 for Windows (version 5.04, Graphpad). 
Setting the baseline as 1 (from the normalization), the software calculated the 
AUC for the defined region by the trapezoid rule (Atkinson, 1989).  
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2.5 In vivo 31P spectroscopy 
The in vivo 31P spectroscopy of the human tumour xenografts implanted into the 
flanks of mice was performed in combination with the DCE-MRI protocol.  
 
31P-MRS data acquisition protocol 
Once the first T1 FSEMS sequence was finished, the coil was programmed to 
the phosphorus channel. A phosphorus orientated SPULS sequence was used 
with the following parameters: a repetition time of 2 s, 64 averages, a pulse 
width of 7 μs, a transmitter pulse power of 45 dB, a transmitter offset (tof) of 
3000 and the phosphorus offset frequency of transmitter (P31 offset) also of 
3000. The parameters allowed calculation of the frequency offset of the centre 
of the phosphorus spectrum from the average of the frequency offsets of the 
peaks at the extremities of the spectrum (monophosphoesters on the left and 
βNTP on the right) as seen in Figure 2.10 as an example. 
 
  
Figure 2.10: Example of an 31P-SPULS spectrum acquired from an A2780 tumour-bearing mouse with the 
extremity peaks used in the calculation of the frequency offset of the centre of the phosphorus spectrum.    
 
This sequence was also used every so often to test/calibrate the coil using a 1.5 
ml Eppendorf tube with 100 mM of Phosphocholine as a phantom. With a 
repetition time of 2 s, 2 averages, the pulse width would be set in an array [1, 2, 
3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20] to determine the best pulse width to 
use in the 31P-MRS acquisition. 
Once the phosphorus offset frequency of the transmitter was set to the centre of 
the spectrum, a phosphorus Image Selected In vivo Spectroscopy (ISIS) 
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sequence was used. This sequence uses HS-AFP pulses (hyperbolic secant 
adiabatic full passage, Silver et al., 1984). The phosphorus signal was acquired 
from the same voxel where the local shim was previously performed, as 
exemplified in Figure 2.11, to verify the quality of the phosphorus spectrum, and 
assess the need to move the position of the acquisition voxel.  
 
Figure 2.11: Example of a voxel used in the 31P-MRS ISIS acquisition from an A2780 tumour-bearing 
mouse.  
 
The chemical shift artefact affecting the spatial location of NTP voxels (gamma, 
alpha and/or beta are shifted compared to inorganic phosphate (Pi)) can be 
calculated. The gradient strength in ISIS was 50 mT/m which is equivalent to a 
31P shift of 865 kHz/m. The Pi and βNTP are approximately 23 ppm apart which 
corresponds to 2.783 kHz, while Pi to γNTP are approximately 8 ppm apart 
which corresponds to 0.968 kHz. The shift between Pi and βNTP is then 3.2 
mm, while the shift between Pi and γNTP is 1.1 mm. If we compare this to an 
average voxel size of 10x 10x 10 mm, there is an overlap of 68% in each 
direction for the βNTP to Pi, and 89% overlap per dimension for the γNTP to Pi. 
The ratios between Pi and βNTP were compared to the ratios between Pi and 
γNTP (data not shown) without a relevant change in the profile over time, 
excluding the possibility systematic errors. 
   
Two blocks of 120 averages were used. As soon as the first dynamic GEMS 
sequence (with the first injection of contrast agent) was over a dynamic ISIS 
sequence was initiated. This sequence had the same parameters as the 
previous test ISIS but 18 blocks of 120 averages, resulting in an 18 spectra 
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array acquired over 72 min (4 min per block). The drug or drug combination 
under study was injected during the 5th block of 120 averages. 
 
31P-MRS data analysis 
For analysis purposes the individual spectra (i.e. for each block) were summed 
in pairs and the final analysis performed in 9 blocks which enclosed 8 minutes 
of acquisition. The data were analysed using jMRUI software (v4.0) with the 
AMARES algorithm (van den Boogaart et al., 1996, van den Boogaart et al., 
1997). AMARES (Advanced Method for Accurate, Robust and Efficient Spectral 
fitting) performs parameter estimation of MRS signals using prior knowledge. 
This interactive time domain method relies on a sophisticated nonlinear least-
squares algorithm. The setting of lower and upper boundaries also increases 
the robustness of this algorithm (Vanhamme et al., 1997, Stefan et al., 2009).  
 
The first step involved the phasing of the spectrum, expansion of the line 
broadening to 75 Hz and setting of the reference frequency in the αNTP peak (-
7.52 ppm). The starting values were defined according to the literature for 7 
main peaks (de Graaf, 2007):  
• AMP 6.33 ppm (representative of phosphomonoester signals); 
• Inorganic phosphate 5.02 ppm; 
• Phosphocreatine 0.00 ppm;  
• γNTP -2.48 ppm;  
• αNTP -7.52 ppm;  
• NAD -8.30 ppm  
• βNTP -16.26 ppm    
Prior knowledge constrains were applied to the frequency of each peak defining 
them in an interval between -0.5 and +0.5 ppm of the reported frequency, and a 
first estimation performed. The damping values were averaged and divided by π 
to obtain the linewidth and applied during the second estimation in order to 
increase the robustness of the estimation and lower the mean error. An 
example of the jMRUI Graphical User Interface is presented in Figure 2.12.  
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Figure 2.12: An example of the jMRUI user interface for one A2780 tumour AMARES final results. On the 
right hand side is, from bottom to top, the original spectrum, the estimated spectrum, the individual 
components of the spectrum and the residue of the estimation. On the left hand side are the numerical 
results including the amplitude and standard deviation of each peak.  
Exclusion criteria for this analysis were:  
• If the ratio between the inorganic phosphate peak amplitude and the 
inorganic phosphate peak amplitude standard deviation;  
• or the ratio between the βNTP peak amplitude and βNTP peak amplitude 
standard deviation;  
were below two, the data were excluded from analysis. 
The lineshape was largely dominated by shimming. Therefore multiplet 
information was not used in the data fitting. That could only be achieved by 
improving the 31P-MRS acquisition (increasing the gradient strength in ISIS to 
reduce chemical shifts artifacts) and/or include additional prior knowledge (e.g. 
31P multiplets) in the data fitting .    
 
Using the dynamic phosphorus spectra analysis a real time evaluation of 
changes in the phosphorus spectrum profile was performed.  
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2.6 Ex vivo Tissue Spectroscopy 
At the end of the MR scan (DCE-MRI and/or 31P-MRS) the mouse was killed by 
cervical dislocation. Immediately the tumour was extracted and freeze-clamped 
in liquid nitrogen. Once the tumour was frozen, the liver was also removed and 
freeze clamped. The tissues were stored at -80°C until extraction.  
   
2.6.1 Extraction Procedure 
Figure 2.13 summarizes the tissue extraction procedure. 
 
 
 
Frozen tumours and livers were ground to powder consistency by mortar and 
pestle in liquid nitrogen. Using a spatula precooled in the liquid nitrogen, the 
tissue powder was transferred to a pre-weighed 15 ml centrifuge tube. The 
difference in the tube weight measured the weight of tissue in the tube.   
Based on the weight and assuming 1 g tissue = 1 ml, 4x the volume of tissue 
of 6% (v/v) PCA  was added and the content of the tube homogenized with a 
motor driven pestle and placed on ice for 15 minutes. 
The tube was centrifuged at 1000 g for 15 minutes in a refrigerated centrifuge 
at 4°C and the supernatant decanted into a pre-weighed 15 ml centrifuge 
tube.  
A few drops of universal indicator were added to the tube and the sample 
neutralised using 20% (v/v) potassium hydroxide (KOH), and 5% (v/v) KOH 
and 2%PCA (v/v) as required.  
When the samples were neutralized, Chelex® beads were added to the tube 
at a ratio of 50 mg of Chelex per ml of supernatant and the pH adjusted again. 
After the tube was thoroughly mixed, it was placed on ice for 15-30 minutes to 
allow full precipitation followed by centrifugation at 1000 g for 15 minutes at 
4°C temperature.  
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Figure 2.13: Flow chart summarizing the tissue extraction protocol.  
 
 
2.6.2 Spectroscopy 
Spectroscopy data acquisition was performed in an 11.4T Bruker Avance III 
500MHz NMR spectrometer located in the Northern Institute for Cancer 
Research Laboratories, School of Chemistry, Newcastle University (Bedson 
Building). The same sequences used for the cell extract spectroscopy 
experiments were used for the tissue extract spectroscopy experiments, all the 
parameters were the same, and the data were analysed using TopSpin® 
software as described in subsection 2.3.4. 
  
 
 
  
The supernatant was transferred into a 50 ml skirted Falcon tube and cooled 
in liquid nitrogen prior to transfer to a freeze dryer where it was left overnight. 
Pierced parafilm was used to reduce sample loss while maintaining drying 
efficiency.  
Once the samples were dry frozen, the contents of each tube was 
resuspended in 0.5 ml of D2O and transferred into a 1.5 ml Eppendorf tubes. 
To separate solid residuals, the samples were centrifuged at 8000 g for 5 
minutes.  
0.4 ml of the supernatant was transferred into NMR tubes which already 
contained 10 μl of 41 mM TSP. 
Once the proton spectrum was acquired, 10 μl of 42 mM MDP was added to 
the sample. 
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2.7 PARP1 KO mouse liver extract spectroscopy 
PARP1 knock out (KO) mice used in this study were provided by the 
Comparative Biology Centre (Newcastle University) from an in-house colony 
originally developed by Professor Gilbert de Murcia. The development of a 
PARP1 KO colony was described by Ménissier de Murcia et al. (de Murcia et al., 
1997) Embryonic 129ySv mouse stem cells were used in which PARP1 was 
inactivated by homologous recombination through the insertion of a 
phosphoglycerate kinase promoter followed by the neo gene (PGK-neo) in the 
fourth exon. Southern blot analysis confirmed the gene targeting. Mutant mice 
were generated from one heterozygote embryonic clone using standard 
procedures. Disruption of both PARP1 alleles was confirmed by Southern blot 
analysis of DNA from tail biopsies. PARP1 was completely absent in mutant 
mice as shown by Western and activity analysis of spleen and testis isolated 
cells. 
 
As with the in vivo 31P-MRS experiments performed in tumour-bearing mice 
(section 2.5, data not shown), the in vivo 31P-MRS study of livers of PARP1 KO 
and WT mice was performed in the Varian 7T horizontal bore preclinical MR 
system using the Rapid 1H-31P 12 mm surface coil. Mice were divided in two 
groups: KO and WT, and in each group there were four subgroups of mice 
treated with:  
• Control (no treatment);  
• 1 mg/kg of rucaparib (10 ml/kg of a 0.1 mg/ml solution in water for 
injection);  
• 68 mg/kg of temozolomide (10 ml/kg of a 6.8 mg/ml solution in saline);  
• 1 mg/kg of rucaparib combined with 68 mg/kg of temozolomide (10 ml/kg 
of a 0.1 mg/ml solution in water for injection with 10 ml/kg of a 6.8 mg/ml 
solution in saline);  
Each animal was treated daily for 5 days and scanned on day 5, 30 minutes 
after the fifth treatment. 31P-MRS acquisition was initiated approximately 1 hour 
after the treatment and 30 minutes after the imaging protocol started. 
 
The setup for this experiment was marginally different from the one used for the 
tumour DCE-MRI/31P-MRS protocol (section 2.5). Here, the mouse was placed 
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in a handmade polystyrene bed in which the coil was inserted in a position that 
allowed the mouse to lie in a prone position over it.  
Because the PARP1 KO and WT mice have a C57 Black 6 background their 
abdomen was shaved under anaesthesia. The lower end of the sternum of the 
mouse was placed at the top limit of the coil to ensure that the liver was over 
the coil. The respiration pillow was attached to a platform taped onto the mouse 
back to monitor respiration. All the treatments were given before the mouse was 
placed into the magnet, hence no lines for injection were necessary.  
    
Once the tray was placed in the magnet, the respiration and bore temperature 
were monitored and data acquisition initiated with a short scout scan of 5 
images over 3 planes to confirm the positioning of the liver over the coil.  
 
Data were then acquired as described in section 2.5 until the ISIS sequence. 
The first ISIS sequence had one block of 64 averages, and as the coil was 
positioned under the mouse ribcage, the sequence acquisition was gated with 
the respiration signal to avoid excessive movement of the mouse compared to 
the acquisition voxel. After verification of the signal quality a dynamic ISIS 
sequence was initiated. This sequence had the same parameters as the 
previous test ISIS for nine blocks of 64 averages, also gated. Depending on the 
breathing rate, the scan took on average 25 minutes. The 9 data blocks were 
summed into one single spectrum and the data analysed in jMRUI. 
 
When the in vivo 31P-MRS acquisition was finished, the mouse was removed 
from the magnet, kept under deep anaesthesia (4% (v/v) isoflurane/oxygen) and 
placed in a supine position on the bench. Abdominal surgery was performed to 
expose the liver which was freeze clamped in situ with tongs precooled in liquid 
nitrogen. The mouse was killed by cervical dislocation as the liver was frozen in 
the tongs and the frozen liver was detached, kept in liquid nitrogen and then 
stored in a -80°C freezer until extraction. The extraction protocol was exactly 
the same as the tissue extraction protocol (section 2.6.1) and the ex vivo 31P-
MRS acquisition was also performed in the 11.4T Bruker NMR spectrometer 
using the same protocols for proton and phosphorus spectroscopy as described 
in section 2.3.4. 
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2.8 PET studies 
The PET studies were performed to assess changes in the mean Standardized 
Uptake Values (SUVs) for different tracers following drug treatment. [18F]Fluoro-
2-deoxy-2-D-glucose ([18F]FDG) was used to assess metabolic changes in the 
tumour, while in the 3'-deoxy-3'-[18F]-fluorothymidine ([18F]FLT) was used to 
assess the proliferative status of the tumour. All the PET studies were carried 
out on a Philips Mosaic HP Small Animal imaging PET scanner (Philips Medical 
Systems, Global Information Center, P.O. Box 1168, 5602 BD Eindhoven, The 
Netherlands) with an Homeothermic Blanket System (Harvard Apparatus Ltd., 
Kent, TN8 6WF, UK) to maintain the body temperature. This particular PET 
scanner has a transverse FOV of 12.8 cm and an axial extent of 11.9 cm 
operating only in 3D mode. The coincidence timing window is 12 ns with a 
standard energy window between 410 and 665 KeV. The spatial resolution 
obtained is approximately 2 mm.  
 
2.8.1 [18F]FDG studies 
Due to previous studies performed by Ian Wilson (personal communication) 
showing poor [18F]-FDG uptake into SW620 tumours, only the A2780 cancer 
cell line was used to assess the effects of drug treatment on [18F]-FDG uptake.  
 
Nude CD1 mice were inoculated with 8-10x106 A2780 cells per 50μl of media 
subcutaneously under anaesthesia. The tumours were allowed to grow until 
they have reached an approximate size of 5x5 mm and then randomized into 
four groups:  
• Control (no treatment);  
• 1 mg/kg of rucaparib (10 ml/kg of a 0.1 mg/ml solution in water for 
injection);  
• 68 mg/kg of temozolomide (10 ml/kg of a 6.8 mg/ml solution in saline);  
• 1 mg/kg of rucaparib combined with 68 mg/kg of temozolomide (10 ml/kg 
of a 0.1 mg/ml solution in water for injection with 10 ml/kg of a 6.8 mg/ml 
solution in saline);  
Mice were treated for 5 days and rucaparib was administrated by i.p. injection 
while the temozolomide dose was given by oral gavage.  
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Data acquisition setup 
On day 5, one hour after the treatment, the mice were anaesthetised with a 
cocktail of ketamine/medetomidine (ketamine 50-75 mg/kg i.p. and 
medetomidine 0.5-1.0 mg/kg i.p. in a volume of 0.1 ml/10 g). This cocktail was 
prepared and supplied by the Comparative Biology Centre, Newcastle 
University.  The tail vein was cannulated using a 30G needle attached to a 1 ml 
syringe containing 20 units/ml of heparin by a BPTE-T10, 0.28 mm ID, 0.61 mm 
OD tubing as in the DCE-MRI protocol as described in section 2.4. Once the tail 
vein was successfully cannulated, the cannula was glued to the tail using 
Hystoacryl®. The mouse was then transferred into the PET scanner and placed 
on the heating blanket on the bed, and using an inbuilt laser marker the mouse 
was centred in the FOV of the scanner. The cannula tubing was then cut and a 
1 ml syringe with a 30G needle which contained approximately 15 MBq of 
[18F]FDG (prepared by dilution in saline) was connected.  
 
As soon as the acquisition sequence was started in the scanner, the radiotracer 
was injected and the syringe and all the tubing removed from the mouse. 
Activity remaining in the syringe and tubing was measured in a scintillation well 
counter, and the difference between the activity in the syringe before and after 
the injection gave the amount of activity injected into the mouse for use with the 
mouse weight in the reconstruction algorithm. Due to the use of an injectable 
anaesthetic and a platform bed with a heating blanket it was possible to scan 
three mice at the same time in the same scan.  
 
Data were acquired in dynamic mode with 10 one minute frames plus 6 five 
minutes frames plus 2 ten minutes frames (i.e. 10x 1 minute, 6x 5 minutes, 2x 
10 minutes). Although reconstruction was concurrent with the data acquisition, 
the software can only have the activity and weight of one mouse at the time. 
Performing scans in 3 mice at a time translated into the repetition of the 
reconstructions with the individual values of activity and weight per mouse. This 
minimizes artifacts and maintains a good accuracy of the SUV measurements 
since the SUV calculation and reconstruction takes into account individual times 
of injection, individual injected doses and individual weights. 
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The reconstruction algorithm used was 3D-RAMLA (decay correction and SUV 
measurement) and the data analysis was performed using Philips Imalytics 
software with the Volume of Interest (VOI) drawn around the tumour and the 
mean SUV measured in the VOI. The variation in SUV was generally between 3 
and 5%. 
 
Data would be excluded from the study if the injection was poor (loss of the 
cannulation, detachment of the i.v. cannula during injection of radiotracer or 
vessel blockage during injection) leading to an injection of less than 5 MBq. 
During data analysis is the tumour did not have at least 6 voxels, it would be 
excluded too.  
 
Once the acquisition terminated the mice were recovered by an i.p. injection of 
atipamezole (1-2.5 mg/kg), which reverses the medetomidine, and were left 
over a heating blanket until they were fully mobile.  
The mice were then returned to the cage and taken back to the animal house.  
 
The tumour volumes were measured until 100 days after treatment or until the 
tumour size reached 10x10 mm (or 15 mm in one direction), which was the 
maximum size allowed under animal welfare considerations. Also if the mouse 
showed signs of distress or poor health (e.g. a significant loss of body weight) it 
was killed. The tumour volume was calculated using the following equation: 
𝑇𝑢𝑚𝑜𝑢𝑟 𝑉𝑜𝑙𝑢𝑚𝑒 = 𝑙𝑜𝑛𝑔 𝑎𝑥𝑖𝑠2 × (𝑠ℎ𝑜𝑟𝑡 𝑎𝑥𝑖𝑠)2 
 
 
2.8.2 [18F]-FLT studies 
The [18F]-FLT study was performed using the exactly same protocol as for the 
[18F]-FDG study, the only difference being that both cancer cell lines, A2780 and 
SW620, were used (section 2.8.1). 
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Chapter 3. Results – Tumour vascular and metabolic changes 
due to hydralazine, rucaparib, temozolomide and combined 
rucaparib with temozolomide treatment as assessed  by in vivo 
MR   
The experiments described in this chapter were performed to test the 
hypothesis that PARP inhibition can modulate tumour vasculature, leading to an 
alteration in tumour energetics, and that the effect may contribute to the 
enhanced efficacy of PARP inhibitor/temozolomide combinations.  
 
Calabrese et al. (2003) reported a statistically significant improvement of 
vascular perfusion in SW620 tumour xenografts treated with AG014361 (a 
forerunner of rucaparib). The Hoechst-stained vessel assay used showed that 
AG014361 had a vasoactive effect in the tumour. In the same study, SW620 
tumour-bearing mice were injected with another PARP1 inhibitor, PD128763 
which caused a drop in the mice body temperature while AG014361 had no 
such effect. This might indicate a direct vascular effect of AG014361 rather than 
an off-target effect.  PARP inhibitors are analogues of nicotinamide and 
Horsman reviewed data showing that nicotinamide was able to reduce tumour 
hypoxia by preventing the transient cessation of blood flow in tumour 
microvasculature, a role that could sensitize to alkylating agent treatment 
(Horsman, 1995). Ali et al. (2009) reported that, although rucaparib failed to 
sensitize SW620 cells to the alkylating agent temozolomide in vitro, 1 mg/kg 
rucaparib improved tumour perfusion in SW620 tumours based on vessel 
mismatch studies and on real time observations of perfusion using SW620 
tumours grown in dorsal window chambers. SW620 cells have low levels of 
ATases and mismatch repair proficiency making them hypersensitive to 
temozolomide. This already existing hypersensitivity is a likely explanation why 
a further potentiation of temozolomide with the treatment with PARP inhibitors is 
not observed in these cells (Calabrese et al., 2004). 
 
Ronen et al. (1999) published work where 31P-MRS was used in SW620 cells 
treated with the anthracycline doxorubicin to assess metabolic changes due to 
chemotherapy-induced apoptosis. Cells treated for 24h with doxorubicin 
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showed a decrease of 30 to 40% in NTP concentration when compared to 
control cells (Ronen et al., 1999).  
 
To test the hypothesis that PARP inhibition induces vascular stabilization and 
metabolic deregulation both Dynamic Contrast Enhanced (DCE) MRI and 31P-
MRS studies were performed in A2780 and SW620 tumour-bearing mice. 
In both experiments there were eight study groups: 
• Control (10μl of saline per g of body weight);  
• 5 mg/kg of hydralazine (10 ml/kg of a 0.5 mg/ml solution in saline);  
• 1 mg/kg of rucaparib (10 ml/kg of a 0.1 mg/ml solution in water for 
injection);  
• 5 mg/kg of rucaparib (10 ml/kg of a 0.5 mg/ml solution in water for 
injection);  
• 50 mg/kg of rucaparib (10 ml/kg of a 5 mg/ml solution in water for 
injection);  
• 68 mg/kg of temozolomide (10 ml/kg of a 6.8 mg/ml solution in saline);  
• 1 mg/kg of rucaparib combined with 68 mg/kg of temozolomide (10 ml/kg 
of a 0.1 mg/ml solution in water for injection with 10 ml/kg of a 6.8 mg/ml 
solution in saline);  
• 5 mg/kg of rucaparib combined with 68 mg/kg of temozolomide (10 ml/kg 
of a 0.5 mg/ml solution in water for injection with 10 ml/kg of a 6.8 mg/ml 
solution in saline).  
These doses were chosen as being the standard clinical dose of temozolomide, 
when expressed as mg/m2 (68 mg/kg ≈ 200 mg/m2), and rucaparib doses which 
are known to potentiate temozolomide (Calabrese et al., 2003; Thomas et al., 
2007; Ali et al., 2011).  
 
In all these experiments the mice received a single treatment, delivered by 
intraperitoneal (i.p.) injection during the course of the experiment. 
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3.1 Vascular effects of rucaparib, temozolomide or combined rucaparib 
and temozolomide treatment as assessed by DCE-MRI 
Dynamic Contrast Enhanced MRI (DCE-MRI) was used to assess acute 
changes in the vascular state of tumours following drug administration. The 
principle underlying DCE-MRI is that drug-induced changes to the tumour 
vascular can be measured by alterations in MR contrast agent uptake. In the 
experiments described in this chapter drug-induced acute effects on the tumour 
vasculature were studied. To do so, a pre-treatment control DCE-MRI scan was 
performed following the injection of a contrast agent (gadoteridol), which was 
repeated 60 minutes after drug administration. Comparisons between the 
uptake curves at the two time points revealed the effect of the drug on the 
vasculature. MR signal intensity and quantitative analysis involving estimation of 
the gadolinium (Gd) concentration was undertaken, and the results presented 
focus on signal intensity before and after treatment. As mentioned in subsection 
1.4.1, the use of a surface coil with variable flip angle across the tumour and the 
lack of arterial input function measurements did not allowed a simple 
extrapolation of Gd concentrations. The use of pre- and post-contrast agent 
injection DCE-MRI parameters has been widely used to assess vasculature 
response to treatment (Robinson et al., 2003; McIntyre et al., 2004).  
 
The data were acquired using an Agilent 7T small bore MR scanner and 
analysed in imageJ, a freeware tool which can open multiple *.fdf (Agilent 
format image data) files at once and gather them into a stack. The dynamic 
acquisition was based on a gradient echo sequence, repeated 100 times over 
the same slice with a temporal resolution of 6 seconds. In the slice a Region Of 
Interest (ROI) was drawn and the average brightness intensity measured. 
Potentially, different ROIs can be drawn and compared, for example, 
vasculature changes in the centre of the tumour in comparison with the outer 
ring, although this was not performed in the current study. 
 
The data analysis involved the definition of the ROI for each mouse and the 
measurement of the average brightness intensity over time in the ROI. 
Normalization to a background level (average of blocks 2-6 prior to contrast 
agent administration) was performed in order to compare the contrast agent 
uptake after both injections as shown in section 2.4. 
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 Figure 3.1 (a) to d)) shows the normalized tumour DCE-MRI uptake curves, in 
pixel mean MR signal intensity for injections of gadoteridol (90 minutes apart) 
before and after the administration of saline (control), 5 mg/kg hydralazine, 1 
mg/kg rucaparib or a combination of 1 mg/kg rucaparib with 68 mg/kg 
temozolomide to A2780 tumour-bearing mice. 
 
Figure 3.1: Normalized DCE-MRI uptake curves in A2780 tumours. In all graphs the uptake curve for the 
first gadoteridol injection is in blue and the uptake curve for the second injection of gadoteridol is in red. a) 
control group (n=8); b) 5 mg/kg hydralazine group (n=6); c) 1 mg/kg rucaparib group (n=8); d) 1 mg/kg 
rucaparib combined with 68 mg/kg temozolomide (n=4). Points are the mean and bars are the standard 
error. 
The Area Under the Curve for MR signal intensity was calculated for the first 
120 seconds after the injection of gadoteridol (AUCMR, 120s) using Prism 5 for 
Windows as described in the Methods (section 2.4) and data are shown in 
Figures 3.2-3.4.  
 
Figure 3.2 (a) and b)) shows the average (mean) A2780 tumour AUCMR, 120s for 
control and 5 mg/kg of hydralazine treated tumours with the corresponding 
standard error of the mean. In Figure 3.3 (a) to d)), A2780 tumour AUCMR, 120s  
data for control and 1, 5 and 50 mg/kg rucaparib-treated mice are depicted with 
the corresponding standard error of the mean. Figure 3.4 (a) to d)) shows the 
A2780 tumour AUCMR, 120s data for control, 68 mg/kg temozolomide and 
98 
rucaparib and temozolomide combination treated mice with the corresponding 
standard error. 
 
Figure 3.2: Average AUCMR,  120s ,with the corresponding standard error, pre and post drug injection for a) 
control group (n=8); b) 5 mg/kg hydralazine group (n=6) in A2780 tumours. In b) the star indicates a 
statistically significant reduction in AUC (p≤0.05). 
 
 
Figure 3.3: Average AUCMR, 120s, with the corresponding standard error, pre and post drug injection for a) 
control group (n=8); b) 1 mg/kg rucaparib group (n=8); c) 5 mg/kg rucaparib group (n=4); d) 50 mg/kg 
rucaparib group (n=4) in A2780 tumours. In b) the star indicates a statistically significant reduction in AUC 
(p≤0.05). 
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Figure 3.4: Average AUCMR, 120s, with the corresponding standard error, pre and post drug injection for a) 
control group (n=8); b) 68 mg/kg temozolomide group (n=5); c) 1 mg/kg rucaparib combined with 68 mg/kg 
temozolomide group (n=4); d) 5 mg/kg rucaparib combined with 68 mg/kg temozolomide group (n=5) in 
A2780 tumours.  
 
Figure 3.5 (a) to d)) shows the tumour DCE-MRI uptake curves (mean MR pixel 
signal intensity) for injections of gadoteridol (90 minutes apart) before and after 
the administration of saline, 5 mg/kg hydralazine, 5 mg/kg or 50 mg/kg 
rucaparib to  SW620 tumour-bearing mice. 
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Figure 3.5: Normalized DCE-MRI uptake curves in SW620 tumours. In all graphs the uptake curve for the 
first gadoteridol injection is in blue and the uptake curve for the second injection of gadoteridol is in red. a) 
control group (n=6); b) 5 mg/kg hydralazine group (n=9); c) 5 mg/kg rucaparib group (n=6); d) 50 mg/kg 
rucaparib  (n=7). Points are the mean and bars are the standard error. 
 
The Area Under the Curve for the MR signal intensity in the first 120 seconds 
after the injection of gadoteridol was calculated, and the average AUCMR, 120s for 
SW620 tumour bearing-mice are shown in Figures 3.6-3.8. 
 
Figure 3.6: Average AUCMR, 120s, with the corresponding standard error, pre and post drug injection for a) 
control group (n=6); b) 5 mg/kg hydralazine group (n=9) in SW620 tumours. In b) the star indicates a 
statistically significant reduction in AUC (p≤0.05).  
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Figure 3.7: Average AUCMR, 120s , with the corresponding standard error, pre and post drug injection for a) 
control group (n=6); b) 1 mg/kg rucaparib group (n=6); c) 5 mg/kg rucaparib group (n=6); d) 50 mg/kg 
rucaparib group (n=7) in SW620 tumours. In c) and d) the star indicates a statistically significant reduction 
in AUC following drug administration (p≤0.05). 
 
Figure 3.8: Average AUCMR, 120s, with the corresponding standard error, pre and post drug injection for a) 
control group (n=6); b) 68 mg/kg temozolomide group (n=5); c) 1 mg/kg rucaparib combined with 68 mg/kg 
temozolomide group (n=5); d) 5 mg/kg rucaparib combined with 68 mg/kg temozolomide group (n=6) in 
SW620 tumours.  
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The data presented in Figures 3.2-3.4 and 3.6-3.8 are summarized in Table 3.1 
and the results of a paired t test statistical analysis of the data are presented in 
Table 3.2. 
 
Tumour  
treatment 
A2780 SW620 
AUCMR, 120s for 
first gadoteridol 
injection 
AUCMR, 120s for 
second 
gadoteridol 
injection 
AUCMR, 120s for 
first gadoteridol 
injection 
AUCMR, 120s for 
second 
gadoteridol 
injection 
Control 7.9±1.2 6.5±1.5 13.9±1.9 13.0±1.7 
5 mg/kg 
hydralazine 17.4±2.4 10.5±2.5* 9.9±0.9 4.9±0.7* 
1 mg/kg rucaparib 17.1±1.5 10.8±1.4* 9.6±1.1 7.6±1.7 
5 mg/kg rucaparib 17.8±3.7 16.4±3.7 7.8±0.9 5.9±0.8* 
50 mg/kg rucaparib 16.4±2.9 16.6±2.8 12.2±1.7 7.7±1.4* 
68 mg/kg 
temozolomide 13.1±1.3 13.0±0.9 11.0±0.8 9.5±0.9 
1 mg/kg rucaparib 
+ 68 mg/kg 
temozolomide 
13.1±2.7 11.1±2.1 10.6±1.2 11.0±1.3 
5 mg/kg rucaparib 
+ 68 mg/kg 
temozolomide 
8.4±1.9 7.6±1.9 8.6±1.2 7.2±1.6 
 
Table 3.1: Summary of the mean AUCMR, 120s data, with the correspondent standard error, from Figures 
3.2-3.4 and 3.6-3.8 in A2780 and SW620 tumour-bearing mice. * Indicates that the values for the first and 
second gadoteridol injections were significantly different (p<0.05). 
 
 
Tumour 
treatment 
A2780 SW620 
p values for the difference between 
the AUCMR, 120s after the first and 
second contrast agent injection 
p values for the difference between 
the AUCMR, 120s after the first and 
second contrast agent injection 
Control 0.16 0.45 
5 mg/kg 
hydralazine 0.029 0.000026 
1 mg/kg 
rucaparib 0.00077 0.37 
5 mg/kg 
rucaparib 0.18 0.020 
50 mg/kg 
rucaparib 0.48 0.024 
68 mg/kg 
temozolomide 0.94 0.18 
1 mg/kg 
rucaparib + 
68 mg/kg 
temozolomide 
0.086 0.69 
5 mg/kg 
rucaparib + 
68 mg/kg 
temozolomide 
0.063 0.25 
 
Table 3.2: p Values generated using a paired t test analysis to evaluate the significance of the difference 
between pre- and post-treatment AUCMR, 120s values in A2780 and SW620 tumour-bearing mice (data from 
Table 3.1).   
 
The results presented above show that in A2780 tumours the low dose (1 
mg/kg) of rucaparib reduced the AUCMR, 120s whereas the higher doses (5 and 
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50 mg/kg) did not. In contrast, in SW620 tumours, the lower dose of rucaparib 
(1 mg/kg) did not alter AUCMR, 120s whilst the higher two doses (5 and 50 mg/kg) 
did. Neither temozolomide alone or in combination with rucaparib induced 
reductions in AUCMR, 120s at any of the doses studied at the 5% significance 
level. However, there was a trend to a reduced AUCMR, 120s for temozolomide in 
combination with both doses of rucaparib (1 mg/kg – p=0.086, 5 mg/kg – 
p=0.063) in A2780 tumours. In addition, the statistical analysis summarized in 
Table 3.2 demonstrated that hydralazine (5 mg/kg) induces a statistically 
significant decrease in the AUCMR, 120s in both A2780 and SW620 tumours. 
Rucaparib alone also produced a significant decrease in AUCMR, 120s which was 
dose dependent in both tumour types; however the dose dependency was 
inverse (the lower dose effecting A2780 tumours and the higher doses effecting 
SW620 tumours).  
 
To allow the comparison between treatment groups it was necessary to 
normalize data and this was achieved by calculating the ratio between the 
AUCMR, 120s for the first injection (AUC120_1) and for the second injection 
(AUC120_2). This ratio will henceforth be termed the Anti-Vascular Index (AVI). 
An increase in this ratio corresponds to a decrease in the AUCMR, 120s for the 
second injection of contrast agent which is related to impairment of the vascular 
supply to the tumour. 
 
Figures 3.9 and 3.10 present the DCE-MRI data as the AVI in A2780 and 
SW620 tumour-bearing mice. 
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 Figure 3.9: Median values and inter-quartile range (error bars) for the AVI in A2780 tumour-bearing mice. 
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Figure 3.10: Median values and inter-quartile range (error bars) for the AVI in SW620 tumour-bearing 
mice. 
 
Although a statistical analysis of the A2780 data using a one-way ANOVA with 
multiple comparisons between all the groups, and using each group as a 
reference, showed no significant differences for the AVI between different 
treatment groups in either tumour type, a Mann-Whitney non-paired t-test 
revealed significant differences between certain groups of A2780 tumour-
bearing mice (Table 3.3). Thus for A2780 tumours the AVI for the 50 mg/kg 
rucaparib group was significantly lower than in controls and in the 1 mg/kg 
rucaparib combined with 68 mg/kg temozolomide group. Similarly, the AVI for 
the 1 mg/kg rucaparib group was significantly higher than all groups except for 
the control and 5 mg/kg hydralazine. 
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 5 mg/kg hydralazine 1 mg/kg rucaparib 5 mg/kg rucaparib 
Control 0.65 0.28 0.26 
5 mg/kg hydralazine  0.57 0.17 
1 mg/kg rucaparib   0.028* 
 
50 mg/kg 
rucaparib 
68 mg/kg 
temozolomide 
1 mg/kg rucaparib + 68 
mg/kg temozolomide 
5 mg/kg rucaparib + 68 
mg/kg temozolomide 
Control 0.049* 0.22 0.74 0.22 
5 mg/kg hydralazine 0.11 0.08 0.33 0.24 
1 mg/kg rucaparib 0.0081* 0.0109* 0.049* 0.019* 
5 mg/kg rucaparib 0.34 0.71 0.49 >0.99 
50 mg/kg rucaparib  0.68 0.029* 0.064 
68 mg/kg 
temozolomide 
  0.56 0.80 
1 mg/kg rucaparib + 68 
mg/kg temozolomide 
   0.19 
 
Table 3.3: p Values generated using a Mann-Whitney (non-paired t test) to evaluate the significance of the 
effect of treatment on AVI in A2780 tumour bearing mice. The star indicates statistically significant values 
(p<0.05). 
 
A corresponding statistical analysis was performed on data generated in 
SW620 tumour bearing mice. As shown in Table 3.4, the AVI for the 5 mg/kg 
hydralazine group was higher than all other groups except 1 mg/kg rucaparib. 
Similarly, the AVI for the 50 mg/kg rucaparib group was significantly higher than 
in controls and the 1 mg/kg rucaparib combined with 68 mg/kg temozolomide 
groups.  
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 5 mg/kg hydralazine 1 mg/kg rucaparib 5 mg/kg rucaparib 
Control 0.0007* 0.79 0.09 
5 mg/kg hydralazine  0.22 0.043* 
1 mg/kg rucaparib   0.79 
 
50 mg/kg 
rucaparib 
68 mg/kg 
temozolomide 
1 mg/kg rucaparib + 68 
mg/kg temozolomide 
5 mg/kg rucaparib + 68 
mg/kg temozolomide 
Control 0.014* 0.65 0.52 0.26 
5 mg/kg hydralazine 0.040* 0.0062* 0.0031* 0.0081* 
1 mg/kg rucaparib 0.29 0.90 0.52 >0.99 
5 mg/kg rucaparib 0.43 0.63 0.08 0.70 
50 mg/kg rucaparib  0.33 0.03* 0.22 
68 mg/kg 
temozolomide 
  0.15 0.71 
1 mg/kg rucaparib + 
68mg/kg temozolomide 
   0.29 
 
Table 3.4: p Values generated using a Mann-Whitney (non-paired t test) to evaluate the significance of the 
effect of treatment on AVI in SW620 tumour bearing mice. The star indicates statistically significant values 
(p<0.05). 
 
Consistently, the DCE-MRI data results demonstrate that hydralazine (5 mg/kg) 
strongly reduces the uptake of contrast agent, measured by the AUCMR, 120s, 
after treatment in both A2780 and SW620 tumour-bearing mice.   
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3.2 Metabolic effects of rucaparib, temozolomide or rucaparib combined 
with temozolomide treatment as assessed by in vivo 31P spectroscopy 
In vivo 31P MR spectroscopy was used to study metabolic changes in tumours 
following treatment. In theory, if a drug affects the tumour vasculature, tumour 
metabolism will also be affected and the ratio between inorganic phosphate (Pi) 
and beta-NTP (βNTP - primarily reflecting ATP) concentrations should change 
accordingly as the delivery of oxygen and nutrients is reduced. Although PARP 
inhibition could lead to an increase of cellular NAD, which could theoretically 
also be studied by 31P-MRS, the coil used in this work was not sensitive enough 
to detect signals from NAD. Also, the protocol did not include an external 
reference, making absolute quantitation of NAD levels in the tumours 
impossible. Furthermore, there is partial overlap between the NAD and αNTP 
signals and, possibly, other signals in the diphosphodiester region of the 31P 
spectrum, further compromising the analysis of NAD. There are numerous 
examples in the literature where in vivo 31P-MRS has been performed to 
estimate absolute concentrations of metabolites (for example, Van Boogaart et 
al., 1995).   
 
In the experiments performed here, the Pi to βNTP ratio was measured and the 
data analysed in relation to the in vivo DCE-MRI results presented in section 3.1. 
The groups studied were the same as those described in section 3.1 and in 
some cases data were derived from the same individual mouse; the phosphorus 
spectra being acquired between the 2 injections of contrast agent in the DCE-
MRI scan. Using a dynamic ISIS sequence, a phosphorus spectrum was 
acquired every 4 minutes, starting 11 minutes and 30 seconds after the first 
contrast injection and lasting for 72 minutes. The drug was injected during the 
acquisition of the phosphorus spectra to allow dynamic assessment of the 
changes in the tumour 31P-MRS spectrum. 
 
Analysis of the data was performed using jMRUI, a freeware software tool for 
MRS analysis (van den Boogaart et al., 1996, van den Boogaart et al., 1997).  
Using the AMARES algorithm within jMRUI, it was possible to estimate the 
amplitudes of several relevant peaks. In the analysis, the spectra were summed 
into 9 blocks of 8 minutes each and phased accordingly. Starting frequency 
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values for each peak, and a soft constraint of bounds for both frequency and 
damping, were used to facilitate the estimation. 
 
Groups studied were: control, 5 mg/kg hydralazine, 1, 5 and 50 mg/kg rucaparib, 
68 mg/kg temozolomide, 1 mg/kg rucaparib combined with 68 mg/kg 
temozolomide and 5 mg/kg rucaparib combined with 68 mg/kg of temozolomide. 
Treatment was given 30 minutes after the first injection of contrast agent, and 
18.5 minutes after the ISIS sequence started, and for at least 45 minutes after 
the drug injection.  
 
Figures 3.11 and 3.12 are examples of 31P-MR spectra from A2780 and SW620 
tumour-bearing mice. The original spectrum is shown in red and the AMARES 
estimation of the spectrum is shown in blue. Figure 3.11 depicts single spectra 
from individual a) control, b) 5 mg/kg hydralazine, c) 1 mg/kg rucaparib and d) 1 
mg/kg rucaparib combined with 68 mg/kg temozolomide treated mice bearing 
A2780 tumours. Figure 3.12 depicts single spectra from individual a) control, b) 
5 mg/kg hydralazine, c) 5 mg/kg rucaparib and d) 50 mg/kg rucaparib treated 
mice bearing SW620 tumours.   
a)                                                        b) 
    
c)                                                         d) 
      
Figure 3.11: 31P-MR spectra from A2780 tumour-bearing mice. a) Control, b) 5 mg/kg hydralazine, c) 1 
mg/kg rucaparib and d) 1 mg/kg rucaparib combined with 68 mg/kg temozolomide. Peaks are labelled 
according to the following numbers: 1 – AMP; 2 – inorganic phosphate; 3 – phosphocreatine; 4 – γNTP; 5 
– αNTP; 6 – NAD; 7 – βNTP. 
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a)                                                       b) 
    
c)                                                         d) 
      
Figure 3.12: 31P-MR spectra from SW620 tumour-bearing mice. a) Control, b) 5 mg/kg hydralazine, c) 5 
mg/kg rucaparib and d) 50 mg/kg rucaparib.  
 
For A2780 tumour-bearing mice Figure 3.13 (a) and b)) presents the normalised 
Pi to βNTP ratio as a percentage (%) of the pre-treatment value for the control 
and 5 mg/kg hydralazine groups, and Figure 3.14 (a) to d)), presents the A2780 
data for the control and 1, 5 and 50 mg/kg rucaparib groups. Figure 3.15 (a) to 
d)) shows correspondent results for the control, 68mg/kg temozolomide, and the 
combination of 1 or 5 mg/kg rucaparib with 68 mg/kg temozolomide. All these 
Figures include the mean and standard error (error bars) and the fitted linear 
regression.  
 
Figure 3.13: Change in the Pi to βNTP ratio and fitted linear regression for a) control (n=7), and b) 5 
mg/kg hydralazine (n=4), treated A2780 tumour-bearing mice during the in vivo 31P MRS acquisition. 
Points are the mean and bars are the standard error. 
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Figure 3.14: Change in the Pi to βNTP ratio and fitted linear regression for a) control (n=7), b) 1 mg/kg 
rucaparib (n=5), c) 5 mg/kg rucaparib (n=4), and d) 50 mg/kg rucaparib (n=3) treated A2780 tumour-
bearing mice during the in vivo 31P MRS acquisition. Points are the mean and bars are the standard error. 
 
 
Figure 3.15: Change in the Pi to βNTP ratio and fitted linear regression for a) control (n=7), b) 68 mg/kg 
temozolomide (n=5), c) 1 mg/kg rucaparib plus 68 mg/kg temozolomide (n=4), and d) 5 mg/kg rucaparib 
plus 68 mg/kg (n=3), treated A2780 tumour-bearing mice during the in vivo 31P MRS acquisition. Points are 
the mean and bars are the standard error. 
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Figures 3.16-3.18 show the corresponding Pi to βNTP ratio data for SW620 
tumour-bearing mice.  
 
Figure 3.16: Change in the Pi to βNTP ratio and fitted linear regression for a) control (n=3), and b) 5 
mg/kg hydralazine (n=6), treated SW620 tumour bearing mice during the in vivo 31P MRS acquisition. 
Points are the mean and bars are the standard error. 
 
 
Figure 3.17: Change of Pi to βNTP ratio and fitted linear regression for a) control (n=3), b) 1 mg/kg 
rucaparib (n=10), c) 5 mg/kg rucaparib (n=6), and d) 50 mg/kg rucaparib (n=4), treated SW620 tumour-
bearing mice during the in vivo 31P MRS acquisition. Points are the mean and bars are the standard error. 
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Figure 3.18: Change in the Pi to βNTP ratio and fitted linear regression for a) control (n=3), b) 68mg/kg 
temozolomide (n=4), c) 1mg/kg rucaparib plus 68mg/kg temozolomide (n=3), and d) 5mg/kg rucaparib plus 
68mg/kg (n=3), treated SW620 tumour bearing-mice during the in vivo 31P MRS acquisition. Points are the 
mean and bars are the standard error. 
 
 
An alternative way to analyse these data is shown in Figures 3.19 and 3.20 
where the percentage change in the Pi/βNTP ratio 8 minutes before drug 
administration (t = -8 min), 8 minutes after (t = 8 min) or 40 minutes (t = 40 min) 
after drug treatment for both tumour types is shown. These time points were 
chosen to assure a maximum total of data elements in all of them. The time 
point before injection was used as a background reading, the 8 minute after 
injection point was set as the earliest time where an acute affect might have 
occurred, and the 40 minute time point was used to as the latest time point and 
that with the maximum number of data elements to assure signal quality. 
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Figure 3.19: Change in Pi/βNTP ratios in A2780 tumour bearing-mice grouped between 8 minutes before 
injection of drug, 8 minutes and 40 minutes after drug injection. The mean ratio and standard error of the 
mean is shown on median and inter-quartile range. 
 
 
Figure 3.20: Change in Pi/βNTP ratios in SW620 tumour bearing-mice grouped between 8 minutes before 
injection of drug, 8 minutes and 40 minutes after drug injection. The mean ratio and standard error of the 
mean is shown on median and inter-quartile range. 
 
The maximum change in the ratio Pi to βNTP in each group independent of the 
time point is shown in Figures 3.21 and 3.22 for A2780 and SW620 tumour-
bearing mice, respectively. 
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Figure 3.21: Median values and inter-quartile range (error bars) for the maximum change in Pi/βNTP 
ratios in each group of A2780 tumour-bearing mice. 
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Figure 3.22: Median values and inter-quartile range (error bars) for the maximum change in Pi/βNTP 
ratios in each group of SW620 tumour-bearing mice. 
 
Jones et al. (2008) have used 31P-MRS to study muscle metabolic responses to 
exercise with linear regression analysis (slope) to define the highest constant 
work rate that can be sustained without a progressive loss of homeostasis 
(Jones et al., 2008). In an analogous manner in the current study, linear 
regression was used to analyse the data depicted in Figures 3.9 to 3.14 and the 
slopes of each fitted line are presented in Table 3.5. 
 
 Control 5 mg/kg hydralazine 1 mg/kg rucaparib 5 mg/kg rucaparib 
A2780 0.2± 1.3 4.3±1.1 1.5±0.06 -0.4±0.4 
SW620 -0.8±0.7 6.3±1.0 -0.1±0.6 0.05±0.3 
 50 mg/kg rucaparib 
68 mg/kg 
temozolomide 
1 mg/kg rucaparib 
+ 68 mg/kg 
temozolomide 
5 mg/kg rucaparib 
+ 68 mg/kg 
temozolomide 
A2780 -0.3±0.3 0.3±0.7 -0.9±0.6 0.4±0.3 
SW620 -0.01±0.4 -0.05±0.5 -0.08±0.3 0.1±0.6 
 
Table 3.5: Slope and standard error for the linear regression analyses of the % change of Pi/βNTP ratio 
data presented in Figures 3.9 to 3.14.  
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The linear regression analysis of the data presented in Figures 3.9-3.14 
generated p values (Table 3.6). Statistical analysis demonstrated that only 5 
mg/kg hydralazine produced an effect where the slope was significantly different 
from zero. In A2780 tumour-bearing mice, 1 mg/kg rucaparib produced an effect 
that was on the borderline of significance at the 95% confidence level (p=0.053), 
suggesting an acute change in the 31P-MR spectrum in this group. 
 
 Control 5 mg/kg hydralazine 1 mg/kg rucaparib 5 mg/kg rucaparib 
A2780 0.88 0.016* 0.053 0.33 
SW620 0.35 0.0038* 0.84 0.86 
 50 mg/kg rucaparib 
68 mg/kg 
temozolomide 
1 mg/kg rucaparib 
+ 68 mg/kg 
temozolomide 
5 mg/kg rucaparib 
+ 68 mg/kg 
temozolomide 
A2780 0.38 0.67 0.26 0.32 
SW620 0.98 0.93 0.8 0.85 
 
Table 3.6: p Values for the linear regression analyses of the % change of Pi/βNTP ratio data presented in 
Figures 3.9 to 3.14.  
 
The maximum values for the change in Pi to βNTP ratio were also analysed 
statistically by using a one-way ANOVA and a Mann-Whitney non-paired t test. 
One-way ANOVA did not reveal any significant difference across groups nor 
across tumour type. Using a Mann-Whitney non-paired t test there were no 
statistically significant difference across treatment groups in A2780 tumour-
bearing mice. In the SW620 tumour-bearing mice, however, the 5 mg/kg 
hydralazine group was significantly different from all the other treatment groups 
(0.047 ≤ p ≤ 0.033), and 1 mg/kg rucaparib alone group was significantly 
different from the combination of 1 mg/kg rucaparib with 68 mg/kg 
temozolomide (p=0.028). 
 
Analysing the data by individual time point was also investigated, and 3 time 
points were chosen: 8 minutes before injection of the drug (t = -8min), 8 minutes 
after the injection of the drug (t = 8min) and 40 minutes after the injection of the 
drug (t = 40min). The change in the pre-treatment to post-treatment Pi to βNTP 
ratio as a percentage was analysed using paired t tests. Analysis of A2780 data 
identified statistically significant differences between pre-treatment and 40 
minutes after drug injection in the 5 mg/kg rucaparib group (p=0.025) 
suggesting a fall in the Pi to βNTP ratio in this group due to treatment. Using the 
same analysis for data generated in SW620 tumour-bearing mice, no 
statistically significant effects at the 5% level of individual drugs or drug 
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combinations on Pi/βNTP ratios could be demonstrated. However, the 5 mg/kg 
hydralazine induced an increase in the Pi/βNTP ratio that was significant at the 
10% level (p=0.082), consistent with a vascular effect.  
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3.3 Discussion 
3.3.1 Vascular effects of rucaparib, temozolomide or combined rucaparib 
and temozolomide treatment as assessed by DCE-MRI 
The vascular effects of hydralazine were described by Horsman et al. (1992) 
and have been reviewed by Gaya and Rustin (2005). In the original paper 
effects of doses between 0.1 and 5 mg/kg hydralazine were investigated, and 
the effect on mean arterial blood pressure studied. The authors found that after 
hydralazine administration the maximum changes in blood pressure were 
apparent within 10 to 15 minutes, and were still measurable at least 30 minutes 
after injection. They also found that a 2.5 mg/kg hydralazine dose caused a 
drop of 50% in the blood pressure, and that 80% - 90% reduction in blood 
pressure can be achieved with doses between 2.5 and 5 mg/kg hydralazine 
(Horsman et al., 1992; Gaya and Rustin, 2005).   
 
Bentzen et al. (2005) published work where DCE-MRI and susceptibility 
contrast MRI assays were used in C3H mouse mammary carcinoma-bearing 
mice to assess tumour blood volumes using a specific blood pool contrast agent 
(BPA NC100150). Changes in tumour blood volume were modulated by the use 
of perfusion reducing drugs: hydralazine and combretastatin A-4 disodium 
phosphate. In this study a reduction in the initial slope between the first and 
second post-contrast signal values of 78% of the tumour blood pool was found. 
Although the cause was unclear, the authors hypothesized that it was the result 
of antihypertensive effects causing a significant decrease in mean arterial blood 
pressure (Bentzen et al., 2005). In the DCE-MRI study results presented in 
section 3.1, in both tumour types, 5 mg/kg hydralazine caused an acute 
decrease in the uptake of MR contrast agent in accordance with these 
previously published studies confirming that this agent is a good positive control. 
 
As reviewed by Jagtap and Szabó (2005), there are several physiological 
processes where PARP deficiency is actually protective, including in 
vasculature. PJ-34 and INO-1001 are two PARP inhibitors which have been 
tested in the settings of diabetic endothelium dysfunction, balloon angioplasty 
and endothelial injury by homocysteine. The inhibition of PARP activity induced 
by these drugs had a protective effect, preventing or reversing the pathologies 
they were tested against (Jagtap and Szabo, 2005).  
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In 2009, Ali et al. published work where the vasoactivity of AG014699 (i.e. 
rucaparib) was studied. In this study, performed in SW620 tumour-bearing mice, 
the authors found that 1 mg/kg rucaparib reduced vessel mismatch in SW620 
tumour xenografts in vivo and, using a dorsal window chamber technique, they 
demonstrated that 1 m/kg rucaparib enhanced tumour perfusion (Ali et al., 
2009). In 2011, the same authors published a further study using the same 
techniques, but with a higher dose of rucaparib (10 mg/kg), which showed that 
although rucaparib improved vessel perfusion in MDA-MB-231 and SW620 
tumours, this effect did not enhance the antitumour activity of the 
chemotherapeutic agent doxorubicin (Ali et al., 2011). The SW620 tumour cell 
line has been used in other vascular studies, and Bradley et al. (2008) has 
published experiments where the SW620 tumour model was used to assess the 
haemodynamic effects of vascular endothelial growth factors (VEGF) (Bradley 
et al., 2008).  
 
In A2780 human tumour xenografts antagonism of vascular endothelial growth 
factors and fibroblast growth factors (FGF) signalling has been studied using E-
3810, a dual VEGFR and FGFR inhibitor. The authors reported a significant 
reduction in tumour vessel density in treated tumours, corroborated after 5 days 
of treatment by reduced tumour distribution of contrast agent during DCE-MRI 
(Bello et al., 2011). 
 
In work published by Zhang et al. (2011), DCE-MRI was used to assess the 
vascular effects of temozolomide on its own, or in combination with radiotherapy 
and/or combined with LY21009761 (a TGF-βRI kinase inhibitor) in 
glioblastomas. In this study, the amplitude parameter in DCE-MRI showed a 
significant decrease in the monotherapy groups, but no further decrease was 
observed with dual or triple combination therapy. The decrease in amplitude 
was thought to be a consequence of a reduction in the tumour relative blood 
volume (Zhang et al., 2011).   
 
As discussed above the PARP inhibitor rucaparib has been reported to have 
nicotinamide-like effects (i.e. as discussed in Horsman, 1995) in SW620 
tumours, thus potentially improving the delivery of temozolomide to the tumour 
resulting in chemopotentiation in vivo (Ali et al., 2009). However, the overall 
121 
result for the DCE-MRI experiments presented in section 3.1 in A2780 tumour-
bearing mice, based on the AUCMR,120, is that, although a significant change 
was observed in the hydralazine group and with the lowest dose (1 mg/kg) of 
the PARP inhibitor, no significant change was observed in any of the other 
groups.  
 
In SW620 tumour-bearing mice, no significant change in AUCMR, 120s was 
observed in the control group. There were, however, significant differences in 
the uptake of contrast agent between injections of hydralazine and the higher 
doses of rucaparib (5 and 50 mg/kg). The Anti-Vascular Index (AVI, the ratio of 
AUCMR, 120s between contrast agent injections) is inverse to the AUC120_2 
(second injection uptake). In the A2780 tumour-bearing mice in control mice 
there was a rather high AVI when compared with SW620 tumour-bearing mice. 
Nevertheless, the hydralazine group had the highest AVI followed by the 1 
mg/kg rucaparib group in A2780 tumours. In SW620 tumours the hydralazine 
group and the 50 mg/kg rucaparib group had higher AVI values than control.  
 
Although the results presented in this chapter are contrary to those published by 
Ali et al. (2009), the experimental conditions are different. While the published 
work reported an increase in the vascular perfusion, the results reported in this 
thesis show a decrease in the vascular function. In the published work a dorsal 
window chamber was applied to the mice and the tumour cell implanted in the 
opening while in the experiment here reported the tumours were implanted 
subcutaneously without further restraints. The solid and constricted nature of 
the dorsal window chamber can be one reason for the difference in the obtained 
results. Nevertheless, in subsection 5.3.1, data will be presented which 
demonstrate chemopotentiation by the use of rucaparib in combination with 
temozolomide in SW620 tumours, a result that is consistent with previous 
studies.  
 
3.3.2 Metabolic effects of rucaparib, temozolomide or rucaparib combined 
with temozolomide treatment as assessed by in vivo 31P spectroscopy 
Thomas et al. in 1994 and Nordsmark et al. in 1997 have used the ratio 
between γ- or βNTP phosphates and inorganic phosphate as a bioenergetic 
indicator in mouse tumours. In the former study 31P-MRS was used to detect 
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phosphomonoester signals from neoplastic and rapidly dividing normal tissues. 
Livers of lymphomatous mice and control mice were examined in vivo by 31P-
MRS 24 days after injection of the cancer cells. At this time point the 
lymphomatous infiltration was about 70% in the liver, and phosphomonoester 
and inorganic phosphate MRS signals had increased and shifted to the right 
(indicating a lower pH). The experiments were extended to liver extracts, where 
a positive correlation between hepatic phosphomonoesther and phosphodiester 
ratios, and the degree of lymphomatous infiltration quantified by histology, was 
observed. In the second paper, C3H mammary carcinoma-bearing mice were 
examined by 31P-MRS, following exposure to atmospheric air or to air 
containing carbon monoxide. The authors concluded that the inhalation of 
carbon monoxide was associated with enhanced radiation resistance, 
decreased tumour oxygenation but an unchanged bioenergetic status 
expressed as the βNTP to Pi ratio (Thomas et al., 1994; Nordsmark et al., 1997). 
Madhu et al. (2008) have reported that the injection of different doses of Gd-
DTPA-BMA caused an increase in the choline peak area (assessed by 1H-MRS 
in HT29 colon carcinomas) dependent on the concentration injected. However, 
Bauer et al. (1994) had investigated the changes in 31P-MRS caused by 
gadolinium chelates. In the study the signals intensities of the phosphorus 
metabolites were not influenced by GdCl3, slightly enhanced by Gd-DTPA and 
highly enhanced by Gd-EOB-DTPA (Madhu et al., 2008; Bauer et al., 1994).   
  
In the current study, the inverse ratio (Pi/βNTP) was used, a higher ratio 
between inorganic phosphate and βNTP indicating a higher concentration of 
inorganic phosphate and/or a lower concentration of βNTP in tumours, due to 
reduced metabolism caused by an impaired blood supply. From Figures 3.19 
and 3.20 it can be seen that by 40 minutes after administration, hydralazine 
treatment had an effect on tumour energy metabolism in both tumour types, 
consistent with previous 31P-MRS studies (Bremner et al., 1991; Wood et al., 
1992). 
  
Although, overall, rucaparib with or without temozolomide did not produce 
marked changes in Pi/βNTP ratios, there was an increase in the Pi/βNTP ratio 
after 1 mg/kg rucaparib in A2780 tumours, based on the slope of the Pi/βNTP 
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ratio over time. This result was an unexpected observation and has no obvious 
explanation. 
  
The results from the 31P-MRS experiments in A2780 tumours show coherence 
with the DCE-MRI data, since the groups which showed a significant decrease 
in the uptake of contrast agent after drug treatment also showed an increase in 
the inorganic phosphate to βNTP ratio, i.e. in A2780 tumour-bearing mice with 5 
mg/kg hydralazine or 1 mg/kg of rucaparib. Thus the effects of 1mg/kg 
rucaparib are consistent with an antivascular action, but there was no logical 
dose-dependence (i.e. no antivascular effect was seen at higher doses of 
rucaparib). To have a better understanding of the dose dependent effect, an 
intermediate dose of rucaparib between 1 and 5 mg/kg will be necessary. 
 
In SW620 tumour-bearing mice, there is again coherence between the DCE-
MRI and MRS results with an increase in the inorganic phosphate to βNTP ratio 
in the 5 mg/kg hydralazine group. These hydralazine results agree with work 
published by Robinson et al. (2000) where GH3 prolactinoma-bearing rats were 
treated with 5 mg/kg hydralazine administered with air breathing for 40 minutes, 
1000 mg/kg nicotinamide and an initial 20 minutes carbogen breathing alone, 
resumption of air breathing for 40 minutes with administration of 1000 mg/kg 
nicotinamide, and finally 30 minutes carbogen breathing, all followed by MRI 
and 31P-MRS. The results presented include a decrease of MR signal and 
βNTP/Pi ratio after hydralazine administration. However, an increase in 
βNTP/Pi ratio after nicotinamide administration was also reported (Robinson et 
al., 2000).  
 
Together, the results presented in this chapter demonstrate that rucaparib has 
no marked or consistent acute effect on tumour vasculature when given alone 
or in combination with temozolomide. In contrast, the positive control compound 
hydralazine induced a significant and consistent antivascular effect which 
resulted in an increased Pi/βNTP ratio, i.e., a decline in tumour energetics. The 
increase in this ratio is the result of a large increase in the Pi levels combined 
with a slight decrease of βNTP levels indicating the consumption without 
replacement of ATP. 
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Chapter 4. Results – The effects of rucaparib, temozolomide 
and rucaparib combined with temozolomide treatment on NAD 
and ATP concentrations as measured by ex vivo 1H/31P MRS 
As described in section 1.2, PARP1 and PARP2 utilize NAD in single strand 
break DNA repair (Schreiber et al., 2006). The results presented in this chapter 
relate to experiments performed to assess changes in ATP and NAD 
concentrations in cells and tissues following treatment with rucaparib, 
temozolomide or rucaparib combined with temozolomide. 
 
In the previous chapter, effects on tumour vasculature and consequently tumour 
energetics in A2780 and SW620 tumour-models were studied. Evelhoch et al. 
(2000) have demonstrated that a drop in ATP is related to a reduction in cellular 
NAD following PARP activation, in apoptotic cells, a result confirmed by Ronen 
et al. (1999). Henning et al. (1997) estimated hepatic levels of PARP activity 
using the enzyme cycling method of Nisselbaum and Green to measure total 
amounts of NAD, and the results presented in this chapter have the additional 
goal of comparing NAD and ATP levels in cell and tissue extracts with the in 
vivo MR results. 
 
To measure NAD and ATP in cell and tissue extracts, a method of addition 
assay was developed and then applied to tumour cells, tumours and to livers 
from PARP1 WT and KO mice treated with rucaparib, temozolomide and the 
combination of rucaparib with temozolomide. All the results in this section were 
obtained using the perchloric acid extraction method described in the sections 
2.3 and 2.6. NMR spectroscopy was performed in the 11.4T Bruker Avance III 
500MHz NMR spectrometer located in the School of Chemistry, Newcastle 
University (Bedson Building). 
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4.1 The effect of rucaparib, temozolomide and rucaparib combined with 
temozolomide treatment on NAD and ATP concentrations in tumour cells 
assessed by in vitro 1H/31P MRS 
4.1.1 Methods of addition 
As discussed in subsection 2.3.1, the method of addition can be used to 
generate quantitative data on analyte levels in a non-homogeneous sample. In 
particular, in a multi-step procedure, the method of addition provides data on 
analyte recovery and assay linearity as well as accounting for inter-sample 
variability.  
 
 A2780 cells 
Experiments were performed as described in subsection 2.3.3. Aliquots of 5 mM 
ATP and 5 mM NAD were added to replicate samples of 1.50x108 cells as 
indicated in Table 4.1. 
 Volume added (μl) Quantity added (nmoles/10
6cells) 
5 mM ATP 5 mM NAD ATP NAD 
Tube 1 0 0 0 0 
Tube 2 75 30 2.5 1 
Tube 3 150 60 5 2 
 
Table 4.1: Volume of 5 mM ATP and 5 mM NAD added to 1.50x108 A2780 cells in the methods of addition 
assay.  
 
After the addition of ATP and NAD, the samples underwent PCA extraction, 
were freeze-dried overnight, and resuspended in 500 μl of D2O prior to the 
transfer of 400 μl into the NMR tubes. Proton (1H) and phosphorus (31P) spectra 
were acquired and quantification was performed as described in subsection 
2.3.4. TSP peaks were identified in the 0.064 ppm to -0.070 ppm region of the 
1H NMR spectra, and MDP peaks were identified in the 17.5 ppm to 15.12 ppm 
region of the 31P NMR spectra. The NAD concentration was measured from the 
doublet at approximately 9.15 ppm in the spectrum and ATP was measured 
from the doublet at approximately -5.5 ppm in the 31P spectra. 
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Figure 4.1: NAD region of 3 superimposed 1H spectra of A2780 cell extracts (tube 1 in blue, tube 2 in red 
and tube 3 in green – see Table 4.1). The NAD peaks were assigned and the doublet at approximately 
9.15 ppm was used for quantification as indicated by the purple integration curve. 
 
 
Figure 4.2: ATP region of 3 superimposed 31P spectra of A2780 cell extracts (tube 1 in blue, tube 2 in red 
and tube 3 in green – see Table 4.1). γ-, α-, and β-ATP peaks were assigned and the doublet at 
approximately -5.5 ppm  corresponding to γ-ATP was used to quantify ATP as indicated by the purple 
integration curve.  
 
In Table 4.2 the results of the ATP and NAD concentrations measured are 
compared to those expected for the quantity of analyte added.  
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Expected concentration  
of added analyte (nmoles/106cells) 
Measured analyte  
concentration (nmoles/106cells) 
ATP NAD ATP NAD 
Tube 1 0 0 0.67 0.04 
Tube 2 2.5 1 1.7 0.93 
Tube 3 5 2 3.1 1.83 
Estimated concentration  
of endogenous analyte 1.25 0.043 
Extraction efficiency 49% 90% 
 
Table 4.2: Expected and measured ATP and NAD concentrations in A2780 cell extracts (samples 
prepared as shown in Table 4.1 and data produced from spectra in Figures 4.1 and 4.2)   
 
Plotting these data and applying a linear regression analysis generated the 
results in Figure 4.3: 
 
Figure 4.3: Linear regression analysis of expected and measured ATP (a) and NAD (b) concentrations in 
A2780 cell extracts. Data from Table 4.2.   
 
From the linear regression analysis shown in Figure 4.3, the endogenous ATP 
concentration prior to addition of exogenous ATP was calculated to be 1.25 
nmole/106 cells. In the case of NAD, the endogenous concentration was 0.043 
nmoles/106 cells. The extraction efficiency or recovery, calculated by multiplying 
the slope of the regression line by 100, was 49% for ATP and 90% for NAD. 
 
SW620 cells 
Analogous experiments were performed to develop the method of addition 
assay for the measurement of ATP and NAD in SW620 cells (Table 4.3 and 4.4, 
and representative spectra in Figures 4.4 and 4.5). 
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  Volume added (μl)  (50 mM ATP/NAD cocktail) 
Quantity added  
(nmoles/106cells) 
ATP NAD 
Tube 1 0 0 0 
Tube 2 7.5 2.5 2.5 
Tube 3 15 5 5 
 
Table 4.3: Volume of 50 mM ATP/NAD cocktail added to 1.5x108 SW620 cells in the method of addition 
assay. 
 
 
 
Figure 4.4: NAD region of 3 superimposed 1H spectra of SW620 cell extracts (tube 1 in blue, tube 2 in red 
and tube 3 in green – see Table 4.3). 
 
 
Figure 4.5: ATP region of 3 superimposed 31P spectra of SW620 cell extracts (tube 1 in blue, tube 2 in red 
and tube 3 in green – see Table 4.3).  
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Expected concentration 
of added analyte (nmoles/106cells) 
Measured analyte 
concentration (nmoles/106cells) 
ATP NAD ATP NAD 
Tube 1 0 0 1.07 0.27 
Tube 2 2.5 2.5 1.83 2.27 
Tube 3 5 5 2.87 4.13 
Estimated concentration 
of endogenous analyte 2.84 0.38 
Extraction efficiency 36% 77% 
 
Table 4.4: Expected and measured ATP and NAD concentrations in SW620 cell extracts (samples 
prepared as shown in Table 4.3 and data produced from the spectra in Figures 4.4 and 4.5)  
 
Plotting these data and applying a linear regression analysis generated the 
results shown in Figure 4.6. 
 
Figure 4.6: Linear regression analysis of expected and measured ATP (a) and NAD (b) concentrations in 
SW620 cell extracts. Data from Table 4.4. 
 
From the linear regression analyse shown in Figure 4.6, the endogenous ATP 
concentration prior to addition of exogenous ATP was calculated to be 2.84 
nmoles/106 cells. In the case of NAD, the endogenous concentration was 0.38 
nmoles/106 cells, and the extraction efficiency was 36% for ATP and 77% for 
NAD. 
 
4.1.2 NAD and ATP concentrations in drug treated cells 
The effects of rucaparib, temozolomide and rucaparib/temozolomide 
combination treatments on ATP and NAD concentrations in A2780 cells were 
studied. Cell cultures were performed as described in section 2.2. Although Lutz 
et al. (1996) have demonstrated the feasibility of measuring individual purine 
and pyrimidine NDP and NTP concentrations by high resolution 31P-NMR, 
several experimental conditions have to be met. In the results presented in this 
subsection, total nucleoside di- and triphosphate (NDP, NTP) levels, as 
opposed to specifically ADP and ATP, were measured (Lutz et al., 1996).  
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 A2780 cells 
For the A2780 cell line, the drug treatments were: 
• Control;  
• 0.1 μM rucaparib; 
• 180 μM temozolomide; 
• 0.1 μM rucaparib combined with 180 μM temozolomide.  
180 μM temozolomide corresponds to the GI50 of temozolomide alone in A2780 
cells and it was combined with 0.1μM rucaparib. This combination has been 
shown to result in potentiation of growth inhibition in this cell line (personal 
communication from Lan-zhen Wang, NICR). 
 
Cells were grown for 40 hours, incubated for 6 hours with the drugs as indicated 
above and then harvested. The number of cells harvested is shown in Table 4.5. 
Subsequently, NAD and ATP concentrations in the cell extracts were measure 
as described in subsection 2.3.4 and a representative spectrum is shown in 
Figure 4.7. 
  
 Control 0.1 μM rucaparib 
180 μM 
temozolomide 
0.1 μM rucaparib + 
180 μM 
temozolomide 
Number of cells 
harvested (x108) 2.13 1.35 2.16 1.54 
 
Table 4.5: Numbers of A2780 cells harvested for the analysis of the effects of rucaparib and temozolomide 
on ATP and NAD concentrations. 
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Figure 4.7: Top: NAD region of the 1H spectra of A2780 in a cell extract of control (red) and following 
treatment with 0.1 μM rucaparib for 6h (blue). Bottom: ATP region of the 31P spectrum in the same 
samples (control in red and following treatment with 0.1 μM rucaparib for 6h in blue). 
 
Figures 4.8 and 4.9 depict the concentrations of NAD and NTP in each sample, 
and also the ratios between the NDP and NTP concentrations and the ratio 
between the inorganic phosphate (Pi) and NTP concentrations. The first 
parameter has been used by Bradbury et al. (2000) as an indicator of cell 
viability, necrosis and apoptosis, while the second parameter (inverted) has 
been used by Nordsmark et al. (1997) to assess the bioenergetic status of the 
tumour. 
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Figure 4.8: a) NAD and b) NTP concentrations in A2780 cells following treatment with 0.1 μM rucaparib, 
180 μM temozolomide or 0.1 μM rucaparib combined with 180 μM temozolomide. 
 
Figure 4.9: a) Ratio between the concentrations of NDP and NTP and b) ratio between Pi and NTP 
concentrations in A2780 cells treated with 0.1 μM rucaparib, 180 μM temozolomide or 0.1 μM rucaparib 
combined with 180 μM temozolomide. These results were not corrected for recovery rates due to the lack 
of information on the ADP recovery rate. 
 
The data presented for A2780 cells are from a single experiment and hence 
primarily demonstrate the feasibility of the methodology. 
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4.2 The effect of rucaparib, temozolomide and rucaparib combined with 
temozolomide treatment on NAD and ATP concentrations assessed in 
mouse liver and human tumour xenografts by 1H/31P MRS 
Bohndiek et al. (2010) studied tumour response to vascular disrupting agents by 
in vivo hyperpolarized 13C-MRS, DCE- and DW-MRI. In addition, they 
performed PCA extraction to measure metabolite concentrations (Bohndiek et 
al., 2010). Beloueche-Babari et al. (2010) investigated the metabolic effects of 
targeted cancer therapeutics by MRS and also compared in vitro 31P-MRS of 
cell extracts with in vivo 31P-MRS of human tumour xenografts in response of a 
histone deacetylase inhibitor treatment in HT29 cancer cells and tumours 
(Beloueche-Babari et al., 2009). Similarly, Solanky et al. (2012) studied the 
metabolic profile of rat livers following hepatobiliary injury by using in vivo and 
ex vivo MRS (Solanky et al., 2012).  
 
4.2.1 Methods of addition 
The methods of addition assay was performed to measure ATP and NAD 
concentrations in livers from CD1 nude mice and in A2780 and SW620 tumours 
grown subcutaneously.  
 
Mouse Livers 
Aliquots of 25 mM ATP and 25 mM NAD were added to replicate samples of 1 g 
wet weight of liver from SW620 tumour-bearing mice as indicated in Table 4.6 
and as described in section 2.6. 
 
 Volume added (μl) Quantity added (μmoles/g of tissue) 25 mM ATP 25 mM NAD ATP NAD 
Tube 1 0 0 0 0 
Tube 2 100 40 2.5 1 
Tube 3 200 80 5 2 
Tube 4 400 160 10 4 
Tube 5 800 320 20 8 
 
Table 4.6: Volume of 25 mM ATP and 25 mM NAD added to 1 g of liver from SW620 tumour-bearing mice 
in the methods of addition assay. 
  
The samples were then analysed as described in subsection 2.3.4 and 
representative spectra are shown in Figures 4.10 and 4.11. 
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Figure 4.10: NAD region of 5 superimposed 1H spectra of extracts of livers from SW620 tumour-bearing 
mice (tube 1 in blue, tube 2 in red, tube 3 in green, tube 4 in purple and tube 5 in yellow – see Table 4.6)  
 
 
Figure 4.11: ATP region of 5 superimposed 31P spectra of extracts of livers from SW620 tumour-bearing 
mice (tube 1 in blue, tube 2 in red, tube 3 in green, tube 4 in purple and tube 5 in yellow – see Table 4.6).  
 
The results obtained are presented in Table 4.7 and linear regression analysis 
of the data in Figure 4.12. 
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Expected concentration of  
added analyte (μmoles/g of tissue) 
Measured analyte  
concentration(μmoles/g of tissue) 
ATP NAD ATP NAD 
Tube 1 0 0 0.48 0.39 
Tube 2 2.5 1 1.99 2.08 
Tube 3 5 2 4.53 2.93 
Tube 4 10 4 10.26 6.12 
Tube 5 20 8 13.81 7.38 
Estimated concentration  
of endogenous analyte 1.46 1.35  
Extraction efficiency 69% 140% 
 
Table 4.7: Expected and measured ATP and NAD concentrations in mouse liver samples from SW620 
tumour-bearing mice. 
 
 
Figure 4.12: Linear regression analysis of expected and measured ATP (a) and NAD (b) concentrations in 
mouse liver samples from SW620 tumour-bearing mice. Data from Table 4.7. 
 
From the linear regression analyses shown in Figure 4.12, the endogenous ATP 
concentration prior to addition of exogenous ATP was 1.46 μmoles/g of tissue (-
2.48 to 10.06 within a 95% confidence interval). In the case of NAD, the 
endogenous concentration was 1.35 μmoles/g of tissue (-0.83 to 8.7 within a 
95% confidence interval). The extraction efficiency or recovery was 69% for 
ATP and 140% for NAD. 
 
 
SW620 Tumours 
The methods of addition assay was also performed in replicates of 0.4 g wet 
weight of SW620 tumours to which aliquots of 25 mM ATP and 25 mM NAD 
were added as shown in Table 4.8.  
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 Volume added (μl) Quantity added (μmoles/g of tissue) 25 mM ATP 25 mM NAD ATP NAD 
Tube 1 0 0 0 0 
Tube 2 40 16 2.5 1 
Tube 3 80 32 5 2 
 
Table 4.8: Volume of 25 mM ATP and 25 mM NAD added to 0.4g of SW620 tumour in the methods of 
addition assay.  
 
The samples were then analysed as described in subsection 2.3.4, and 
representative spectra are shown in Figures 4.13 and 4.14 
 
 
Figure 4.13: NAD region of 3 superimposed 1H spectra of extracts of SW620 tumour (tube 1 in blue, tube 
2 in red and tube 3 in green – see Table 4.8). 
 
. 
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Figure 4.14: ATP region of 3 superimposed 31P spectra of extracts of SW620 tumour (tube 1 in blue, tube 
2 in red and tube 3 in green – see Table 4.8). 
 
The results obtained for the method of addition assay in SW620 tumours are 
presented in Table 4.9 and linear regression analysis of the data in Figure 4.15.  
 
Expected concentration  of  
added analyte (μmoles/g of tissue) 
Measured analyte  
concentration (μmoles/g of tissue) 
ATP NAD ATP NAD 
Tube 1 0 0 0.63 0.13 
Tube 2 2.5 1 1.58 1.07 
Tube 3 5 2 4.24 1.98 
Estimated concentration  
of endogenous analyte 0.48 0.14 
Extraction efficiency  72% 93% 
 
Table 4.9: Expected and measured ATP and NAD concentrations in SW620 tumour extracts (samples 
prepared as shown in Table 4.10 and data derived from the spectra in Figures 4.13 and 4.14.  
 
 
Figure 4.15: Linear regression analysis of expected and measured ATP (a) and NAD (b) concentrations in 
SW620 tumour extracts (data from Table 4.9).  
 
From the linear regression analyses shown in Figure 4.18, the endogenous ATP 
concentration prior to addition of exogenous ATP was 0.48 μmoles/g of tissue. 
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In the case of NAD, the endogenous concentration was 0.14 μmoles/g of tissue 
(-0.05 to 0.4 within a 95% confidence interval). The extraction efficiency or 
recovery was 72% for ATP and 93% for NAD. 
 
 A2780 tumours 
A procedure similar to that described in subsection 2.3.1 was followed using 0.3 
g wet weight of A2780 tumour material. The standards used were a 25 mM 
solution of ATP and 2 mM NAD solution, and the volumes of the standard 
solutions used are presented in Table 4.10. 
 Volume added (μl) Quantity added (μmoles/g of tissue) 25 mM ATP 2 mM NAD ATP NAD 
Tube 1 0 0 0 0 
Tube 2 30 37.5 2.5 0.25 
Tube 3 120 150 10 1 
 
Table 4.10: Volume of 25 mM ATP and 2 mM NAD added to 0.3 g of A2780 tumour in the methods of 
addition assay. 
  
The samples were analysed as described in subsection 2.3.4, and 
representative spectra are shown in Figures 4.16-4.17 
 
 
Figure 4.16: NAD region of 3 superimposed 1H spectra of extracts of A2780 tumours (tube 1 in blue, tube 
2 in red and tube 3 in green – see Table 4.10).  
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Figure 4.17: ATP region of 3 superimposed 31P spectra of extracts of A2780 tumours (tube 1 in blue, tube 
2 in red and tube 3 in green – see Table 4.10) from A2780 tumours in the methods of addition.  
 
The results obtained are presented in Table 4.11 and linear regression analysis 
of the data in Figure 4.18. 
 
Expected concentration of  
added analyte (μmoles/g of tissue) 
Measured analyte  
concentration (μmoles/g of tissue) 
ATP NAD ATP NAD 
Tube 1 0 0 0.34 0.02 
Tube 2 2.5 0.25 1.35 0.2 
Tube 3 10 1 4.62 0.55 
Estimated concentration  
of endogenous analyte  0.73 0.081 
Extraction efficiency 43% 51% 
 
Table 4.11: Expected and measured ATP and NAD concentrations in A2780 tumour extracts (samples 
prepared as shown in Table 4.8 and data produced from the spectra in Figures 4.13 and 4.14).    
 
Figure 4.18: Linear regression analysis of expected and measured ATP (a) and NAD (b) concentrations in 
A2780 tumour extracts (data from Table 4.11).  
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From the linear regression analyses shown in Figure 4.18, the endogenous ATP 
concentration prior to addition of exogenous ATP was 0.73 μmoles/g of tissue (-
0.35 to 2.17 within a 95% confidence interval). In the case of NAD, the 
endogenous concentration was 0.081 μmoles/g of tissue, and the extraction 
efficiency or recovery was 43% for ATP and 51% for NAD. 
 
 
4.2.2 The effect of rucaparib, temozolomide and rucaparib combined with 
temozolomide treatment on NAD and ATP concentrations in the liver of 
PARP1 WT and PARP1 KO mice assessed by 1H/31P-MRS 
Experiments were performed as described in section 2.7, to identify the impact 
of PARP1 expression on NAD and NTP concentrations in the liver of mice by 
comparison of data from PARP1 WT and KO (i.e. null) mice.  
The hypothesis is that PARP inhibition will cause a rise in NAD levels, 
temozolomide action will lead to a PARP activation, hence a decrease in NAD 
levels and the combination will have a balancing effect in NAD levels. Whether 
the NAD changes depend on the mice genotype is also an object of the study. 
Groups of PARP1 WT and PARP1 KO mice were treated as summarized in 
Table 4.12. 
Treatment groups and 
route of administration PARP1 WT (n) PARP1 KO (n) 
Control 7 5 
1 mg/kg rucaparib (i.p.) 6 4 
68 mg/kg temozolomide 
(orally) 5 5 
1 mg/kg rucaparib (i.p.) 
+ 68mg/kg 
temozolomide (orally) 
6 4 
 
Table 4.12: Treatment groups and the number (n) of PARP1 WT and PARP1 KO mice studied. 
 
Mice were treated daily for 5 days, and 1 hour after treatment on day 5 an in 
vivo liver MRS study was performed as described in section 2.7. However, the 
resulting data are not shown due to the poor quality of the spectra. Possible 
reasons for the poor quality and poor SNR are that the coil was optimized for 
tumour not liver imaging and that it was not tunable (no variable capacitors). 
ISIS uses adiabatic pulses, however the pulse width was not calibrated using 
tumours and the surface of the coil is limited, reducing quality of the acquired 
spectra. Following MRS, livers were then freeze-clamped, removed and placed 
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in liquid nitrogen, prior to PCA extraction and analysis by high resolution 1H and 
31P spectroscopy as described in subsection 2.3.4.  
 
Figure 4.19 shows the NAD concentrations per gram of liver wet weight for 
control and rucaparib, temozolomide and rucaparib combined with 
temozolomide treated PARP1 WT and KO mice. 
 
Figure 4.19: Effect of daily x5 treatment with 1 mg/kg rucaparib, 68 mg/kg temozolomide, or 1 mg/kg 
rucaparib combined with 68 mg/kg temozolomide on the concentration of NAD in the livers of a) PARP1 
WT and b) PARP1 KO mice. The median with inter-quartile range of concentrations is shown and the 
groups sizes are given in Table 4.12. The * indicate a statistically significant difference. 
 
Performing a Mann-Whitney (non-paired) t-test on the data for the PARP1 WT 
mice, generated a p value of 0.065 for the difference between the control and 1 
mg/kg rucaparib treated mice. The p value for the difference between the NAD 
concentrations in the livers of the 1 mg/kg rucaparib and 1 mg/kg rucaparib 
combined with 68 mg/kg temozolomide treated mice is 0.03, i.e. a statistically 
significant difference at the 5% level. None of the other differences between the 
groups were statistically significant. Furthermore, there were no statistically 
significant differences when the data for the PARP1 WT mouse livers were 
analysed using a one-way ANOVA analysis.  
 
Applying the Mann-Whitney (non-paired) t-test to the data from PARP1 KO mice, 
the only statistically significant difference was between 1 mg/kg rucaparib and 1 
mg/kg rucaparib combined with 68 mg/kg temozolomide (p value 0.032). A one-
way ANOVA evaluation of the data from the livers of PARP1 KO mice 
demonstrated statistically significant differences between the 1 mg/kg rucaparib 
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and 68 mg/kg temozolomide groups, and between 1 mg/kg rucaparib and 68 
mg/kg temozolomide treated groups, both with a p value of 0.043.  
 
These experiments demonstrated that there are higher levels of NAD in the 
livers of mice after 1mg/kg rucaparib treatment regardless of PARP1 gene 
status and higher baseline concentrations of NAD in the livers of PARP1 WT 
mice than in the livers of PARP1 knockout mice. 
 
Figure 4.20 shows the NDP to NTP concentration ratios for extracts of both 
PARP1 WT and KO livers. 
 
Figure 4.20: Effect of 1 mg/kg rucaparib, 68 mg/kg temozolomide and 1 mg/kg rucaparib plus 68 mg/kg 
temozolomide treatment on the ratio of NDP to NTP concentrations in a) PARP1 WT livers and b) PARP1 
KO livers. The median with inter-quartile range of concentrations is shown. 
 
Statistical analysis (Mann-Whitney non-paired t-test or one-way ANOVA) of the 
NDP to NTP concentration ratios in the livers of PARP1 WT mice showed that 
there is not a statistically significant difference between the treatment groups. In 
the extracts of livers from PARP1 KO mice one-way ANOVA demonstrated 
significant differences between the NDP/NTP ratio in control and 1 mg/kg 
rucaparib; between 1 mg/kg rucaparib and 68 mg/kg temozolomide, and 
between 1 mg/kg rucaparib and 1 mg/kg rucaparib combined with 68 mg/kg 
temozolomide treatments (one-way ANOVA p=0.019). The difference between 
the 1 mg/kg rucaparib and 68 mg/kg temozolomide groups was confirmed using 
the Mann-Whitney test (p=0.03). 
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Thus the NDP/NTP ratio is higher following treatment with 1 mg/kg rucaparib in 
the livers of PARP1 KO but not PARP1 WT mice. 
 
In Figure 4.21, the ratio between the Pi and NTP concentrations in extracts of 
livers from PARP1 WT and PARP1 KO mice is depicted.  
 
Figure 4.21: Effect of 1 mg/kg rucaparib, 68 mg/kg temozolomide and 1 mg/kg rucaparib plus 68 mg/kg 
temozolomide treatment on the ratio of Pi /NTP concentrations in liver extracts of a) PARP1 WT and b) 
PARP1 KO mice. The median with inter-quartile range of concentrations is shown. 
 
 
Statistical analysis of the data did not reveal any significant differences between 
the Pi to NTP ratios following treatment with rucaparib, temozolomide or a 
combination of rucaparib and temozolomide in extracts of livers regardless of 
PARP1 gene status.  
 
According to Nijsten and van Dam (2009) elevated lactate levels and local 
acidosis are characteristic of many tumours and more pronounced acidosis is 
associated with invasive potential, as it believed that the local lactic acidosis 
degrades the stroma surrounding the cancer by inducing apoptosis and 
necrosis in the non-malignant cells (Nijsten and van Dam, 2009). 
 
Figure 4.22 summarizes lactate concentrations, an anaerobic by-product of 
glycolysis, in the extracts of livers from PARP1 WT or KO mice after 5 days 
treatment with 1 mg/kg rucaparib, 68 mg/kg temozolomide or the combination of 
1 mg/kg rucaparib and 68 mg/kg temozolomide.  
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Figure 4.22: Effect of 1 mg/kg rucaparib, 68 mg/kg temozolomide and 1 mg/kg rucaparib plus 68 mg/kg 
temozolomide treatment on the concentration of lactate per gram of tissue in extracts of liver from a) 
PARP1 WT and b) PARP1 KO mice. The median with inter-quartile range of concentrations is shown. 
 
 
Mann-Whitney (non-paired) t test and one-way ANOVA analysis of the data 
from the PARP1 WT mice did not reveal any statistically significant differences 
in lactate concentration. In the PARP1 KO mice, although one-way ANOVA did 
not demonstrate any statistically significant differences, the Mann-Whitney test 
showed that liver extracts from 1 mg/kg rucaparib-treated mice had significantly 
lower lactate concentrations than the 68 mg/kg temozolomide treated mice 
(p=0.03).  
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4.3 Discussion  
4.3.1 The effect of rucaparib, temozolomide and rucaparib combined with 
temozolomide treatment on NAD and ATP concentrations assessed by in 
vitro 1H/31P MRS 
The methods of addition procedure developed demonstrated higher recovery of 
NAD (77-90%) than for ATP (36-49%), in the two cell lines studied. Assuming 
that 106 cells have a volume of 1μl the concentrations of ATP and NAD 
produced from the methods of addition in SW620 cell extracts can be converted 
from 2.8 nmoles/106 cells and 0.38 nmoles/106 cells into approximately 2.8 mM 
ATP and 0.38 mM NAD. These values are consistent with the literature where 
ATP concentrations in cells are reported to range from 1-10 mM (Beis and 
Newsholme, 1975), and NAD concentration in cells to be around 0.3 mM 
(Yamada et al., 2006; Yang et al., 2007). 
  
For the treatment of cells with rucaparib, temozolomide, or rucaparib and 
temozolomide, the concentrations used were based on previous data and were 
GI50 (concentration to produce 50% growth inhibition) values for temozolomide 
and a concentration of rucaparib (0.1 μM) known to produce temozolomide 
sensitization (Huw Thomas, Lan-zhen Wang, NICR, personal communication). 
In the A2780 cell line treatment of the cells with rucaparib appeared to increase 
the NAD levels. However, although treatment with temozolomide would be 
expected to create DNA damage and activate PARP thereby utilising NAD, 
there was no obvious change in cellular NAD concentration following 
temozolomide treatment. The combination treatment appeared to produce an 
intermediate effect on the NAD concentration. However, replicate experiments 
were not performed in A2780 cells and hence statistical analysis could not be 
performed. Furthermore, studies should be extended to SW620 cells. 
 
4.3.2 The effect of rucaparib, temozolomide and rucaparib combined with 
temozolomide treatment on NAD and ATP concentrations in mouse liver 
and human tumour xenografts assessed by 1H/31P MRS 
The methods of addition procedure was also successfully applied to mouse liver 
with recovery rates of 69% for ATP and 140% for NAD. For ATP, the estimated 
amount of ATP in the liver was 1.46 μmoles/g of tissue. Considering that 1g 
tissue wet weight is approximately equivalent to 1ml, then 1.46 μmoles/g of 
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tissue ATP concentration is equivalent to 1.46 mM. Iles et al. (1985) studied 
phosphorylation status of liver by 31P-MRS in rats and reported a concentration 
of 2.80 mM ATP (Iles et al., 1985). Similar experiments have been published by 
Corbin et al. (2003) and hepatic ATP concentrations of 3.04 mM reported 
(Corbin et al., 2003). The estimated NAD concentration in the liver was 1.35 
μmoles/g of tissue which equates to 1.35 mM NAD. There must be some 
uncertainty about the absolute concentration in the current assay, given the 
calculated extraction efficiency is not feasible, at 140%. According to Brosnan et 
al. (1970), in studies performed to assess effects of ischaemia on metabolite 
concentrations in rat liver the NAD concentration was 0.83 μmoles/g wet weight 
(Brosnan et al., 1970).  
 
Application of the assay to the analysis of extracts of livers of PARP1 WT or 
PARP1 KO mice removed after 5 daily treatments with rucaparib, temozolomide 
or a combination of rucaparib and temozolomide demonstrated that rucaparib 
treatment increases NAD concentrations presumably due to reduced utilization; 
however the effect was only significant in the PARP1 KO mouse liver extracts. 
 
The ADP to ATP ratio has been reported to be an indicator of cell viability 
(Bradbury et al., 2000), and the ratio between inorganic phosphate and NTP 
used to measure the metabolic status in the livers (Kimura et al., 1994). 
However, in the current study none of the treatments investigated affected the 
Pi/βNTP ratio or the NDP/NTP ratio in either PARP1 WT or PARP1 KO mouse 
liver extracts.  
 
The lactate results show a lactate level in the 1 mg/kg rucaparib group that was 
45% lower than in the 68 mg/kg temozolomide group in PARP1 KO mice, but no 
significant differences in the PARP1 WT group. 
  
The methods of addition for the analysis of NAD and ATP concentrations was 
also successfully applied to the analysis of concentrations in A2780 and SW620 
human tumour xenografts grown in immune-deprived mice. In the literature, 
ATP concentrations in viable (non-necrotic) tumour is 1.9 mM (Walenta et al., 
1992) while the values from the experiment described in this chapter were 0.73 
μmoles/g of tissue and 0.48 μmoles/g of tissue for A2780 and SW620 tumours, 
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respectively. Regarding the NAD concentrations in the tumours, the values of 
the experiment described in this chapter were 0.081 μmoles/g of tissue and 
0.14 μmoles/g of tissue for A2780 and SW620 tumours respectively which is 
different from the average 206 μM NAD concentration reported for A12B3 
sarcoma tumours, measured by HPLC (Ohlson et al., 1995). The difference in 
the tumour type could be the reason for that discrepancy.  
 
Unfortunately, there was insufficient time to investigate the effect of rucaparib, 
temozolomide and rucaparib plus temozolomide combination treatment on 
tumour NAD and ATP concentration, although a some preliminary results will be 
presented in chapter 6 in relation to the in vivo MRS data. 
 
Overall, the method of addition has been proven feasible, however the recovery 
rates were variable depending on the sample. Application of the assay to study 
the effects of treatment with rucaparib, temozolomide, and rucaparib combined 
with temozolomide in cells has been proven not only feasible, but a preliminary 
experiment also generated results consistent with NAD elevation due to PARP 
inhibition. 
 
Studies in PARP1 WT and KO mouse liver extracts again demonstrated that the 
assay methodology was applicable, generating results consistent with the 
literature, and suggestive that NAD levels are influenced by PARP1 genotype 
and rucaparib administration, although further experiments are required. 
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Chapter 5. Results – An evaluation of the utility of [18F]FDG- 
and [18F]FLT-PET as surrogate response biomarkers for PARP 
inhibitors 
There are several examples in the literature of PET studies where both 
[18F]FDG and [18F]FLT have been used in the assessment of post-treatment 
changes in the glycolytic and proliferative status of tumours. In 2010, Honer et 
al. published data for several tumour models where [18F]FDG and [18F]FLT 
uptake changes induced by the rapamycin-based mTOR inhibitor everolimus 
were studied. The results of this study showed that the allosteric mTOR inhibitor 
everolimus decreased the [18F]FDG and [18F]FLT uptake in tumours after 
treatment (Honer et al., 2010).  
 
Munk Jensen et al. (2010) also used [18F]FDG and [18F]FLT for the early 
detection of response to the mTOR inhibitor Top216 in A2780 human ovary 
cancer xenografts grown in mice (A2780). In this study mice underwent 
[18F]FDG- or [18F]FLT-PET scanning 18 hours before treatment (baseline), 6 
hours after treatment (t = 6h), 24 hours (t = 24h) after a second treatment on 
day 2 and at 72 hours (t = 5 days). The results of this experiment showed a 
rapid and significant decrease in cell proliferation at early time points. However, 
on day 5 the [18F]FLT uptake in the treated group was comparable to the control 
group suggesting that the proliferative capacity of the tumour had recovered. 
Since the [18F]FLT uptake did not change over the 5 days in the control group 
the anti-proliferative effect of Top216 was established. There was a small but 
significant decrease in [18F]FDG uptake at 6 hours, and on day 1 and day 5, i.e. 
in the treated groups the [18F]FDG uptake remained lower than in the control 
group where the [18F]FDG uptake increased over the experiment. Overall, this 
study concluded that [18F]FLT is superior to [18F]FDG in the assessment of early 
response to treatment with the mTOR inhibitor Top216 (Munk Jensen et al., 
2010).  
 
Moroz et al. (2011) followed a similar approach by using [18F]FDG and [18F]FLT 
to study the response of colon cancer xenografts to treatment with the aurora B 
kinase inhibitor AZD1152. In this study HCT116 and SW620 tumours were used. 
HCT116 xenografts responded more rapidly and to a greater extent with 
marked decreases in [18F]FDG and [18F]FLT uptake in the treated groups 
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associated with decreases in tumour volumes over time. In contrast SW620 
xenografts continued to grow during treatment, and the growth rate only 
decreased after three cycles of treatment. The authors reported that sequential 
[18F]FDG-PET showed no significant difference between treated and untreated 
mice throughout the experiment in SW620 tumours, suggesting that the 
treatment did not interfere with glucose utilization, whereas SW620 xenografts 
showed very little or no accumulation of [18F]FLT above background levels. The 
authors concluded that [18F]FLT-PET can be used as a surrogate response 
biomarker in HCT116 xenografts but not in SW620 tumours, suggesting that 
SW620 cells predominantly use the de novo rather than the salvage pathway to 
generate thymidine nucleotides for DNA synthesis (Moroz et al., 2011).  
 
One final example, published by Corroyer-Dulmont et al. (2012), involved DCE-
MRI, [18F]FDG- and [18F]FLT-PET studies to investigate tumour response to the 
anti-angiogenic drug bevacizumab, the alkylating agent temozolomide, and a 
combination of bevacizumab with temozolomide in glioblastoma xenografts. The 
use of a cytotoxic treatment with a vascular targeting molecule resulted in both 
anti-vasculature and direct anti-tumour effects. The results of this study, once 
more, showed that [18F]FLT-PET was a superior surrogate response biomarker 
to [18F]FDG-PET (Corroyer-Dulmont et al., 2012). The use of [18F]FDG- and 
[18F]FLT-PET has been reviewed by Perumal et al. (2012). 
  
The preclinical Positron Emission Tomography (PET) studies described in this 
chapter were performed to examine the potential value of PET as a surrogate 
response biomarker following treatment with rucaparib and/or temozolomide. 
The tracers used were [18F]FDG, an indicator of tumour metabolism, and 
[18F]FLT as a measure of proliferation.  
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5.1Treatment groups and imaging protocol 
The treatment groups and the imaging protocols were the same for both the 
[18F]FDG and [18F]FLT experiments and the studies were performed as 
described in section 2.8. 
 
Once tumours had grown to approximately 5 by 5 millimetres the mice were 
randomly assigned to four treatment groups: 
• Control (no injection); 
• 1 mg/kg of rucaparib (10 ml/kg of a 0.1 mg/ml solution in water for 
injection);  
• 68 mg/kg of temozolomide (10 ml/kg of a 6.8 mg/ml solution in saline);  
• 1 mg/kg of rucaparib combined with 68 mg/kg of temozolomide (10 ml/kg 
of a 0.1 mg/ml solution in water for injection with 10 ml/kg of a 6.8 mg/ml 
solution in saline). 
 
The mice were treated and tumour volumes were measured once a day for five 
days. On day five the mice were treated and the PET scan performed one hour 
later. The PET scan lasted for one hour, after which mice recovered and were 
monitored for up to 100 days, or until the tumours reached a size that required 
killing on the basis of animal welfare considerations. All the PET image analysis 
was performed by Ian Wilson using the Imalytics software package from Philips, 
as described in section 2.8.  
 
As in previous chapters, the dose of rucaparib (1 mg/kg) used in this experiment 
has previously been shown to result in extensive PARP inhibition and, when 
used in combination with temozolomide, marked chemopotentiation. The dose 
of temozolomide used (68 mg/kg) equates to the routine daily dose of the drug 
in patients (~ 200 mg/m2) (Calabrese et al., 2003; Thomas et al., 2007).  
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5.2 Metabolic changes in A2780 human tumour xenografts following 
treatment with rucaparib, temozolomide or rucaparib combined with 
temozolomide as assessed with [18F]FDG-PET  
Only A2780 tumour bearing mice were scanned using [18F]FDG because 
preliminary tests in SW620 tumours showed very limited uptake of the tracer 
(Ian Wilson, personal communication).  
 
Mice were injected with an average of 10 MBq (range of activities from 9 MBq to 
16 MBq) of [18F]FDG and scanned for one hour. The number of imaged mice, n, 
per group was: 
• Control: n=3; 
• 1 mg/kg rucaparib: n = 3 
• 68 mg/kg temozolomide: n = 3 
• 1 mg/kg rucaparib combined with 68 mg/kg temozolomide: n = 5. 
 
5.2.1 Effect of drug treatment on A2780 tumour growth  
Tumour volumes were measured before and after the PET scan (see section 
2.8), and tumour growth data from both the [18F]FDG- and [18F]FLT-PET studies 
were combined. In both experiments the treatment procedure was exactly the 
same, and the total number of treated and measured mice in each group was : 
• Control n = 8; 
• 1 mg/kg rucaparib n = 8; 
• 68 mg/kg temozolomide n = 8; 
• 1 mg/kg rucaparib combined with 68 mg/kg temozolomide n = 10. 
 
The time taken for individual tumours to reach a relative tumour volume 4 times 
that of the volume on the day of the first treatment (time to RTV4) is shown in 
Figure 5.1 and the data are presented in detail in Table 5.1. 
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Figure 5.1: Effect of 1 mg/kg rucaparib, 68 mg/kg temozolomide or 1 mg/kg rucaparib plus 68 mg/kg 
temozolomide on A2780 tumour growth. Points are the individual mice, lines are the median and the error 
bars the inter-quartile range. 
 
Group Median time to RTV4 (range) in days Tumour growth delay (days) 
Control 13 (7-46) ̶ 
1 mg/kg rucaparib 6 (5-15) -7 
68 mg/kg temozolomide 14 (8-46) +1 
1 mg/kg rucaparib + 68 
mg/kg temozolomide 15 (9-21) +2 
 
Table 5.1: Median time to reach a tumour volume of RTV4 and tumour growth delay in A2780 tumour-
growth following daily x5 treatment with rucaparib, temozolomide or rucaparib plus temozolomide. 
 
The time to RTV4 data presented in Figure 5.1 and Table 5.1 were subjected to 
statistical evaluation using one-way ANOVA and Mann-Whitney (non-
parametric t test) analyses. The one-way ANOVA did not demonstrate any 
significant differences between the groups (p > 0.05). The Mann-Whitney test 
did reveal significant differences and the p values are presented in Table 5.2. 
Thus treatment with 1 mg/kg rucaparib appears to result in accelerated tumour 
growth, while neither temozolomide alone or in combination with rucaparib had 
significant activity. 
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 1 mg/kg rucaparib 
68 mg/kg 
temozolomide 
1 mg/kg rucaparib +  
68 mg/kg 
temozolomide 
Control 0.048 0.77 0.67 
1 mg/kg 
rucaparib  0.030 0.019 
68 mg/kg 
temozolomide   0.81 
 
Table 5.2: Mann-Whitney (non-paired t test) statistical analysis of the time to RTV4 data for A2780 tumour-
bearing mice presented in Figure 5.1 and Table 5.1. 
 
5.2.2 [18F]FDG-PET images in A2780 tumour bearing mice 
Figure 5.2 shows representative [18F]FDG-PET images (axial slices through the 
animal) of a control A2780 tumour-bearing mouse compared with an A2780 
tumour-bearing mouse treated with rucaparib. These images are from 60 
minutes after [18F]FDG injection and a lower uptake in the 1 mg/kg rucaparib 
treated tumour is suggested. 
 
Figure 5.2: [18F]FDG-PET scans of a) a control A2780 tumour bearing mouse, b) a A2780 tumour-bearing 
mouse treated with 1 mg/kg rucaparib daily x5. In both images the arrow indicates the tumour. 
 
5.2.3 Effects of rucaparib, temozolomide and rucaparib combined with 
temozolomide treatment on [18F]-FDG uptake in A2780 tumour-bearing 
mice 
Mean Standardised Uptake Values [18F]-FDG (SUV) were calculated as 
described in section 2.8 for A2780 tumours after 5x daily treatment with 1 mg/kg 
rucaparib, 68 mg/kg temozolomide or 1 mg/kg rucaparib and 68 mg/kg 
temozolomide. Figure 5.3 shows the dynamic SUVmean data and Figure 5.4 the 
SUVmean data from the 1 hour time point in the scan (SUVmean@1h). 
a) b) 
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Figure 5.3: Mean tumour [18F]FDG SUV vs time in A2780 tumour-bearing mice following 5 daily 
treatments with 1 mg/kg rucaparib, 68 mg/kg temozolomide or the combination of 1 mg/kg rucaparib with 
68 mg/kg temozolomide. Points are the mean and the bars are the standard error.  
 
Figure 5.4: Mean tumour [18F]FDG SUV with standard error (bars) one hour after tracer administration in 
A2780 tumour-bearing mice following 5 daily treatments with 1 mg/kg rucaparib, 68 mg/kg temozolomide 
or the combination of 1 mg/kg rucaparib with 68 mg/kg temozolomide. 
 
In addition to the mean [18F]FDG SUV in each tumour at each time point, the 0-
60minute area under the mean SUV versus time curve was calculated and the 
data are presented in Figure 5.5 normalized to the mean SUV AUC1h in the 
control untreated tumours.  
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Figure 5.5: Percentage change with standard error (bars) relative to control in [18F]FDG SUV AUC1h 
following daily x5 treatment with 1 mg/kg rucaparib, 68 mg/kg temozolomide or the combination of 1 mg/kg 
rucaparib with 68 mg/kg temozolomide relative to control. 
 
Table 5.3 presents results of a Mann-Whitney (non-paired t test) statistical 
analysis of the [18F]FDG mean SUV values (data presented in Figure 5.3). 
There was a significant difference in the mean SUV between the 1 mg/kg 
rucaparib and 68 mg/kg temozolomide (p=0.0008) groups and between the 68 
mg/kg temozolomide and the combination of 1mg/kg rucaparib with 68 mg/kg 
temozolomide groups. Thus rucaparib alone or in combination with 
temozolomide, reduced [18F]FDG uptake whereas temozolomide alone did not. 
 
 1 mg/kg rucaparib 
68 mg/kg 
temozolomide 
1 mg/kg 
rucaparib +  68 
mg/kg 
temozolomide 
Control p=0.14 p=0.62 p=0.10 
1 mg/kg 
rucaparib  p=0.0008 p> 0.99 
68 mg/kg 
temozolomide   p=0.0001 
 
Table 5.3 Statistical analysis (Mann-Whitney non-paired t test) of the [18F]FDG SUV data presented in 
Figure 5.3 assessing the effect of rucaparib, temozolomide and rucaparib plus temozolomide treatment on 
the mean in A2780 tumour-bearing mice.  
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However, performing a one-way ANOVA with multiple comparisons between all 
the groups and using each group as a reference, no significant differences are 
found between the SUVmean of any groups. 
 
Applying the same statistical tests (one-way ANOVA and Mann-Whitney) to the 
SUVmean@1h data (for the one hour time point, i.e. static data only) there were 
also no significant differences between groups. 
 
Overall, the groups treated with rucaparib appeared to show a small decrease 
in the uptake of the tracer [18F]FDG when compared with the control and 
temozolomide alone groups. However, the analysis of data using the last time 
point (SUVmean@1h) only generated different results from to those generated 
from the overall SUVmean (0-1 hour period). Furthermore, the significance of the 
small effect of rucaparib on [18F]FDG uptake that was observed was not 
demonstrated in all of the statistical analysis undertaken. 
The uptake of [18F]FDG was lower in the treated groups. However, it should be 
noted that in the 1 mg/kg rucaparib treated group, tumour growth was 
accelerated but the [18F]FDG did not reflect that fact. 
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5.3 Proliferation changes in A2780 and SW620 human tumour xenografts 
following treatment with rucaparib, temozolomide or rucaparib combined 
with temozolomide as assessed with [18F]FLT-PET 
The [18F]FLT-PET studies were performed to evaluate the potential of [18F]FLT 
as a surrogate response imaging biomarker. [18F]FLT-PET was performed after 
treatment with rucaparib, temozolomide or with a rucaparib and temozolomide 
in combination in both A2780 and SW620 tumour-bearing mice. The number of 
mice per group and the average and range of injected [18F]FLT doses are 
summarized in Table 5.4 
 
Number of mice per 
treatment group 
Average [18F]FLT activity 
injected (range, MBq) 
A2780 SW620 A2780 SW620 
Control 3 3 
10 (8-12) 11 (8-13) 
1 mg/kg rucaparib 3 5 
68 mg/kg temozolomide 2 3 
1 mg/kg rucaparib + 68 
mg/kg temozolomide 
3 3 
 
Table 5.4: Number of mice per treatment group and [18F]FLT activities injected in A2780 and SW620 
tumour-bearing mice. 
 
[18F]FLT-PET scanning was performed 1 hour after the last one of a daily x5 
treatment protocol as described in section 2.8. 
The amount of activity injected is variable due to factors such as initial activity in 
the syringe prior to injection and length of the cannulation tube.  
 
5.3.1 Effects of drug treatment on tumour growth  
The effects of treatment with 1 mg/kg rucaparib, 68 mg/kg temozolomide or 1 
mg/kg rucaparib and 68 mg/kg temozolomide on the tumour growth of A2780 
tumours was presented in subsection 5.2.1. For the tumour growth study in 
SW620 tumours, all the groups had 18 mice apart from the control group which 
contained 20 mice.  
 
The time taken for individual tumours to reach a relative tumour volume 4 times 
that of the volume on the day of the first treatment volume (time to RTV4) is 
shown in Figure 5.6 and the data are presented in detail in Table 5.5. 
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Figure 5.6: Effect of 1 mg/kg rucaparib, 68 mg/kg temozolomide or 1 mg/kg rucaparib plus 68 mg/kg 
temozolomide on SW620 tumour growth. Points are the individual mice, lines are the median and the error 
bars the inter-quartile range.  
 
Group Median time to RTV4 (range) in days 
Tumour growth 
delay (days) 
Control 17 (8-99) ̶ 
1 mg/kg rucaparib 21 (7-51) +4 
68 mg/kg temozolomide 41 (36-113) +24 
1 mg/kg rucaparib + 68 mg/kg temozolomide 70 (51-87) +53 
 
Table 5.5: Median time to reach a tumour volume of RTV4 and tumour growth delay in SW620 tumour-
bearing mice following daily x5 treatment with rucaparib, temozolomide or rucaparib plus temozolomide. 
 
Analysis of the data in Figure 5.6 (Mann-Whitney non-paired t test) 
demonstrated a statistically significant difference between all the groups apart 
from the between control and 1mg/kg rucaparib treated animals (Table 5.6). A 
one-way ANOVA with multi-comparisons between all groups also demonstrated 
a statistical difference between all groups apart from the control and 1mg/kg 
rucaparib groups, and the 68mg/kg temozolomide and 1mg/kg rucaparib plus 
68mg/kg temozolomide groups. In all the other comparisons the p value was < 
0.0001. 
 1 mg/kg rucaparib 
68 mg/kg 
temozolomide 
1 mg/kg rucaparib +  68 
mg/kg temozolomide 
Control p = 0.602 p = 0.017 p = 0.0014 
1 mg/kg rucaparib  p = 0.0015 p < 0.0001 
68 mg/kg temozolomide   p = 0.0133 
 
Table 5.6: Statistical analysis (Mann-Whitney non-paired t test) of the effect of rucaparib, temozolomide or 
rucaparib plus temozolomide treatment on tumour growth in SW620 tumour-bearing mice. Data analysed 
and the time to RTV4 values are from Figure 5.6 and Table 5.5. 
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5.3.2 [18F]-FLT images 
Figure 5.7 shows [18F]FLT-PET scan images of a control A2780 tumour-bearing 
animal in comparison with an A2780 tumour-bearing mouse treated with 
temozolomide. Three time points are shown: 1, 10 and 60 minutes after 
[18F]FLT injection. The top row, Figure 5.9 a), b) and c), shows the distribution 
of [18F]FLT in the control mouse, while in the second row, Figure 5.9 d), e) and 
f), scans at the same time points are shown for a mouse treated with 68 mg/kg 
temozolomide daily for 5 days. For the first time point (Figure 5.7, a and d) the 
image reveals [18F]FLT in the heart and kidneys. At 10 minutes the [18F]FLT is 
distributed throughout the body and starting to accumulate in the bladder. By 60 
minutes the tumour has retained more radioactivity than normal tissues, with the 
bladder the main site of FLT accumulation. Comparing Figure 5.9 c) and f) there 
is less [18F]FLT uptake in tumour of the temozolomide-treated mouse when 
compared with the control mouse. 
 
Figure 5.7: Representative images of an [18F]FLT PET acquisition. Images a), b) and c) are from a mouse 
implanted with an A2780 tumour (control) and injected with 8.18 MBq of [18F]FLT and collected 1, 10 and 
60 minutes after [18F]FLT injection. Images d), e) and f) are from a mouse implanted with an A2780 tumour 
and treated for 5 days with 68 mg/kg temozolomide, injected with 10.38 MBq of [18F]FLT and collected 1, 
10 and 60 minutes after [18F]FLT injection. 
heart 
kidneys bladder 
A2780 
tumour 
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Figure 5.8 shows [18F]FLT-PET images of a control SW620 tumour-bearing 
animal in comparison with an SW620 tumour-bearing mouse treated with 1 
mg/kg rucaparib combined with 68 mg/kg temozolomide. These images are 
from 60 minutes after the [18F]FLT injection and the non-tumour tissue 
background in the control image does not allow the ready visualization of any 
differences. However, these images only show one slice of the tumour and 
hence have a merely illustrative role. The SUV is calculated over all the volume 
of the tumour and not only in the central slice. 
   
 
 
Figure 5.8: Representative images of an [18F]FLT-PET acquisition scans of a) a control SW620 tumour-
bearing mouse, b) A2780 tumour-bearing mouse treated daily x5 with 1 mg/kg rucaparib combined with 68 
mg/kg temozolomide. In both images the arrow indicates the tumour. 
 
5.3.3 Effects of rucaparib, temozolomide or rucaparib plus temozolomide 
treatment on [18F]-FLT uptake in A2780 and SW620 tumour-bearing mice 
Mean Standardised [18F]-FLT Uptake Values (SUV) were calculated as 
described in section 2.8 for A2780 and SW620 tumours after 5x daily treatment 
with 1 mg/kg rucaparib, 68 mg/kg temozolomide or 1 mg/kg rucaparib combined 
with 68 mg/kg temozolomide. These calculations are performed by the software 
taking into account the injected activity, time of injection and the animal weight. 
The intended injectable activity (10 MBq) was general for all the treatment 
groups. 
Figures 5.9 and 5.10 shows the dynamic SUVmean data for A2780 and SW620 
tumour-bearing mice, respectively, and Figures 5.11 and 5.12 the SUVmean data 
for the 1 hour timepoint only (SUVmean@1h). 
a) b) 
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Figure 5.9: Mean tumour [18F]FLT SUV vs time in A2780 tumour-bearing mice following 5 daily treatments 
with 1 mg/kg rucaparib, 68 mg/kg temozolomide or the combination of 1 mg/kg rucaparib with 68 mg/kg 
temozolomide. Points are the mean and the bars are the standard error.  
 
Figure 5.10: Mean tumour [18F]FLT SUV vs time in SW620 tumour-bearing mice following 5 daily 
treatments with 1 mg/kg rucaparib, 68 mg/kg temozolomide or the combination of 1 mg/kg rucaparib with 
68 mg/kg temozolomide. Points are the mean and bars are the standard error. 
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Figure 5.11: Mean tumour [18F]FLT SUV with standard error (bars) at one hour after tracer injection in 
A2780 tumour-bearing mice following 5 daily treatments with 1 mg/kg rucaparib, 68 mg/kg temozolomide 
or the combination of 1 mg/kg rucaparib with 68 mg/kg temozolomide. 
 
Figure 5.12: Mean tumour [18F]FLT SUV with standard error (bars) at one hour after tracer injection in 
SW620 tumour-bearing mice following 5 daily treatments with 1 mg/kg rucaparib, 68 mg/kg temozolomide 
or the combination of 1 mg/kg rucaparib with 68 mg/kg temozolomide. 
 
Figures 5.13 and 5.14 present the 0-60minute area under the mean SUV versus 
time curve calculated from the data presented in Figures 5.9 and 5.10, and 
normalized to the mean SUV AUC1h in the control untreated tumours.  
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Figure 5.13: Percentage change with standard error (bars) relative to control in [18F]FLT SUV AUC1h 
following daily x5 treatment with 1 mg/kg rucaparib, 68 mg/kg temozolomide or the combination of 1 mg/kg 
rucaparib with 68 mg/kg temozolomide relative to control in the A2780 tumours. 
 
Figure 5.14: Percentage change with standard error (bars) relative to control in [18F]FLT SUV AUC1h 
following daily x5 treatment with 1 mg/kg rucaparib, 68 mg/kg temozolomide or the combination of 1 mg/kg 
rucaparib with 68 mg/kg temozolomide relative to control in the SW620 tumours. 
 
 
Statistical analysis of the [18F]FLT SUV AUC1h data for A2780 human tumour 
xenografts presented in Figure 5.13 demonstrated that 1 mg/kg rucaparib alone 
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increases [18F]FLT uptake in comparison to both control and 1 mg/kg rucaparib 
plus 68 mg/kg temozolomide treated mice (Table 5.7). A one-way ANOVA 
statistical analysis with multiple comparisons confirms that there is a statistically 
significant difference between the control and the 1 mg/kg rucaparib groups (p = 
0.022), and between the 1 mg/kg rucaparib and the 1 mg/kg rucaparib plus 68 
mg/kg temozolomide (p = 0.022) treatment groups.   
 
 1 mg/kg rucaparib 
68 mg/kg 
temozolomide 
1 mg/kg rucaparib +  68 
mg/kg temozolomide 
Control p = 0.019 p = 0.103 p = 0.103 
1 mg/kg 
rucaparib  p = 0.103 p = 0.047 
68 mg/kg 
temozolomide   p = 0.18 
 
Table 5.7: Statistical analysis (Mann-Whitney non-paired t test) of the [18F]-FLT PET data presented in 
Figure 5.13 assessing the effect of rucaparib, temozolomide and rucaparib plus temozolomide treatment 
on the SUVmean values over an hour in A2780 tumour-bearing mice. 
 
Statistical analysis of the [18F]FLT SUV AUC1h data for SW620 human tumour 
xenografts presented in Figure 5.14 demonstrated that 1 mg/kg rucaparib alone 
or in combination with 68 mg/kg temozolomide decreased [18F]FLT uptake in 
comparison to both control and 68 mg/kg temozolomide alone treated mice 
(Table 5.8). A one-way ANOVA statistical analysis with multiple comparisons 
only confirms that there is a statistically significant difference between the 
control and 1mg/kg rucaparib plus 68mg/kg temozolomide combination 
treatment groups (p=0.0087). 
 
 1mg/kg rucaparib 
68mg/kg 
temozolomide 
1mg/kg rucaparib +  
68mg/kg temozolomide 
Control p=0.040 p=0.37 p=0.0008 
1mg/kg 
rucaparib  p=0.14 p=0.11 
68mg/kg 
temozolomide   p=0.013 
 
Table 5.8: Statistical analysis (Mann-Whitney non-paired t test) of the [18F]-FLT PET data presented in 
Figure 5.3 assessing the effect of rucaparib, temozolomide and rucaparib plus temozolomide treatment in 
the SUVmean values over an hour in SW620 tumour-bearing mice experiment. 
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5.4 Discussion 
5.4.1 The effect of rucaparib, temozolomide and rucaparib plus 
temozolomide on tumour growth and [18F]FLT uptake in SW620 human 
tumour xenografts  
Tumour growth 
In the experiments described in this chapter, rucaparib was shown to enhance 
the anti-tumour activity of temozolomide in the SW620 human tumour 
xenografts model (Figure 5.6). Temozolomide alone at a dose equivalent to the 
standard clinical dose (68 mg/kg/day ~ 200mg/m2) was active; however, 
rucaparib at 1 mg/kg was not.  
 
These results are consistent with previously published studies. Calabrese et al., 
in 2004 published a study in which chemosensitization and radiosensitization by 
the PARP inhibitor AG14361 (a precursor of rucaparib) was demonstrated. 
Temozolomide administered as a single agent or in combination with the PARP 
inhibitor resulted in a delay in SW620 tumour growth similar to that observed in 
the current studies (Calabrese et al., 2004). Subsequently, Thomas et al. in 
2007 demonstrated that AG14447, the phosphate salt equivalent to rucaparib, 
also resulted in chemosensitization in combination with temozolomide in SW620 
xenografts, of a similar magnitude to the effect reported in this chapter (Thomas 
et al., 2007).  
 
[18F]FLT PET  
In SW620 tumours, [18F]FLT uptake was unchanged following temozolomide 
treatment; however, [18F]FLT uptake was reduced by the combination of 
rucaparib and temozolomide (Figures 5.10, 5.12 and 5.14). The effect on 
[18F]FLT uptake correlates closely with the effects on tumour growth (Figure 5.6), 
and these data support the use of [18F]FLT-PET as a surrogate response 
biomarker for rucaparib/temozolomide combination treatment. 
 
 
 
 
166 
5.4.2 The effect of rucaparib, temozolomide and rucaparib plus 
temozolomide on tumour growth and [18F]FLT and [18F]FDG uptake in 
A2780 human tumour xenografts  
 
Tumour growth 
In contrast to the data from the SW620 human tumour model temozolomide 
alone or rucaparib combined with temozolomide did not inhibit A2780 tumour 
growth. In vitro data show that A2780 cells are markedly less sensitive to 
temozolomide treatment than SW620 cells (see Chapter 4). However, higher 
temozolomide doses could not be given to mice bearing A2780 tumours 
because of toxicity limitations. Unexpectedly, rucaparib alone may have 
increased tumour growth rate (Figure 5.1 and Table 5.1). A2780 cells have a 
doubling time of 26.3h which is very similar to the 24h doubling time of SW620 
cells (Li and Lin, 1995; Maybaum et al., 1991). This similarity in growth time in 
vitro suggests a physiological mechanism to explain the difference in tumour 
growth rates. 
 
[18F]FLT-PET 
Consistent with the results of the tumour growth delay studies, neither 
temozolomide alone or in combination with rucaparib reduced [18F]FLT uptake 
in A2780 tumour after 5 daily dosing (Figure 5.13, Table 5.7). Again 
unexpectedly, but consistent with the tumour growth data, rucaparib alone 
increased [18F]FLT uptake (Figure 5.13, Table 5.7). The correlation of the 
tumour growth (Figure 5.1, Table 5.1 and 5.2) and [18F]FLT uptake data (Figure 
5.13 and Table 5.7) suggest that PARP inhibition may have accelerated tumour 
growth in this model and this possibility requires confirmation and extension to 
other pre-clinical models.  
 
[18F]FDG-PET 
Although [18F]FDG studies could not be performed in SW620 tumour-bearing 
mice, tracer uptake in A2780 tumours was sufficient to evaluate the effect of 
rucaparib, temozolomide and rucaparib/temozolomide combination therapy. 
Although there was a suggestion that rucaparib either alone or in combination 
with temozolomide reduced [18F]FDG uptake (Figure 5.5 and Table 5.3), the 
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effect was not statistically significant in all the tests performed, consistent with 
the lack of any antitumour effects in the growth delay studies. 
 
In an article published by Ebenhan et al. (2009) several PET tracers were used 
in various tumour models to assess the suitability of each tracer as a surrogate 
response PET biomarker.  Several important conclusions were drawn by these 
authors, notably that [18F]FDG-PET in preclinical human tumour models has low 
tracer uptake, [18F]FDG SUV does not correlate with tumour volume and that 
the tracer accumulates more in the tumour periphery than the central area, 
which may be due to a dependence on the vasculature of the tumour for tracer 
access. In contrast, [18F]FLT uptake was less heterogeneous and gave good 
visualization in all the models studied suggesting that [18F]FLT uptake is less 
dependent upon the tumour blood supply (Ebenhan et al., 2009).  
 
Overall, the results presented in this chapter demonstrate that [18F]FLT-PET 
can be used as a surrogate response imaging biomarker for 
temozolomide/rucaparib combinations. Thus in a model where there was 
significant chemosensitization (SW620) increased activity (chemosensitization) 
was predicted by a significant decrease in [18F]FLT uptake, whereas in a model 
where there was no chemosensitization (A2780) there was no significant 
change in [18F]FLT uptake.   
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Chapter 6. General discussion 
This chapter considers how the potential biomarkers explored in earlier 
chapters may be used to provide greater insights into the biological effects of 
PARP inhibitors such as rucaparib and their interaction with DNA damaging 
agents such as temozolomide. 
 
6.1 The relationship between changes in tumour vasculature and tumour 
energetics 
As introduced in subsection 1.5.1 DCE-MRI can be used to predict the outcome 
of a specific treatment by the characterization of changes to tumour vasculature 
prior to tumour volume changes (Reiser et al., 2008), and 31P-MRS can be used 
to assess changes in metabolic status as reflected by changes in NTP levels 
(Ronen et al., 1999). The ratio between the AUCMR,120 for the first injection 
(AUCMR,120_1) of contrast agent and for the second injection (AUCMR120_2) has 
been termed the Anti-Vascular Index (AVI). An increase in this ratio 
corresponds to a decrease in the AUCMR, 120s for the second injection of contrast 
agent which can be due to an impairment in the vascular supply to the tumour, 
while the ratio between the inorganic phosphate (Pi) and beta-NTP (βNTP) 
(primarily reflecting ATP) concentrations change in relation to the supply of 
oxygen and nutrients. The study of both biomarkers in the same experiment has 
been widely published in the literature in the study of anti-vascular agents such 
as combretastatin A4 phosphate (anti-tubulin agent), DMXAA (tumour necrosis 
stimulator), docetaxel (anti-mitotic agent) (Beauregard et al., 2001; Beauregard 
et al., 2002; Maxwell et al., 2002; Jensen et al., 2010). Bevacizumab is an anti-
VEGF agent which has been studied with DCE-MRI and 1H/31P-MRS (Hattingen 
et al., 2011). 
  
In Figure 6.1, the AVI in both tumour types (A2780 and SW620) is compared 
with the percentage change in the inorganic phosphate to βNTP ratio following 
treatment with rucaparib, temozolomide, or rucaparib/temozolomide 
combinations.  
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Figure 6.1: Effect of hydralazine, rucaparib, temozolomide and rucaparib/temozolomide combinations on 
a) median values and inter-quartile range (error bars) for the AVI in A2780 tumour-bearing mice; b) mean 
change with standard error (bars) in Pi/βNTP ratios in A2780 tumour bearing-mice grouped between 8 
minutes before injection of drug, 8 minutes and 40 minutes after drug injection; c) median values and inter-
quartile range (error bars) for the AVI in SW620 tumour-bearing mice; d) mean change with standard error 
(bars) in Pi/βNTP ratios in SW620 tumour bearing-mice grouped between 8 minutes before injection of 
drug, 8 minutes and 40 minutes after drug injection. 
 
Figure 6.1 (a)-(d)) shows that in the groups where the treatment caused a 
reduction of contrast agent uptake after the second injection, there was also an 
increase in the inorganic phosphate (Pi) to βNTP ratio. This relationship is 
clearly observed following hydralazine which causes vessel collapse preventing 
the tumour from obtaining oxygen and nutrients, resulting in metabolic stress 
and an increase in inorganic phosphate and decrease in βNTP. This effect is 
seen in A2780 tumours in mice treated with 5 mg/kg hydralazine and with 1 
mg/kg rucaparib, and possibly with the combination of 1 mg/kg rucaparib with 
68 mg/kg temozolomide. In SW620 tumours in mice treated with 5 mg/kg 
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hydralazine the dual increase in AVI and associated increase in Pi/βNTP ratio is 
again observed. There is a less prominent effect at the higher doses of 
rucaparib given alone (5 and 50 mg/kg). The fact that the hydralazine effects 
are replicated in tumours derived from two different cell lines increases the 
confidence in the techniques used and results obtained. However, the fact that 
the Pi/βNTP ratio is measured before the second contrast agent injection might 
be sub-optimal, and longer acquisition period for the phosphorus spectra could 
provide different results. 
 
In Figures 6.2 and 6.3 AVI is plotted against the ratio of inorganic phosphate to 
βNTP ratio 40 minutes after the drug injection (Pi/βNTP@40’) to the same ratio 
8 minutes before the drug injection (Pi/βNTP@-8’), for both tumour types in 
individual animals. A higher ratio between Pi/βNTP@40’ and Pi/βNTP@-8’ 
indicates metabolic stress and an increased AVI indicates that the uptake of 
contrast agent after the second injection was lower, therefore the vasculature of 
the tumour has been compromised. In these figures, the data presented relates 
only to animals which underwent both imaging protocols (and passed signal-
noise criteria for 31P-MRS analysis), DCE-MRI and 31P-MRS. The resulting 
graphs were analysed to determine if the change in Pi/βNTP ratio was related to 
AVI (nonparametric Spearman correlation analysis).   
 
Figure 6.2: Ratio of Pi to βNTP ratios at 40min after and 8min before drug injection versus the anti-
vascular index in A2780 tumour-bearing mice following treatment as indicated in the figure key. Each point 
is the AVI and corresponding Pi/ βNTP value for each individual mouse.  
171 
 
Figure 6.3: Ratio of Pi to βNTP ratios at 40min after and 8min before drug injection versus the anti-
vascular index in SW620 tumour-bearing mice following treatment as indicated in the figure key. Each 
point is the AVI and corresponding Pi/ βNTP value for each individual mouse. 
 
In A2780 tumours the nonparametric Spearman correlation coefficient, r, was 
0.505 with a p value of 0.003 (statistically significant). This r value indicates a 
correlation between the two variables. For SW620 tumours the correlation 
coefficient was 0.36 with a p value of 0.06 (not statistically significant at the 95% 
level). However, the r value for the SW620 results indicates a similar trend to 
the data for A2780 tumours. It is important to note that these low p values in the 
correlation might be somehow forced by the some extreme or “outliers” values. 
In the absence of a valid reason for exclusion, these “outliers” have to be 
included. These relationships indicate a likely link between drug effects on 
tumour vasculature and tumour energetics.  
 
Some of the tumours examined in the in vivo MR studies were harvested and 
freeze clamped after the DCE-MRI, and ex vivo 31P-MRS analysis performed as 
reported in chapter 4. Samples were extracted according to the PCA protocol 
and the results obtained were compared with the AVI data from the in vivo 
experiments. Due to limited time available on the high resolution NMR only a 
few samples were selected to provide preliminary results. This cross analysis is 
important to assess if the in vivo results are coherent with the ex vivo results 
and if the vascular and metabolic effects can be seen in the extracted tissues. 
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Figures 6.4 and 6.5 show the amount of NTP (primarily reflecting ATP in μmoles 
per gram of tissue wet weight) measured from the ex vivo analysis against the  
AVI in A2780 and SW620 tumours, respectively, where both in vivo DCE-MRI 
and ex vivo  31P-MRS analyses were performed. 
 
 
Figure 6.4: Relationship between NTP concentration measured ex vivo in A2780 tumour extracts and the 
AVI in individual mice. Treatments are as indicated in the figure key. 
 
 
 
Figure 6.5: Relationship between NTP concentration measured ex vivo in SW620 tumour extracts and the 
AVI in individual mice. Treatments are as indicated in the figure key. 
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Spearman rank correlation analysis demonstrated that there was a significant 
negative correlation in both tumour types between tumour AVI and tumour NTP 
concentration (A2780: r = -0.47, p = 0.04; SW620: r = -0.5, p = 0.035). Thus a 
high AVI has associated reduced tumour NTP concentrations when measured 
ex vivo in tumour extracts. The mechanism underlying the relationship is most 
probably that vasculature damage results in a reduced oxygen and nutrient 
supply which in turn decreases tumour ATP production. 
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6.2 The relation between in vivo and ex vivo measurements of NTP 
Figures 6.6 and Figure 6.7 compare NTP levels measured by MRS in tumour 
extracts ex vivo with the ratio between βNTP 40 minutes after drug injection 
(βNTP@40) and βNTP 8 minutes before the drug injection (βNTP@-8) 
measured in vivo in A2780 and SW620 tumours, respectively. 
 
Figure 6.6: Amount of NTP in ex vivo A2780 tumour extracts in relation to the ratio between βNTP@40’ 
and βNTP@-8’ in vivo in individual mice. Treatments are as indicated in the figure key. 
 
Figure 6.7: Amount of NTP in ex vivo SW620 tumour extracts in relation to the ratio between βNTP@40’ 
and βNTP@-8’ in vivo in individual mice. Treatments are as indicated in the figure key. 
 
For data in Figures 6.6 and 6.7, the Spearman correlation coefficients, r, were 
0.078 with a p value of 0.74 (not significant) for the A2780 tumours and 0.31 
with p value of 0.22 (not significant) for SW620 tumours, and hence there was 
no significant relationship between the two parameters.  
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 The studies described in this thesis also allow a comparison of tumour 
energetics measured non-invasively by single voxel in vivo MRS and ex vivo 
using MRS to study tumour extracts. In Figures 6.8 and 6.9 NTP levels 
measured by ex vivo MRS in tumours extracts are compared with the Pi/βNTP 
ratio 40 minutes after drug injection as measured by in vivo 31P-MRS.  
 
Figure 6.8: Relationship between NTP concentrations measured ex vivo in A2780 tumour extracts and 
Pi/βNTP@40’ratio in vivo in the same mouse. Treatments are as indicated in the figure key. 
 
Figure 6.9: Relationship between NTP concentrations measured ex vivo in SW620 tumour extracts and 
Pi/βNTP@40’ratio in vivo in the same mouse. Treatments are as indicated in the figure key. 
 
 
The Spearman correlation coefficient for the data for A2780 tumours was -0.15 
(p = 0.53), and for SW620 tumours 0.04 (p = 0.87). Thus there was no 
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significant relationship between the parameters, perhaps reflecting the fact that 
the Pi/βNTP ratio, and not the actual NTP level, was measured in vivo.  
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6.3 Comparison of drug treatment-induced changes in MR and PET 
biomarkers 
Figure 6.10 compares the results of all the techniques applied to A2780 
tumours or cells (DCE-MRI, 31P-MRS and [18F]FDG and [18F]FLT PET), where 
only the treatments used in all experiments are shown.  
 
Figure 6.10: Comparison of MR and PET biomarker data in A2780 tumours and cells. a) NAD 
concentration in nanomoles per million cells in the four different groups of A2780 treated cells; b) Median 
and inter-quartile range for the AVI in A2780 tumour-bearing mice; c) Percentage change of Pi/βNTP ratios 
in A2780 tumour-bearing mice grouped between 8 minutes before injection of drug, 8 minutes after drug 
injection and 40 minutes after drug injection; d) Mean [18F]FDG SUV for each treatment group at the one 
hour time point in A2780 tumour-bearing mice; e) Mean [18F]FLT SUV for each treatment group at the one 
hour time point in A2780 tumour-bearing mice; f) Median time in days for A2780 tumours to reach four 
times their initial volume and inter-quartile range. Treatments were as indicated in each figure.  
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From data in Figure 6.10 several comparisons can be made. In doing so, it is 
important to note that the DCE-MRI and 31P-MRS results relate to an acute 
experiment with a single treatment while the PET and growth delay experiments 
involve a 5 day treatment schedule, and cells were treated in vitro for 6 hours. 
The different experiments had different time points regarding the acute or 
prolonged effected of drugs. Still it is worth of comparison as the it might 
indicate if prolonged effects can be identified earlier in the acute studies. 
 
In addition to the DCE-MRI and 31P-MRS comparisons discussed above, the 
results from these two techniques can be compared with the [18F]FDG-PET 
results, and the decrease of contrast agent uptake in the second injection may 
possibly be reflected in a lower uptake of [18F]FDG, potentially due to damage 
to the tumour vasculature. In contrast, from the [18F]FLT-PET and tumour 
growth results, it appears that there is an increase in the growth and 
proliferative status of A2780 tumours when treated with 1mg/kg rucaparib. 
 
Although preliminary, the results from A2780 cells treated in vitro are consistent 
with data presented by Sims et al. (1981) and more recently by Bai et al. (2011). 
In both papers, inhibition of PARP lead to an increase of NAD levels, dose 
dependant and of 50% in the Bai et al. paper (Sims et al., 1981; Bai et al., 2011). 
However, the results presented here are limited and further experiments are 
required. 
 
Figure 6.11 presents the comparative DCE-MRI, 31P-MRS and [18F]FLT-PET 
data for SW620 tumours in rucaparib, temozolomide and rucaparib plus 
temozolomide treated mice. 
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Figure 6.11: Comparison of MR and PET biomarkers data in SW620 tumours. a) AVI (median and inter-
quartile range); b) Percentage change in Pi/βNTP ratios 8 minutes before drug injection, 8 minutes after 
drug injection and 40 minutes after drug injection; c) Mean [18F]FLT SUV for each treatment group at the 
one hour time point in A2780 tumour-bearing mice; d) Median time in days for A2780 tumours to reach 
four times their initial volume and inter-quartile range with the star indicating statistically significant 
difference between all the groups apart from between control and 1 mg/kg rucaparib groups. Treatments 
were as indicated in each figure. 
 
The DCE-MRI and 31P-MRS data have been compared previously and no 
significant changes were produced by drug treatment in the SW620 tumour 
model. As previously discussed, chapter 5, the most notable result in the 
SW620 tumour model was the prediction of chemosensitization in the rucaparib 
plus temozolomide combination group by the [18F]FLT-PET scan. 
 
Although only studied in one tumour cell line and the data are preliminary, the 
increase in NAD levels in A2780 cells treated with rucaparib is consistent with 
PARP inhibition, as is the decrease in NAD when A2780 cells are treated with 
temozolomide, potentially due to hyperactivation of PARP. In work by Horsman 
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et al. C3H mouse mammary carcinoma growth inhibition after administration of 
a high dose of nicotinamide (1000 mg/kg) resulted in a similar level of growth 
inhibition to that caused by fumagillin (angiogenesis inhibitor). However, the 
mechanism underlying the nicotinamide effect was not established (Horsman et 
al., 1995).      
 
Overall, the imaging biomarker studies have shown that [18F]FLT-PET can be 
used as a surrogate response biomarker for PARP inhibitor-temozolomide 
combination. Intriguingly, data generated in A2780 tumour model suggest that 
[18F]FLT-PET may also be able to predict enhanced tumour growth following 
single agent rucaparib administration, although further experiments are needed 
to confirm this unexpected observation. 
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6.4 The effect of rucaparib, temozolomide, and rucaparib plus 
temozolomide on NAD concentrations in the livers of PARP1 WT and KO 
mice 
 
 
Figure 6.12: Effect of daily x5 treatment with rucaparib, temozolomide, or rucaparib combined with 
temozolomide on the concentration of NAD in the livers of a) PARP1 WT and b) PARP1 KO mice. The 
median with inter-quartile range of concentrations is shown and the stars indicate the statistically 
significant differences. 
 
The studies in PARP1 WT and PARP1 KO mice were performed to determine 
whether PARP1 status influenced the impact of rucaparib, temozolomide or 
rucaparib plus temozolomide combination treatment on NAD levels. The liver 
was chosen as a large-volume relatively homogeneous organ that is amenable 
to non-invasive in vivo MRS. However, satisfactory in vivo MRS data could not 
be obtained and hence studies were performed ex vivo on liver extracts. Dual in 
vivo/ex vivo liver 31P-MRS study can be found in the literature, and 
Sevastianova et al. (2010) described in vivo clinical MRS measurements of 
nicotinamide adenine dinucleotide phosphate (NADP) in human liver and ex 
vivo analysis of biopsies (Sevastianova et al., 2010).  
 
As expected, in the PARP1 WT mice, PARP inhibition lead to an increase in 
liver NAD. The PARP1 KO mouse livers had a lower endogenous NAD 
concentration, and again rucaparib treatment increased NAD levels potentially 
as a result of PARP2 inhibition.  
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Other NAD+-dependent enzymes that might be affected by a PARP inhibitor 
such as rucaparib include mono-ADP- ribosyltransferases (reviewed by Hassa 
et al., 2006) and sirtuins (Benavente et al., 2012). However, the real effects of 
PARP inhibitors in the catalytic activity of these enzymes are not fully 
understood (reviewed by Rouleau et al., 2010).  
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6.5 Future work 
Reviewing the work developed in this thesis, some methodological alterations 
should be implemented. In the DCE-MRI/31P-MRS studies it would be 
worthwhile to perform the scans with the surface coil but the inside the 72mm 
volume coil to optimize the proton imaging. The possible loss of SNR in the 31P-
MRS could be compensated with the built of a more sensitive and/or tunable 
coil. 
 
The extraction protocol for tissues and cells could and should be optimized in 
order to provide clearer spectra. Also the use of different doses and different 
incubation times in the cell treatment protocol could provide valuable extra 
information. 
 
Regarding the PET experiments, instead of having a separate control group, it 
would be more robust to have each mouse scanned prior to treatment so each 
individual can be its own control. 
 
In addition, several questions regarding the effects of rucaparib, temozolomide 
or rucaparib combined with temozolomide remain unanswered.  
 
Firstly the studies described in this thesis have not addressed the impact of 
rucaparib delivery to the tumour on the pharmacodynamics of the drug, and 
PET can be used to assess the penetration of drugs into the tumours by using a 
PET isotope labelled version. For PARP inhibitors Tu et al. (2005) have 
described experiments where a phenanthridinone derivative, PJ34, which has 
high affinity for PARP1, was labelled with [11C]methyl iodide ([11C]MeI). The 
compound production had a yield of 60% based on the starting amount of 
[11C]MeI, and a radiochemistry purity of 99%. Rats were injected with 
streptozocin, an alkylating agent which causes damage to the beta cells of the 
pancreas and consequent activation of PARP activity. One week after treatment 
the streptozocin treated rats had developed diabetes and were injected with 
[11C]PJ34 followed by tissue removal for radioactivity measurements 5 and 30 
minutes after tracer injection. The results of the experiment revealed higher 
uptake of the radiotracer in the pancreas and liver of the streptozocin-treated 
rats relative to control rats suggesting higher levels of PARP enzyme(s) (Tu et 
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al., 2005). Similarly, Reiner et al. (2011) described experiments where the 
PARP inhibitor olaparib was radiolabelled with [18F], using rapid orthogonal 
conjugation chemistry, and used to measure PARP levels in tumours. It was 
shown that co-administration of non-radioactive olaparib reduced the tumour 
[18F]-olaparib uptake, demonstrating that drug-target (PARP) interaction could 
be measured by PET (Reiner et al., 2011).  
 
For the PARP inhibitor rucaparib, an [18F] labelled version could be generated 
using an 18F/19F exchange strategy. As shown in Figure 6.13, rucaparib 
possesses a fluorine atom making it suitable for fluorine substitution by 
exchange with [18F]. Studies to produce [18F]-rucaparib are ongoing. 
 
 
 
Figure 6.13: Chemical structure of the PARP inhibitor rucaparib in two dimensions on the left and in three 
dimensions on the right. In the 3D picture, the carbon atoms are depicted in grey, the nitrogen atoms in 
blue, the oxygen atom in red, the fluorine atom in green and the hydrogen atoms in white. The fluorine 
present in the structure is the best candidate to be replaced by 18F in the radiolabelling process. Copied 
from (ChemSpider; ChemSpider).  
 
Once delivery of rucaparib to the tumour has been established, the proof of 
PARP inhibition should be demonstrated. As indicated above Reiner et al. 
(2011) have demonstrated that a PET isotope-labelled PARP inhibitor can be 
used to determine whether PARP has been saturated with an inhibitor, and 
hence would in theory be inactive. To measure the biochemical impact of PARP 
inhibition, determination of the NAD (substrate) to ADP-ribose (breakdown 
product of poly(ADP)ribose) ratio may be informative, and it may be possible to 
use MRS to do so.  
 
Data presented in this thesis on the impact of rucaparib on tumour vasculature 
are not consistent with those reported by Ali et al. (2009). However, longer 
treatment duration may be required to study effects, and further studies are 
warranted. To aid these studies, histological studies and other vascular 
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measurements (i.e. Time Of Flight angiography) would be extremely helpful to 
clarify the data here presented. A comparative study between the implanted 
xenografts as described here with naturally arising tumour could also provide 
more information between an atypical vascular supply (subcutaneous 
xenografts) and the resort to an already established one (naturally arising 
tumours. 
 
With regards to imaging biomarker techniques, in addition to the MR and PET 
methods used in these studies, diffusion-weighted MR, hyperpolarized MR, and 
PET using alternative tracers (e.g. labelled amino acids) could be investigated 
and these methods are being implemented more widely in pre-clinical and 
clinical studies (Hara, 2001; Thoeny et al., 2005; Langen et al., 2006; Jamin et 
al., 2009).  
 
In conclusion, the work developed and presented in this thesis demonstrates 
that [18F]FLT-PET can be used as a surrogate response biomarker for rucaparib 
and temozolomide combination. DCE-MRI and 31P-MRS to measure effects on 
tumour vasculature and the impact on tumour energetics have been validated 
using hydralazine treatment. However, neither rucaparib nor temozolomide 
alone or in combination had a marked or consistent effect on tumour 
vasculature. Multiple imaging techniques were used and provided consistent 
results, and these studies have shown that multimodality imaging can be used 
in the assessment of novel anticancer therapies in preclinical investigations. 
This information should help in the design of in vivo biomarker measurements 
for clinical trials. 
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